WO2022078462A1 - Novel glutamine analogs - Google Patents
Novel glutamine analogs Download PDFInfo
- Publication number
- WO2022078462A1 WO2022078462A1 PCT/CN2021/123878 CN2021123878W WO2022078462A1 WO 2022078462 A1 WO2022078462 A1 WO 2022078462A1 CN 2021123878 W CN2021123878 W CN 2021123878W WO 2022078462 A1 WO2022078462 A1 WO 2022078462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- alkylene
- aryl
- coo
- membered heterocyclyl
- Prior art date
Links
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims description 1070
- 125000003118 aryl group Chemical group 0.000 claims description 662
- 125000000623 heterocyclic group Chemical group 0.000 claims description 594
- 229910052736 halogen Inorganic materials 0.000 claims description 272
- 229910052805 deuterium Inorganic materials 0.000 claims description 244
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 242
- 150000002367 halogens Chemical class 0.000 claims description 209
- 125000003545 alkoxy group Chemical group 0.000 claims description 186
- 150000001875 compounds Chemical class 0.000 claims description 145
- 125000001424 substituent group Chemical group 0.000 claims description 142
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 126
- 229910052739 hydrogen Inorganic materials 0.000 claims description 118
- 239000001257 hydrogen Substances 0.000 claims description 118
- 150000002431 hydrogen Chemical class 0.000 claims description 107
- 125000003342 alkenyl group Chemical group 0.000 claims description 102
- 125000001072 heteroaryl group Chemical group 0.000 claims description 91
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 83
- 125000004043 oxo group Chemical group O=* 0.000 claims description 82
- 150000003839 salts Chemical class 0.000 claims description 80
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 78
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 67
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 60
- -1 methoxy, ethoxy, propoxy, isopropoxy, vinyl Chemical group 0.000 claims description 60
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 59
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 59
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 125000000304 alkynyl group Chemical group 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 44
- 229920002554 vinyl polymer Polymers 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 31
- 229910052801 chlorine Inorganic materials 0.000 claims description 30
- 229910052731 fluorine Inorganic materials 0.000 claims description 30
- 229910052794 bromium Inorganic materials 0.000 claims description 29
- 229910052740 iodine Inorganic materials 0.000 claims description 29
- 125000001188 haloalkyl group Chemical group 0.000 claims description 27
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 26
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 125000002837 carbocyclic group Chemical group 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 16
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 150000002772 monosaccharides Chemical class 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 11
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 6
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 6
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 239000002212 purine nucleoside Substances 0.000 claims description 3
- 239000002718 pyrimidine nucleoside Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 66
- 125000005843 halogen group Chemical group 0.000 description 66
- 239000000243 solution Substances 0.000 description 50
- 239000011541 reaction mixture Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 12
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 239000007858 starting material Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000012267 brine Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 150000002309 glutamines Chemical class 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 210000001589 microsome Anatomy 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- BFGQSHBGAAGGRX-IRXDYDNUSA-N (2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-6-diazo-5-oxohexanoic acid Chemical compound C(C)(=O)N[C@H](C(=O)N[C@H](C(=O)O)CCC(C=[N+]=[N-])=O)CC1=CNC2=CC=CC=C12 BFGQSHBGAAGGRX-IRXDYDNUSA-N 0.000 description 6
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229940122697 Glutamine antagonist Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HJGRUNYOBIYANY-ZEQRLZLVSA-N CC(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(NCC(C=C1)=CC=C1F)=O)=O)=O Chemical compound CC(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(NCC(C=C1)=CC=C1F)=O)=O)=O HJGRUNYOBIYANY-ZEQRLZLVSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- ORPFFAMAZAPHMB-QHCPKHFHSA-N CC(C)(C)[Si](C)(C)O[C@@H](CC1=CN(C(OCC2=CC=CC=C2)=O)C2=CC=CC=C12)C(OC)=O Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](CC1=CN(C(OCC2=CC=CC=C2)=O)C2=CC=CC=C12)C(OC)=O ORPFFAMAZAPHMB-QHCPKHFHSA-N 0.000 description 3
- AIOMZLFZNKUWAG-ZEQRLZLVSA-N CC(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(NCC1=CC=CC=C1)=O)=O)=O Chemical compound CC(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(NCC1=CC=CC=C1)=O)=O)=O AIOMZLFZNKUWAG-ZEQRLZLVSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- WZVZUKROCHDMDT-YFKPBYRVSA-N (2s)-2-acetamidobutanoic acid Chemical compound CC[C@@H](C(O)=O)NC(C)=O WZVZUKROCHDMDT-YFKPBYRVSA-N 0.000 description 2
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 2
- RWFYCMYJDAYDDT-UHFFFAOYSA-N 2-acetamido-3-(7-fluoro-1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1F RWFYCMYJDAYDDT-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- MQMLFKYGSDPZNC-SFTDATJTSA-N CC(C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(OC(C)C)=O)=O)=O Chemical compound CC(C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(OC(C)C)=O)=O)=O MQMLFKYGSDPZNC-SFTDATJTSA-N 0.000 description 2
- KEYYOCJSFDOEMI-QMMMGPOBSA-N CC(C)OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] Chemical compound CC(C)OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] KEYYOCJSFDOEMI-QMMMGPOBSA-N 0.000 description 2
- SCHDISOZCQAMBJ-VXKWHMMOSA-N CC(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(NCC(C=C1)=CC=C1F)=O)=O)=O Chemical compound CC(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(NCC(C=C1)=CC=C1F)=O)=O)=O SCHDISOZCQAMBJ-VXKWHMMOSA-N 0.000 description 2
- OGQPKXRQXUTUCN-QWRGUYRKSA-N CC[C@@H](C(N[C@@H](CCC(C=[N+]=[N-])=O)C(OC)=O)=O)NC(C)=O Chemical compound CC[C@@H](C(N[C@@H](CCC(C=[N+]=[N-])=O)C(OC)=O)=O)NC(C)=O OGQPKXRQXUTUCN-QWRGUYRKSA-N 0.000 description 2
- HQPMMTYDDNGJHK-IBGZPJMESA-N CO[C@@H](CC1=CN(C(OCC2=CC=CC=C2)=O)C2=CC=CC=C12)C(OC)=O Chemical compound CO[C@@H](CC1=CN(C(OCC2=CC=CC=C2)=O)C2=CC=CC=C12)C(OC)=O HQPMMTYDDNGJHK-IBGZPJMESA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000005518 carboxamido group Chemical group 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- LCFXLZAXGXOXAP-QPJJXVBHSA-N ethyl (2e)-2-cyano-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(=N\O)\C#N LCFXLZAXGXOXAP-QPJJXVBHSA-N 0.000 description 2
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- UFTMSANGGFIYHL-INIZCTEOSA-N methyl (2s)-2-[tert-butyl(dimethyl)silyl]oxy-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@@H](C(=O)OC)O[Si](C)(C)C(C)(C)C)=CNC2=C1 UFTMSANGGFIYHL-INIZCTEOSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- CHWRDHPLSIVPKS-WMZOPIPTSA-N propan-2-yl (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-6-diazo-5-oxohexanoate Chemical compound CC(C)OC(=O)[C@H](CCC(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N CHWRDHPLSIVPKS-WMZOPIPTSA-N 0.000 description 2
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 231100000004 severe toxicity Toxicity 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- MGHMWKZOLAAOTD-DEOSSOPVSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-DEOSSOPVSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- KRMRBEXBEPMAQT-UHFFFAOYSA-N 2-acetamido-3-(5-fluoro-1h-indol-3-yl)propanoic acid Chemical compound C1=C(F)C=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 KRMRBEXBEPMAQT-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
- XONKJZDHGCMRRF-UHFFFAOYSA-N 7-fluoro-1h-indole Chemical compound FC1=CC=CC2=C1NC=C2 XONKJZDHGCMRRF-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 1
- 206010057654 Breast cancer female Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- FXBMSSRWYXELDN-ROUUACIJSA-N CC(C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O)=O)=O Chemical compound CC(C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O)=O)=O FXBMSSRWYXELDN-ROUUACIJSA-N 0.000 description 1
- GIJFMTYTTYQKTF-RBUKOAKNSA-N CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@@H](CC(C1=CC=C2)=CNC1=C2F)NC(C)=O)=O)=O Chemical compound CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@@H](CC(C1=CC=C2)=CNC1=C2F)NC(C)=O)=O)=O GIJFMTYTTYQKTF-RBUKOAKNSA-N 0.000 description 1
- GIJFMTYTTYQKTF-OALUTQOASA-N CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C1=CC=C2)=CNC1=C2F)NC(C)=O)=O)=O Chemical compound CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C1=CC=C2)=CNC1=C2F)NC(C)=O)=O)=O GIJFMTYTTYQKTF-OALUTQOASA-N 0.000 description 1
- ARYYFMXQALIODA-UHFFFAOYSA-N CC(C)SC(C(CCC(C=[N+]=[N-])=O)NC(C(CC1=CNC2=CC=CC=C12)NC(C)=O)=O)=O Chemical compound CC(C)SC(C(CCC(C=[N+]=[N-])=O)NC(C(CC1=CNC2=CC=CC=C12)NC(C)=O)=O)=O ARYYFMXQALIODA-UHFFFAOYSA-N 0.000 description 1
- AFEVGMSYNUJGQN-GJZGRUSLSA-N CC(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O)=O)=O Chemical compound CC(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O)=O)=O AFEVGMSYNUJGQN-GJZGRUSLSA-N 0.000 description 1
- JVWYVNFDBLHIJD-DJNXLDHESA-N CC(N[C@@H](CC1=CNC2=CC=CC=C12)C(NC(CCC(C=[N+]=[N-])=O)C(O)=S)=O)=O Chemical compound CC(N[C@@H](CC1=CNC2=CC=CC=C12)C(NC(CCC(C=[N+]=[N-])=O)C(O)=S)=O)=O JVWYVNFDBLHIJD-DJNXLDHESA-N 0.000 description 1
- XLZHCDCJQHRUSO-GFCCVEGCSA-N CCS[C@H](CC1=CNC2=CC=CC=C12)C(O)=O Chemical compound CCS[C@H](CC1=CNC2=CC=CC=C12)C(O)=O XLZHCDCJQHRUSO-GFCCVEGCSA-N 0.000 description 1
- HXFZEKXSOCISBB-UWVGGRQHSA-N CC[C@@H](C(N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O)=O)NC(C)=O Chemical compound CC[C@@H](C(N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O)=O)NC(C)=O HXFZEKXSOCISBB-UWVGGRQHSA-N 0.000 description 1
- WTRLCCDSRUPILA-NSHDSACASA-N CO[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O Chemical compound CO[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O WTRLCCDSRUPILA-NSHDSACASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 241000940612 Medina Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- DFBKLUNHFCTMDC-PICURKEMSA-N dieldrin Chemical compound C([C@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@H]2[C@@H]2[C@H]1O2 DFBKLUNHFCTMDC-PICURKEMSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- PQGVTLQEKCJXKF-RGMNGODLSA-N ethyl (2s)-2-amino-3-methylbutanoate;hydron;chloride Chemical compound Cl.CCOC(=O)[C@@H](N)C(C)C PQGVTLQEKCJXKF-RGMNGODLSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000005358 mercaptoalkyl group Chemical group 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- UJEWHZZRQBIEMD-LURJTMIESA-N methyl (2S)-2-amino-6-diazo-5-oxohexanoate Chemical compound COC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] UJEWHZZRQBIEMD-LURJTMIESA-N 0.000 description 1
- YKNYRRVISWJDSR-VKHMYHEASA-N methyl (2s)-oxirane-2-carboxylate Chemical compound COC(=O)[C@@H]1CO1 YKNYRRVISWJDSR-VKHMYHEASA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052815 sulfur oxide Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- BUJKNFNMGRYZBV-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+);hydrate Chemical compound O.[Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F BUJKNFNMGRYZBV-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
- C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
- C07C245/18—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Definitions
- the invention relates to a novel glutamine analogs, a composition containing the glutamine analogs and the use thereof.
- Glutamine analogs such as 6-diazo-5-oxo-L-norleucine (DON) have been shown to exhibit anti-cancer activities.
- severe toxicity e.g., dose limiting GI toxicities, such as oral mucositis, gastric bleeding, nausea and vomiting, and abdominal pain
- dose limiting GI toxicities such as oral mucositis, gastric bleeding, nausea and vomiting, and abdominal pain
- a compound of formula I and a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotope substitutant thereof:
- Z is (OR 1 ) 1-2 , (C (R 1 ) 2 ) 1-6 , (N (R 1 ) ) 1-2 R 1 ’, or (SR 1 ) 1-2 ;
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -NH 2 , -CN, -OH, -C 1-6 alkyl, -C 2-6 alkenyl, C 2-6 alkynyl, -C 5-12 aryl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkylene-5-12 membered aryl, -C 0-6 alkylene-C 5-12 aryl, -C 0-6 alkylene -5-12 membered heteroaryl, -C 0-6 alkylene-5-12 membered heterocyclyl, -C 1-6 alkylene-N (C 1-6 alkyl) 2 , -C 1-6 alkylene-O-C 1-6 alkyl, -C 1-6 alkylene-CO-NH-C 1-6 alkyl, -C 1-6 alkylene-CO-5-12 membered hetero
- R 1 and R 1 ’ together with the nitrogen atom to which they are both attached form 4-8 membered heterocyclyl, and wherein said 4-8 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and said 4-8 membered heterocyclyl can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6
- W is oxygen, CO or a bond
- n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
- p and q are each independently selected from 0, 1 or 2, provided that the sum of p and q is 2;
- R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C 1-6 alkyl, -C 1-6 alkylene-SH, -C 1-6 alkylene-C 2-6 alkenyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 3-8 cycloalkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-CONH 2 , -C 1-6 alkylene-Se-C 1-6 alkyl, -C 1-6 alkylene-SH, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-CO 2 -C 1-6 alkyl, C 5-12 aryl, -C 1-6 alkylene-C 5-12 aryl, -C 1-6 alkylene-5-12 membered heteroaryl, -C 1-6 alkylene-5-12 membered heterocyclyl
- R X1 and R X2 together with the carbon atom to which they are attached form C 3-10 carbocyclic ring, C 5-10 aryl, C 5-10 heteroaryl, C 2-4 alkenyl, C 3-10 heterocyclyl, and wherein said C 3-10 carbocyclic ring, C 5-10 aryl, C 5-10 heteroaryl, C 2-4 alkenyl, C 3-10 heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-
- R X1 and R 5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-12 membered heterocyclyl, and wherein said 5-12 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -
- each of R 6 is independently selected from the group consisting of hydrogen, deuterium, -C 1-6 alkyl, -C 3-8 cycloalkyl, 5-12 membered heterocyclyl, -C 2-6 alkenyl, and -C 3-8 cycloalkenyl, and wherein said -C 1-6 alkyl, said -C 3-8 cycloalkyl, said 5-12 membered heterocyclyl, said -C 1-6 alkenyl, and said -C 3-8 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl,
- each of R 7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, 5-12 membered heterocyclyl, C 1-6 alkenyl, C 3-8 cycloalkenyl, C 5-12 aryl, and 5-12 membered heteroaryl, and wherein said C 1-6 alkyl, said C 3-8 cycloalkyl, said 5-12 membered heterocyclyl, said C 1-6 alkenyl, said C 3-8 cycloalkenyl, said C 5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8
- R 8 and R 9 are each independently selected from the group consisting of C 1-6 alkyl, C 3-8 cycloalkyl, monosaccharide, acylated monosaccharide, C 5-12 aryl, and 5-12 membered heteroaryl, and wherein said C 1-6 alkyl, said C 3-8 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C 5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -C
- R 11 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- G is C 5-12 aryl, or 5-12 membered heteroaryl, and wherein said C 5-12 aryl, and said 5-12 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alky
- R 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- R 3 and R 3 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alky
- Y is a bond, oxygen, or - (CR Y1 R Y2 ) n -;
- n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
- R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C
- R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- R 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- provided here is a compound of formula Ia or Ib, and a pharmaceutically acceptable salt thereof or a stereoisomer thereof
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C 1-6 alkyl, -C 2-6 alkenyl, C 2-6 alkynyl, -C 5-12 aryl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-C 5-12 aryl, -5-12 membered heteroaryl, -5-12 membered heterocyclyl, -C 1-6 alkylene-N (C 1-6 alkyl) 2 , -C 1-6 alkylene-O-C 1-6 alkyl, -C 1-6 alkylene-CO-NH-C 1-6 alkyl, -C 1-6 alkylene-CO-5-12 membered heterocyclyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl and C 3-8 cycloalkyl-C 5-12 aryl,
- R 1 and R 1 ’ together with the nitrogen atom to which they are both attached form 4-8 membered heterocyclic ring, and wherein said 4-8 membered heterocyclic ring can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and said 4-8 membered heterocyclic ring can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -
- W is oxygen or a bond
- n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
- p and q are each independently selected from 0, 1 or 2, provided that the sum of p and q is 2;
- R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C 1-6 alkyl, -C 1-6 alkylene-SH, -C 1-6 alkylene-C 2-6 alkenyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 3-8 cycloalkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-CONH 2 , -C 1-6 alkylene-Se-C 1-6 alkyl, -C 1-6 alkylene-SH, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-CO 2 -C 1-6 alkyl, C 5-12 aryl, -C 1-6 alkylene-C 5-12 aryl, -C 1-6 alkylene-5-12 membered heteroaryl, -C 1-6 alkylene-5-12 membered heterocyclyl
- R X1 and R X2 together with the carbon atom to which they are attached form 5-10 membered carbocyclic ring, C 3-8 cycloalkyl, C 2-4 alkenyl, 5-10 membered heterocyclic ring, and wherein said 5-10 membered carbocyclic ring, said C 2-4 alkenyl, said 5-10 membered heterocyclic ring can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6
- R X1 and R 5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-12 membered heterocyclic ring, and wherein said 5-12 membered heterocyclic ring can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and said 5-12 membered heterocyclic ring can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO
- each of R 6 is independently selected from the group consisting of hydrogen, deuterium, -C 1-6 alkyl, -C 3-8 cycloalkyl, 5-12 membered heterocyclyl ring, -C 1-6 alkenyl, and -C 3-8 cycloalkenyl, and wherein said -C 1-6 alkyl, said -C 3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said -C 1-6 alkenyl, and said -C 3-8 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alken
- each of R 7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, 5-12 membered heterocyclyl ring, C 1-6 alkenyl, C 3-8 cycloalkenyl, C 5-12 aryl, and 5-12 membered heteroaryl, and wherein said C 1-6 alkyl, said C 3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said C 1-6 alkenyl, said C 3-8 cycloalkenyl, said C 5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -
- R 8 and R 9 are each independently selected from the group consisting of C 1-6 alkyl, C 3-8 cycloalkyl, monosaccharide, acylated monosaccharide, C 5-12 aryl, and 5-12 membered heteroaryl, and wherein said C 1-6 alkyl, said C 3-8 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C 5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -C
- R 11 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- G is C 5-12 aryl, or 5-12 membered heteroaryl, and wherein said C 5-12 aryl, and said 5-12 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alky
- R 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- R 3 and R 3 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alky
- Y is a bond, oxygen, or - (CR Y1 R Y2 ) n -;
- n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
- R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C
- R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- R 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C 1-3 alkyl, -C 2-3 alkenyl, C 2-3 alkynyl, -C 5-10 aryl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-C 5-10 aryl, -5-10 membered heteroaryl, -5-10 membered heterocyclyl, -C 1-3 alkylene-N (C 1-3 alkyl) 2 , -C 1-3 alkylene-O-C 1-3 alkyl, -C 1-3 alkylene-CO-NH-C 1-3 alkyl, -C 1-3 alkylene-CO-5-10 membered heterocyclyl, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl and C 3-6 cycloalkyl-C 5-10 aryl, and where
- R 1 and R 1 ’ together with the nitrogen atom to which they are both attached form 4-6 membered heterocyclyl, and wherein said 4-6 membered heterocyclyl can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO 2 , and said 4-6 membered heterocyclyl can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alky
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C 1-3 alkyl, -C 2-3 alkenyl, C 2-3 alkynyl, -C 5-10 aryl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-C 5-10 aryl, -5-10 membered heteroaryl, -5-10 membered heterocyclyl, -C 1-3 alkylene-N (C 1-3 alkyl) 2 , -C 1-3 alkylene-O-C 1-3 alkyl, -C 1-3 alkylene-CO-NH-C 1-3 alkyl, -C 1-3 alkylene-CO-5-10 membered heterocyclyl, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl and C 3-6 cycloalkyl-C 5-10 aryl, and where
- R 1 and R 1 ’ together with the nitrogen atom to which they are both attached form 4-6 membered heterocyclyl, and wherein said 4-6 membered heterocyclyl can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO 2 , and said 4-6 membered heterocyclyl can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2 -C 1-3 alkyl,
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, vinyl, allyl, ethyne, propyne, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, -CH 2 -COO-CH 3 , - (CH 2 ) 2 -COO-CH 3 , - (CH 2 ) 3 -COO-CH 3 , -CH 2 -COO-CH 2 CH 3 , - (CH 2 ) 2 -COO-CH 2 CH 3 , - (CH 2 ) 2 -COO-CH 2 CH 3 , - (CH 2 ) 3 -COO-CH 2 CH 3 , - (CH 2 ) 3 -COO-CH 2 CH 3 , -CH 2 ) 3 -COO-
- R 1 and R 1 ’ together with the nitrogen atom to which they are both attached form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO 2 , and said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, vinyl, allyl, ethyne, propyne, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, -CH 2 -COO-CH 3 , - (CH 2 ) 2 -COO-CH 3 , - (CH 2 ) 3 -COO-CH 3 , -CH 2 -COO-CH 2 CH 3 , - (CH 2 ) 2 -COO-CH 2 CH 3 , - (CH 2 ) 2 -COO-CH 2 CH 3 , - (CH 2 ) 3 -COO-CH 2 CH 3 , - (CH 2 ) 3 -COO-CH 2 CH 3 , -CH 2 -COO-CH 2 CH 3 ,
- R 1 and R 1 ’ together with the nitrogen atom to which they are both attached form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO 2 , and said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO 2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C 3 cycloalkyl, -
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl,
- R 1 and R 1 ’ together with the nitrogen atom to which they are both attached form said and wherein said and said said can be optionally substituted with one or more substituents, said which are independently selected from the group consisting of F, Cl, Br, I, -OH, oxo, -CN, -C 1-4 alkyl, -C 1-4 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -4-6 membered heterocyclyl, -COO-C 1-3 alkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl.
- substituents said which are independently selected from the group consisting of F, Cl, Br, I, -OH, oxo, -
- R 1 and R 1 ’ together with the nitrogen atom to which they are both attached form said and wherein said and said said can be optionally substituted with one or more substituents, said which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH 3 , -COO-CH 2 CH 3 , -COO-CH 2 CH 2 CH 3 , -COO-CH (CH 3 ) 2
- W is oxygen or a bond
- n is selected from 1, 2, or 3;
- R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C 1-3 alkyl, -C 1-3 alkylene-SH, -C 1-3 alkylene-C 2-3 alkenyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 3-6 cycloalkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-CONH 2 , -C 1-3 alkylene-Se-C 1-3 alkyl, -C 1-3 alkylene-SH, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-CO 2 -C 1-3 alkyl, C 5-10 aryl, -C 1-3 alkylene-C 5-10 aryl, -C 1-3 alkylene-5-10 membered heteroaryl, -C 1-3 alkylene-5-10 membered heterocyclyl,
- R X1 and R X2 together with the carbon atom to which they are attached form 5-8 membered carbocyclic ring, C 3-6 cycloalkyl, C 2-3 alkenyl, 5-8 membered heterocyclyl, and wherein said 5-8 membered carbocyclic ring, said C 3-6 cycloalkyl, said C 2-3 alkenyl, and said 5-8 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 al
- R X1 and R 5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-10 membered heterocyclyl, and wherein said 5-10 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -
- R 11 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- the compound of formula I or Ia a pharmaceutically acceptable salt thereof or a stereoisomer thereof, wherein
- W is oxygen or a bond
- n is selected from 1, 2, or 3;
- R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C 1-3 alkyl, -C 0-3 alkylene-SH, -C 0-3 alkylene-C 2-3 alkenyl, -C 3-6 cycloalkyl, -C 0-3 alkylene-C 3-6 cycloalkyl, -C 0-3 alkylene-S-C 1-3 alkyl, -C 0-3 alkylene-CONH 2 , -C 0-3 alkylene-Se-C 1-3 alkyl, -C 0-3 alkylene-SH, -C 0-3 alkylene-SO 2 -C 1-3 alkyl, -C 0-3 alkylene-CO 2 -C 1-3 alkyl, C 5-10 aryl, -C 0-3 alkylene-C 5-10 aryl, -C 0-3 alkylene-5-10 membered heteroaryl, -C 0-3 al
- R X1 and R X2 together with the carbon atom to which they are attached form 5-8 membered carbocyclic ring, C 3-6 cycloalkyl, C 2-3 alkenyl, 5-8 membered heterocyclyl, and wherein said 5-8 membered carbocyclic ring, said C 3-6 cycloalkyl, said C 2-3 alkenyl, and said 5-8 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-4 alkenyl, -C 2-4 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-4 al
- R X1 and R 5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-10 membered heterocyclyl, and wherein said 5-10 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-4 alkenyl, -C 2-4 alkynyl, -C 3-6 cycloalkyl, -C 1-4 alkylene-C 2-4 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-4 alkylene-COO-C 1-3 alkyl, -C 1-4 alkylene-SO 2 -
- R 11 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-4 alkenyl, -C 2-4 alkynyl, -C 3-6 cycloalkyl, -C 1-4 alkylene-C 2-4 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-4 alkylene-COO-C 1-3 alkyl, -C 1-4 alkylene-SO 2 -C 1-3 alkyl, -C 1-4 alkylene-SO-C 1-3 alkyl, -C
- W is a bond
- n 1;
- R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, -CO-CH 3 , -SO-CH 3 , -SO 2 -CH 3 , -NH-CO-CH 3 , and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6
- W is a bond
- n 1;
- R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, -CO-CH 3 , -SO-CH 3 , -SO 2 -CH 3 , -NH-CO-CH 3 , and each of which can be optional substituted with one or more substituents, said which are independently selected from the group consisting of can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalky
- R X1 and R 5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, and wherein said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium,
- R 11 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; and each of which is optional substituted with one or more substituents, which are independently selected from deuterium, halogen, -OH, oxo, -CN, -NO 2 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy -C 2-4 alkenyl, -C 2-4 alkynyl, -C 1-4 alkylene-C 2-4 alkenyl, -NH-CO-CH 3 , -CO-NH-CH 3 , -CO-N (CH 3 ) 2 , -COO-CH 3 , -CH 2 -COO-CH 3 , -CH 2 -SO 2 -CH 3 , -CH 2 e-SO-CH 3
- R 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- R 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alky
- R 3 and R 3 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alky
- R 3 and R 3 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl,
- R 3 and R 3 ’ are each independently hydrogen, or deuterium.
- Y is - (CR Y1 R Y2 ) n -;
- n is selected from 1, 2, or 3;
- R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C
- Y is - (CR Y1 R Y2 ) n -;
- n 1;
- R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alky
- Y is - (CR Y1 R Y2 ) n -;
- n 1;
- R Y1 and R Y2 are each independently hydrogen or deuterium.
- R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alky
- R 4 is hydrogen or deuterium.
- R 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2 -C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C
- R 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alky
- the compound of formula I, Ia, Ib or Ic a pharmaceutically acceptable salt thereof or a stereoisomer thereof, wherein
- R 10 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-4 alkyl, -C 1-4 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -4-6 membered heterocyclyl, -COO-C 1-3 alkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 ,
- R 10 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -4 membered heterocycl
- provided here is a compound of formula Ia-1-3, Ib-1-3 or Ic-1-2, and a pharmaceutically acceptable salt thereof or a stereoisomer thereof
- the stereoisomer thereof, the tautomer thereof defined herein wherein the configuration of the chiral atom in the compound represented by the general formula I, Ia, Ib, Ia-1, Ia-2, Ia-3, Ib-1, Ib-2, Ib-3, Ic-1, Ic-2, is S-or R-configuration.
- provided here is a compound of formula Id-1-4, Ie-1-4, If 1-4. Ig 1-4, Ih 1-4, Ii 1-4, Ij 1-4, or Ik 1-4, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, the tautomer thereof
- the compound is of formula Ia-3, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof:
- a compound of formula II or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, the tautomer thereof
- R 1 , R 1 ’, R X1 , R X2 , R 5 , and R 5’ is the same as defined herein.
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C 1-3 alkyl, -C 2-3 alkenyl, C 2-3 alkynyl, -C 5-10 aryl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-C 5-10 aryl, -5-10 membered heteroaryl, -5-10 membered heterocyclyl, -C 1-3 alkylene-N (C 1-3 alkyl) 2 , -C 1-3 alkylene-O-C 1-3 alkyl, -C 1-3 alkylene-CO-NH-C 1-3 alkyl, -C 1-3 alkylene-CO-5-10 membered heterocyclyl, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl and C 3-6 cycloalkyl-C 5-10 aryl; each of
- R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C 1-3 alkyl, -C 1-3 alkylene-SH, -C 1-3 alkylene-C 2-3 alkenyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 3-6 cycloalkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-CONH 2 , -C 1-3 alkylene-Se-C 1-3 alkyl, -C 1-3 alkylene-SH, -C 1-3 alkylene-SO 2 -C 1-3 alkyl, -C 1-3 alkylene-CO 2 -C 1-3 alkyl, C 5-10 aryl, -C 1-3 alkylene-C 5-10 aryl, -C 1-3 alkylene-5-10 membered heteroaryl, -C 1-3 alkylene-5-10 membered heterocyclyl,
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, vinyl, allyl, ethyne, propyne, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, -CH 2 -COO-CH 3 , - (CH 2 ) 2 -COO-CH 3 , - (CH 2 ) 3 -COO-CH 3 , -CH 2 -COO-CH 2 CH 3 , - (CH 2 ) 2 -COO-CH 2 CH 3 , - (CH 2 ) 2 -COO-CH 2 CH 3 , - (CH 2 ) 3 -COO-CH 2 CH 3 , - (CH 2 ) 3 -COO-CH 2 CH 3 , -CH 2 -COO-CH 2 CH 3 ,
- R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, -CO-CH 3 , -SO-CH 3 , -SO 2 -CH 3 , -NH-CO-CH 3 , and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; or
- R 1 and R 1 ’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, tert-butyl,
- R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium methyl, ethyl, propyl, isopropyl, tert-butyl,
- a pharmaceutical composition comprising the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention; and a pharmaceutically acceptable carrier, diluent or excipient.
- a method of treating a subject having a cancer comprising administering to the subject a therapeutically effective amount of the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention; or the pharmaceutical composition of the present invention.
- the presently disclosed subject matter provides the use of a compound of the present invention, or a pharmaceutical composition thereof, for treating a disease or condition.
- the disease or condition is selected from the group consisting of an infection, cancer, an autoimmune disease, an inflammatory disease, and a neurodegenerative or neurological disease.
- a "cancer” in a patient refers to the presence of cells possessing characteristics typical of cancer-causing cells, for example, uncontrolled proliferation, loss of specialized functions, immortality, significant metastatic potential, significant increase in anti-apoptotic activity, rapid growth and proliferation rate, and certain characteristic morphology and cellular markers.
- cancer cells will be in the form of a tumor; such cells may exist locally within an animal, or circulate in the blood stream as independent cells, for example, leukemic cells.
- a “tumor, " as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues.
- a "solid tumor, " as used herein, is an abnormal mass of tissue that generally does not contain cysts or liquid areas.
- a solid tumor may be in the brain, colon, breasts, prostate, liver, kidneys, lungs, esophagus, head and neck, ovaries, cervix, stomach, colon, rectum, bladder, uterus, testes, and pancreas, as non-limiting examples.
- the solid tumor regresses or its growth is slowed or arrested after the solid tumor is treated with the presently disclosed methods.
- the solid tumor is malignant.
- the cancer comprises Stage 0 cancer.
- the cancer comprises Stage I cancer.
- the cancer comprises Stage II cancer.
- the cancer comprises Stage III cancer. In some embodiments, the cancer comprises Stage IV cancer. In some embodiments, the cancer is refractory and/or metastatic. For example, the cancer may be refractory to treatment with radiotherapy, chemotherapy or monotreatment with immunotherapy.
- Cancer as used herein includes newly diagnosed or recurrent cancers, including without limitation, acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, breast carcinoma, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, colorectal carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, head and neck squamous cell carcinoma, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung carcinoma, Lewis lung carcinoma, lymphoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premen
- the cancer is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, colon cancer, leukemia, glioblastoma or head and neck cancer.
- provided here is use of the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention; or the pharmaceutical composition of the present invention for the manufacture of a medicament for the treatment of a cancer.
- the cancer is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, colon cancer, leukemia, glioblastoma or head and neck cancer.
- the medicament is used as a glutamine antagonist.
- glutamine antagonist refers to a glutamine analog that interfers with a glutamine metabolic pathway, e.g., the inhibition or blocking of a metabolic pathway downstream of glutamine in which glutamine acts as a precursor of one or more non-glutamine compounds.
- glutamine metabolic pathway e.g., the inhibition or blocking of a metabolic pathway downstream of glutamine in which glutamine acts as a precursor of one or more non-glutamine compounds.
- Examples of such metabolic pathways are well known (see, e.g., Hensley et al, "Glutamine and cancer: cell biology, physiology, and clinical opportunities” J Clin Invest. 2013; 123 (9) : 3678-3684; DeBerardinis et al, "Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer” Oncogene.
- glutamine antagonist also includes glutamine analogs that inhibit glutamine uptake by cells, thereby reducing its biological activity. Diseases or conditions wherein excess and/or aberrant glutamine.
- the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention for use in treating the disease or condition.
- the disease or condition is selected from the group consisting of an infection, cancer, an autoimmune disease, an inflammatory disease, and a neurodegenerative or neurological disease.
- provided here is the compound, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention; or the pharmaceutical composition of the present invention for use in therapy.
- provided here is the compound, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention; or the pharmaceutical composition of the present invention for use as a medicament.
- the compound, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention for use in treating the disease or condition.
- the disease or condition is selected from the group consisting of an infection, cancer, an autoimmune disease, an inflammatory disease, and a neurodegenerative or neurological disease.
- the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention or the pharmaceutical composition of the present invention for use in the treatment of a cancer.
- the cancer is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, colon cancer, leukemia, glioblastoma or head and neck cancer.
- FIG. 1 is a graph showing the concentrations of DON and reference compound over time after IV infusion.
- FIG. 2 is a graph showing the concentrations of DON and compound 2 over time after IV infusion.
- FIG. 3 is a graph showing the concentrations of DON and compound 1 over time after IV infusion.
- FIG. 4 is a bar graph showing the stability of compounds after incubation for 60 minutes in the presence of human microsomes.
- FIG. 5 is a bar graph showing the stability of compounds after incubation for 60 minutes in the presence of human microsomes.
- FIG. 6 is a graph showing the body weight changes of the mice in the different groups.
- FIG. 7 is a graph showing anti-tumor activity of test compounds in MC38 syngeneic model.
- halogen or “halo” , as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo.
- the preferred halogen groups include -F, -Cl and -Br.
- alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched.
- alkyl radicals include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl.
- C 1-6 as in C 1-6 alkyl is defined to identify the group as having 1, 2, 3, 4, 5 or 6 carbon atoms in a linear or branched arrangement.
- alkylene means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above.
- methylene i.e., -CH 2 -
- ethylene i.e., -CH 2 -CH 2 -or -CH (CH 3 ) -
- propylene i.e., -CH 2 -CH 2 -CH 2 -, -CH (-CH 2 -CH 3 ) -or -CH 2 -CH (CH 3 ) -
- alkenyl means a straight or branch-chained hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms in length.
- C 2-6 alkenyl contains from 2 to 6 carbon atoms.
- Alkenyl group include, but are not limited to, for example, ethenyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, hepetenyl, octenyl and the like.
- alkynyl contains a straight or branch-chained hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms in length.
- C 2-6 alkynyl contains from 2 to 6 carbon atoms.
- Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
- alkoxy radicals are oxygen ethers formed from the previously described alkyl groups.
- aryl refers to an unsubstituted or substituted mono or polycyclic aromatic ring system containing carbon ring atoms.
- the preferred aryls are mono cyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls.
- heterocyclyl refers to unsubstituted and substituted mono or polycyclic non-aromatic ring system containing one or more heteroatoms, which comprising moncyclic heterocyclyl, bicyclic heterocyclyl, bridged heterocyclyl, fused heterocyclyl or sipro heterocyclyl.
- Preferred heteroatoms include N, O, and S, including N-oxides, sulfur oxides, and dioxides.
- the ring is three to ten membered and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, preferably one, two or three, are included within the present definition.
- heterocyclic groups include, but are not limited to azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone and oxadiazolyl.
- heteroaryl represents an aromatic ring system containing carbon (s) and at least one heteroatom.
- Heteroaryl may be monocyclic or polycyclic, substituted or unsubstituted.
- a monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms.
- a polycyclic heteroaryl ring may contain fused, spiro or bridged ring junction, for example, bycyclic heteroaryl is a polycyclic heteroaryl.
- Bicyclic heteroaryl rings may contain from 8 to 12 member atoms.
- Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (cabons and heteroatoms) .
- heteroaryl groups include, but are not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adeninyl, quinolinyl or isoquinolinyl.
- cycloalkyl refers to a substituted or unsubstituted monocyclic ring, bicyclic ring bridged ring, fused ring, sipiro ring non-aromatic ring system onle containing carbon atoms.
- Examplary “cycloalkyl” groups includes but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and so on.
- carbocycle refers to a substituted or unsubstituted monocyclic ring, bicyclic ring bridged ring, fused ring, sipiro ring non-aromatic ring system only containing carbon atoms ( (i.e., C 3-14 ) .
- Non-limiting exemplary carbocycle groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, and cyclopentenyl, cyclohexenyl.
- the term "carbocycle" as used by itself or as part of another group means that the carbocycle as defined above substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino) alkyl, (carboxamido) alkyl, mercaptoalkyl, and (heter
- fused ring refers to a cyclic group formed by substituents on separate atoms in a straight or branched alkane, or to a cyclic group formed by substituents on separate atoms in another ring.
- spirocycle or "spirocyclic ring” refers to a pendant cyclic group formed by substituents on a single atom.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
- the compounds of the present invention may also be present in the form of pharmaceutically acceptable salt (s) .
- the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salt (s) " .
- the pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
- the pharmaceutically acceptable acidic/anionic salt generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid.
- organic or inorganic acids include hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic.
- Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.
- the present invention includes within its scope the prodrugs of the compounds of this invention.
- such prodrugs will be functional derivatives of the compounds that are readily converted in vivo into the required compound.
- the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs” , ed. H. Bundgaard, Elsevier, 1985.
- the present invention includes compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
- the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof.
- the present invention includes all stereoisomers of the compound and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.
- stereoisomer refers to an isomer in which atoms or groups of atoms in the molecule are connected to each other in the same order but differ in spatial arrangement, including conformational isomers and conformational isomers.
- the configuration isomers include geometric isomers and optical isomers, and optical isomers mainly include enantiomers and diastereomers.
- the invention includes all possible stereoisomers of the compound.
- the present invention is intended to include all isotopes of atoms occurring in the present compounds.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include deuterium and tritium.
- the isotopes of hydrogen can be denoted as 1 H (hydrogen) , 2 H (deuterium) and 3 H (tritium) . They are also commonly denoted as D for deuterium and T for tritium.
- CD 3 denotes a methyl group wherein all of the hydrogen atomsare deuterium.
- Isotopes of carbon include 13 C and 14 C.
- Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent.
- the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
- the present invention includes any possible solvates and polymorphic forms.
- a type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable.
- water, ethanol, propanol, acetone or the like can be used.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
- the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases.
- the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Since the compounds are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60%pure, more suitably at least 75%pure, especially at least 98%pure (%are on a weight for weight basis) .
- compositions of the present invention comprise a compound (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
- the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
- the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
- the compounds or a prodrug or a metabolite or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous) .
- the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
- compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion.
- the compound or a pharmaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
- the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
- the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
- compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt.
- the compounds or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
- the pharmaceutical carrier employed can be, for example, a solid, liquid or gas.
- solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
- liquid carriers are sugar syrup, peanut oil, olive oil, and water.
- gaseous carriers include carbon dioxide and nitrogen.
- oral liquid preparations such as suspensions, elixirs and solutions
- carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
- oral solid preparations such as powders, capsules and tablets.
- tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
- tablets may be coated by standard aqueous or nonaqueous techniques.
- a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
- Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
- a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 0.05 to about 95 percent of the total composition.
- Unit dosage forms will generally contain between from about 0.0lmg to about 2g of the active ingredient, typically 0.01mg, 0.02mg, 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg or l000mg.
- compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
- a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
- compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
- the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
- the final injectable form must be sterile and must be effectively fluid for easy syringability.
- the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
- compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound of this invention or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 0.05wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
- compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
- the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
- dosage levels on the order of from about 0.001mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions or alternatively about 0.05mg to about 7g per patient per day.
- inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS) may be effectively treated by the administration of from about 0.001 to 50mg of the compound per kilogram of body weight per day or alternatively about 0.05mg to about 3.5g per patient per day.
- Step a To a solution of (S) -2- (l2-azaneyl) butanoic acid (1023 mg, 9.9205 mmol) in acetic acid (10 mL) was added acetic anhydride (1769 mg, 17.3281 mmol) . The mixture was stirred for 2h at 100 °C. The reaction mixture was concentrated under reduced pressure. The residue was stirred in EA, then filtered and the solid was collected to afford (S) -2-acetamidobutanoic acid (628 mg, 4.3264 mmol) . MS: m/z 144 (M-H) -
- Step b To a solution of (S) -2-acetamidobutanoic acid (0.628 g, 4.3264 mmol) and methyl (S) -2-amino-6-diazo-5-oxohexanoate (498 mg, 2.6893 mmol) in DCM (5 mL) was added ethyl cyanoglyoxylate-2-oxime (624 mg, 4.3909 mmol) , N, N'-Diisopropylcarbodiimide (539 mg, 4.2710 mmol) and 2, 4, 6-Collidine (679 mg, 5.6033 mmol) at 0 °C. The mixture was stirred at RT for 1 h.
- Step c To a solution of methyl (S) -2- ( (S) -2-acetamidobutanamido) -6-diazo-5-oxohexanoate (1.269 g, 4.0631 mmol) in THF (10 mL) added LiOH (156.2 mg, 6.5224 mmol) in water (5 mL) at 0°C. The mixture was stirred for 1h at RT and the reaction mixture was purified by FLASH (MeCN/H2O, 0 ⁇ 10%) . The product’s solution was concentrated under reduced pressure and the residue was further purified by pre-HPLC.
- Step a To a solution of DL-Serine (1.64 g, 15.6054 mmol) , 5-Fluoroindole (1.01 g, 7.4738 mmol) was added acetic anhydride (5 mL) and acetic acid (20mL) under N 2 protection. The mixture was stirred at 80 °C for 3 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC. The product’s solution was concentrated under reduced pressure to afford 2-acetamido-3- (5-fluoro-1H-indol-3-yl) propanoic acid (2044 mg, 7.7350 mmol) . MS: m/z 265 (M+H) + ,
- Step a To a solution of Nalpha-Fmoc-L-Tryptophan (1348 mg, 3.161 mmol) , isopropyl (S) -2-amino-6-diazo-5-oxohexanoate (452 mg, 2.120 mmol) and 4-Methylmorpholine (666 mg, 6.584 mmol) in DMF (10 mL) was added HATU (1226 mg, 3.224 mmol) at 0°C. The mixture was stirred for 3h at 0 °C ⁇ RT, then to the mixture was added water (10 mL) and DCM (10 mL) . The reaction mixture was filtered and the organic phase was collected.
- Step b To a solution of isopropyl (S) -2- ( (S) -2- ( ( ( (9H-fluoren-9-yl) methoxy) carbonyl) amino) -3- (1H-indol-3-yl) propanamido) -6-diazo-5-ox ohexanoate (469 mg, 754.406 ⁇ mol) in DCM (50 mL) was added piperidine (224 mg, 2.631 mmol) at 0 °C. The mixture was stirred for 6h at 0 °C ⁇ RT. The reaction mixture was concentrated under reduced pressure.
- Step c To a solution of isobutyric acid (0.0813 g, 922.765 ⁇ mol) , N, N'-Diisopropylcarbodiimide (0.1202 g, 952.464 ⁇ mol) 2, 4, 6-Collidine (0.1642 g, 1.355 mmol) and Ethyl cyanoglyoxylate-2-oxi (0.1876 g, 1.320 mmol) in DMF (5 mL) was added isopropyl (S) -2- ( (S) -2-amino-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoate (0.0938 g, 234.827 ⁇ mol) at 0 °C.
- the mixture was stirred for 5 h at 0 °C ⁇ RT and to the mixture was added water (10 mL) and DCM (10 mL) , then the reaction mixture was filtered and the organic phase was collected. The aqueous solution was extracted with DCM (10 mL ⁇ 2) and the organic phase was combined. The combined organic phase washed with brine (10 mL ⁇ 3) and dried over anhydrous Na 2 SO 4 . The resulting mixture was concentrated under reduced pressure.
- Step d To a solution of
- Step b To a 0°C solution of methyl (S) -2-hydroxy-3- (1H-indol-3-yl) propanoate (0.283g, 1.291 mmol) in DCM (3 mL) was added TEA (498 mg, 4.921 mmol) , then 4-methylbenzenesulfonyl chloride was added dropwise. The mixture was stirred for 1 h at this temperature and the reaction mixture was quenched with NaHCO 3 (aq) (10 mL) . The aqueous layer was separated and extracted with DCM (2 ⁇ 10 mL) .
- Step c To a 0°C solution of ethanethiol (327 mg, 5.263 mmol) and MeONa (286 mg, 5.294 mmol) in MeOH (3 mL) under nitrogen atmosphere was added methyl (S) -3- (1H-indol-3-yl) -2- (tosyloxy) propanoate (482. mg, 1.291 mmol) in MeOH (2 mL) dropwise. Then the resulting solution was stirred for 2 hours at room temperature. HCl (4M solution in EA, 3 mL) was added, the solid was filtered through a pad of Celite followed by MeOH washing and the filtrate was concentrated under reduced pressure.
- Step d To a solution of methyl (R) -2- (ethylthio) -3- (1H-indol-3-yl) propanoate (125 mg, 474.644 ⁇ mol) in THF (2 mL) was added LiOH (2M solution in water, 1 mL) . The mixture was stirred for 2 h at room temperature. After citric acid (solid) was added, the reaction was diluted with water (5mL) and extracted with EA (2 ⁇ 10 mL) .
- Step a To a solution of methyl (S) -2-hydroxy-3- (1H-indol-3-yl) propanoate (2 g, 9.123 mmol) in DCM (20 mL) was added Imidazole (2061 mg, 30.274 mmol) and TBDMS-Cl (2980 mg, 19.772 mmol) . The mixture was stirred for overnight at RT. The reaction mixture was quenched with Water (10 mL) and extracted with DCM (10 mL) . The reaction mixture was separated and organic extracts were collected. The aqueous solution was extracted with DCM (2 ⁇ 10 mL) . The residue was purified by wet column chromatography with EA/Hex (0-20%) .
- Step b To a -78°C solution of methyl (S) -2- ( (tert-butyldimethylsilyl) oxy) -3- (1H-indol-3-yl) propanoate (3.099g, 9.292 mmol) in THF (30 mL) was added LiHMDS (10.5 mL, 10.491 mmol) . The mixture was stirred for 30min at -78°C. Then Carbobenzyloxy chloride (4623 mg, 27.100 mmol) was dropped into the mixture at -78°C. The reaction mixture was stirred for 1h at this temperature. The reaction was quenched with sat.
- Step c To a solution of benzyl (S) -3- (2- ( (tert-butyldimethylsilyl) oxy) -3-methoxy-3-oxopropyl) -1H-indole-1-carboxylate (4.345 g, 9.292 mmol) in THF (30 mL) was added Tetrabutylammonium fluoride (5 mL) . The mixture was stirred for overnight at RT. The reaction mixture was concentrated under reduced pressure. The residue was purified by FLASH with EA/Hex (0-60%) . The product’s solution was concentrated under reduced pressure.
- Step d To a solution of benzyl 3- [ (2S) -2-hydroxy-3-methoxy-3-oxo-propyl] indole-1-carboxylate (103 mg, 291.481 ⁇ mol) , and 4A molecular sieve in CH 3 I (1mL) was added Silver oxide (216 mg, 932.098 ⁇ mol) . The mixture was stirred for overnight at RT. The reaction mixture was concentrated under reduced pressure. The reaction mixture was diluted with EA (5mL) and filtered, the filtrate was concentrated to afford benzyl (S) -3- (2, 3-dimethoxy-3-oxopropyl) -1H-indole-1-carboxylate (107.088 mg, 100.000%yield) . MS: m/z 368 (M+H) + .
- Step e To a solution of benzyl (S) -3- (2, 3-dimethoxy-3-oxopropyl) -1H-indole-1-carboxylate (0.107g, 291.240 ⁇ mol) in THF (5 mL) and MeOH (5mL) was added NaOH (3mL, 3M/L) . The mixture was stirred for 1h at RT. The reaction mixture was adjusted the pH to 3 with 1M HCl. The aqueous solution was extracted with EA (2 ⁇ 10 mL) . The combined organic extracts were washed with brine (3 ⁇ 10 mL) , dried over anhydrous Na 2 SO 4 . The organic phase was concentrated under reduced pressure and (S) -3- (1H-indol-3-yl) -2-methoxypropanoic acid (71 mg) was obtained. MS: m/z 220 (M+H) + .
- Ethyl cyanoglyoxylate-2-oxime (0.1079 g, 759.2576 ⁇ mol) and Glycine methyl ester hydrochloride (0.1582 g, 1.2600mmol) at 0 °C.
- the mixture was stirred at 0 °C ⁇ RT for 3h.
- the aqueous solution was extracted with DCM (10 mL ⁇ 2) .
- the combined organic extracts were washed with brine (10 mL ⁇ 3) and dried over anhydrous Na 2 SO 4 .
- the reaction mixture was purified by FLASH.
- the residue was further purified by pre-HPLC.
- Step b To a solution of 2-acetamido-3- (7-fluoro-1H-indol-3-yl) propanoic acid (0.122 g,461.681 ⁇ mol) , isopropyl (S) -2-amino-6-diazo-5-oxohexanoate (101 mg, 473.660 ⁇ mol) and DIPEA (164 mg, 1.269 mmol) in DCM was added HATU (182 mg, 478.659 ⁇ mol) . The mixture was stirred at RT for one night. The reaction mixture was concentrated under reduced pressure.
- the dog pharmacokinetic study was conducted in accordance with the guidelines recommended in Guide for the Care and Use of Laboratory Animals and approved by the Beijing Piroma Biotech Inc.
- Blood sample were collected at 0min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 24h, post dose, in tubes with EDTA-K2. Blood samples were centrifuged at a temperature of 4 °C at 3000g for 10 min. All samples were kept chilled throughout processing. Plasma samples were collected in polypropylene tubes and stored at -80 °C until bioanalysis.
- plasma samples 50 ⁇ L were processed using a single liquid extraction method by addition of 200 ⁇ L of acetonitrile containing internal standard (Dexamethasone 100 ng/mL) , followed by vortex-mixing for 30 s and then centrifugation at 15000g for 5 min at 4 °C. 100 ⁇ L of the supernatant was diluted with 100 ⁇ L of water and transferred to a 250 ⁇ L polypropylene vial sealed with a Teflon cap. Prodrug and DON disappearance was monitored over time using a liquid chromatography and tandem mass spectrometry (LC-MS/MS) .
- LC-MS/MS liquid chromatography and tandem mass spectrometry
- DON was analyzed on an ExionLC system coupled with a REF Triple Quad 5500+ mass spectrometer. Separation was achieved at 25 °C using an HALO Penta-HILIC 2.7 ⁇ M 90A (2.1x100 mm) .
- the mass spectrometer controlled by Analyst software 1.6.3 was operated with a heated ESI ionsource in positive ionization mode.
- FIG. 1 is a graph showing the concentrations of DON and reference compound over time after IV infusion (intravenous infusion) .
- FIG. 2 is a graph showing the concentrations of DON and compound 2 over time after IV infusion.
- FIG. 3 is a graph showing the concentrations of DON and compound 1 over time after IV infusion. The pharmacokinetic data was shown in the following Table 1.
- Reference compound, reference compound 1, compound 494, compound 495, compound 499, compound 501, compound 527 and compound 530 were provided for metabolic stability in human plasma and microsomes, and they were shown as below:
- Reference compound reference compound 1, compound 494, compound 495, compound 499, compound 501, compound 527 and compound 530 (the concentration of the each compound was 1 ⁇ M) were spiked in each microsomes matrix and incubated in an orbital shaker at 37 °C respectively.
- 50 ⁇ L aliquots of the mixture in duplicate were obtained, and 200 ⁇ L of ice cold acetonitrile spiked with the internal standard (Dexamethasone 100 ng/mL) was added into the obtained mixture to quench the reaction of the obtained mixture.
- the samples were vortexed for 30 s and centrifuged at 15000g for 5 min.
- FIG. 4 and FIG. 5 is a bar graph showing the stability of compounds after incubation for 60 minutes in the presence of human microsomes.
- the MC38 tumor cells were maintained in vitro in DMEM medium supplemented with 10%FBS at 37 °C, 5%CO 2 .
- the cells growing in an exponential growth phase were harvested and counted for tumor inoculation.
- the culture MC38 were harvested, re-suspended in PBS containing 50%Matrigel at a density of 1 ⁇ 10 7 cells/mL.
- Each mouse was inoculated subcutaneously in the right flank region with 1 ⁇ 10 6 cells in 0.1 mL of PBS containing 50%Matrigel for tumor development.
- the treatments were started when the mean tumor size reached 46-132mm 3 (average tumor size 95 mm 3 ) .
- Each group contained 5 tumor bearing mice.
- Group 1 was treated with Vehicle (10%DMSO + 90%Saline) , S.C., QD (Subcutaneous injection, quaque die) .
- Group 2 was given treatments with reference compound at 2 ⁇ mol/kg, S.C., QD.
- Group 3 was given treatments with compound 35 at 2 ⁇ mol/kg, S.C., QD.
- Group 4 was given treatments with compound 3 at 2 ⁇ mol/kg, S.C., QD.
- Table 2 was treated with Vehicle (10%DMSO + 90%Saline) , S.C., QD (Subcutaneous injection, quaque die) .
- Group 3 was given treatments with compound 35 at 2 ⁇ mol/kg, S.C., QD.
- Group 4 was given treatments with compound 3 at 2 ⁇ mol/kg, S.C., QD.
- Table 2 was given treatments with compound
- TGI tumor growth inhibition
- Group treated with reference compound showed some body weight loss, but the group treated with vehicle, the group treated with compound 505 and the group treated with compound 474 were well-tolerated by the tumor-bearing mice.
- the results of the body weight changes in the tumor-bearing mice are shown in Table 3, FIG. 6.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Glutamine analogs are provided, a composition containing the glutamine analogs and the use thereof.
Description
Cross Reference To Related Applications
The application claims the benefit of PCT application Ser. No. PCT/CN2020/121114 filed on Oct. 15, 2020; PCT application Ser. No. PCT/CN2021/072115 and PCT/CN2021/072122 filed on Jan. 15, 2021; and PCT application Ser. No. PCT/CN2021/076480 and PCT/CN2021/076483 filed on Feb. 10, 2021. The entire contents of these applications are incorporated herein by reference in their entirety.
The invention relates to a novel glutamine analogs, a composition containing the glutamine analogs and the use thereof.
Background Art
Glutamine analogs, such as 6-diazo-5-oxo-L-norleucine (DON) have been shown to exhibit anti-cancer activities. However, the occurrence of severe toxicity (e.g., dose limiting GI toxicities, such as oral mucositis, gastric bleeding, nausea and vomiting, and abdominal pain) has hampered their clinical development when administering such glutamine antagonists at therapeutic dose levels.
Prior attempts to mitigate the severe toxicity associated with glutamine antagonists such as DON, have been unsuccessful. Therefore, it’s needed to develop novel glutamine antagonists to meet the clinical needs.
Summary of Invention
In one aspect, provided here is a compound of formula I, and a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotope substitutant thereof:
Wherein,
Z is (OR
1)
1-2, (C (R
1)
2)
1-6, (N (R
1) )
1-2 R
1’, or (SR
1)
1-2;
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -NH
2, -CN, -OH, -C
1-6 alkyl, -C
2-6 alkenyl, C
2-6 alkynyl, -C
5-12 aryl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkylene-5-12 membered aryl, -C
0-6 alkylene-C
5-12 aryl, -C
0-6 alkylene -5-12 membered heteroaryl, -C
0-6 alkylene-5-12 membered heterocyclyl, -C
1-6 alkylene-N (C
1-6 alkyl)
2, -C
1-6 alkylene-O-C
1-6 alkyl, -C
1-6 alkylene-CO-NH-C
1-6 alkyl, -C
1-6 alkylene-CO-5-12 membered heterocyclyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-SH, and C
3-8 cycloalkyl-C
5-12 aryl, and each of which can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6alkylene-5-12 membered aryl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6alkyl, -C
1-6alkylene-COO-C
1-6alkyl, -C
1-6 alkylene-SO
2-C
1-6alkyl, -C
1-6alkylene-SO-C
1-6alkyl, -C
1-6alkylene-SH, -C
1-6alkylene-S-C
1-6alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl; or
R
1 and R
1’ together with the nitrogen atom to which they are both attached form 4-8 membered heterocyclyl, and wherein said 4-8 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO
2, and said 4-8 membered heterocyclyl can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
X is selected from the group consisting of hydrogen, deuterium, C
1-6 alkyl, –C (=O) -G, –C (=O) -W- (CR
X1R
X2)
m-G, –C (=O) -W- (CR
X1R
X2)
m-NR
5R
5’, –C (=O) -W- (CR
X1R
X2)
m-OR
11, –C (=O) -W- (CR
X1R
X2)
m-SR
11, , C (=O) -W- (CR
X1R
X2)
m-SOR
11, C (=O) -W- (CR
X1R
X2)
m-SO
2R
11, -P (=O) (OR
6)
p (NHR
7)
q, -P (=O) (OG)
p, –C (=O) -W- (CR
X1R
X2)
m-G-O-C (=O) -R
8, –C (=O) -W- (CR
X1R
X2)
m-G-O-R
8, –C (=O) -O- (CR
X1R
X2)
m-O-C (=O) -R
9, -C (=O) -O-R
7, –C (=O) -W- (CR
X1R
X2)
m-G-O-C (=O) -G, and –C (=O) -W- (CR
X1R
X2)
m-G-NR
5R
5’;
W is oxygen, CO or a bond;
m is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
p and q are each independently selected from 0, 1 or 2, provided that the sum of p and q is 2;
R
X1 and R
X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C
1-6 alkyl, -C
1-6 alkylene-SH, -C
1-6 alkylene-C
2-6 alkenyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
3-8 cycloalkyl, -C
1-6alkylene-S-C
1-6alkyl, -C
1-6 alkylene-CONH
2,
-C
1-6 alkylene-Se-C
1-6 alkyl, -C
1-6alkylene-SH, -C
1-6alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-CO
2-C
1-6 alkyl, C
5-12aryl, -C
1-6 alkylene-C
5-12 aryl, -C
1-6 alkylene-5-12 membered heteroaryl, -C
1-6 alkylene-5-12 membered heterocyclyl, and 5-12 membered heteroaryl, and wherein said C
1-6 alkyl, said -C
1-6 alkylene-SH, said -C
1-6 alkylene-C
2-6 alkenyl, said -C
3-8 cycloalkyl, said -C
1-6 alkylene-C
3-8 cycloalkyl, said -C
1-6 alkylene-S-C
1-6 alkyl, said -C
1-6 alkylene-CONH
2, said
said
said -C
1-6 alkylene-Se-C
1-6 alkyl, said -C
1-6 alkylene-SH, said -C
1-6 alkylene-SO
2-C
1-6 alkyl, said -C
1-6 alkylene-CO
2-C
1-6 alkyl, said C
5-12aryl, said -C
1-6 alkylene-C
5-12 aryl, said -C
1-6 alkylene-5-12 membered heteroaryl, said -C
1-6 alkylene-5-12 membered heterocyclyl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
or R
X1 and R
X2 together with the carbon atom to which they are attached form C
3-10 carbocyclic ring, C
5-10 aryl, C
5-10 heteroaryl, C
2-4 alkenyl, C
3-10 heterocyclyl, and wherein said C
3-10 carbocyclic ring, C
5-10 aryl, C
5-10 heteroaryl, C
2-4 alkenyl, C
3-10heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl; R
5 and R
5’ are each independently selected from the group consisting of hydrogen, deuterium, -C
1-6 alkyl, -C
3-8 cycloalkyl, -C (=O) -C
1-6 alkyl, -C (=O) -C
3-8 cycloalkyl, -C (=O) -5-12 membered heterocyclyl, -C (=O) -5-12 membered carbocyclic, -C (=O) -adamantanyl, -C (=O) -C
1-6 alkylene-O-C
1-6 alkyl, -C (=O) -C
1-6 alkylene-NH-C
1-6 alkyl, -C (=O) -C
1-6 alkylene-N (C
1-6 alkyl)
2, and wherein said -C
1-6 alkyl, said -C
3-8 cycloalkyl, said -C (=O) -C
1-6 alkyl, said -C (=O) -C
3-8 cycloalkyl, -C (=O) -5-12 membered heterocyclyl, -C (=O) -5-12 membered carbocyclic, -C (=O) -C
1-6 alkylene-O-C
1-6 alkyl, -C (=O) -C
1-6 alkylene-NH-C
1-6 alkyl, -C (=O) -C
1-6 alkylene-N (C
1-6 alkyl)
2, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted or unsubstituted with halogen and -C
1-6 haloalkyl;
or R
X1 and R
5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-12 membered heterocyclyl, and wherein said 5-12 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO
2, and said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted or unsubstituted with halogen and -C
1-6 haloalkyl;
each of R
6 is independently selected from the group consisting of hydrogen, deuterium, -C
1-6 alkyl, -C
3-8 cycloalkyl, 5-12 membered heterocyclyl, -C
2-6 alkenyl, and -C
3-8 cycloalkenyl, and wherein said -C
1-6 alkyl, said -C
3-8 cycloalkyl, said 5-12 membered heterocyclyl, said -C
1-6 alkenyl, and said -C
3-8 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted or unsubstituted with halogen and -C
1-6 haloalkyl;
or R
6 together with the oxygen atom to which it is attached forms a purine or pyrimidine nucleoside;
each of R
7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, C
3-8 cycloalkyl, 5-12 membered heterocyclyl, C
1-6 alkenyl, C
3-8 cycloalkenyl, C
5-12 aryl, and 5-12 membered heteroaryl, and wherein said C
1-6 alkyl, said C
3-8 cycloalkyl, said 5-12 membered heterocyclyl, said C
1-6 alkenyl, said C
3-8 cycloalkenyl, said C
5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted or unsubstituted with halogen and -C
1-6 haloalkyl;
R
8 and R
9 are each independently selected from the group consisting of C
1-6 alkyl, C
3-8 cycloalkyl, monosaccharide, acylated monosaccharide, C
5-12 aryl, and 5-12 membered heteroaryl, and wherein said C
1-6 alkyl, said C
3-8 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C
5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted or unsubstituted with halogen and -C
1-6 haloalkyl;
R
11 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted or unsubstituted with halogen and -C
1-6 haloalkyl;
G is C
5-12 aryl, or 5-12 membered heteroaryl, and wherein said C
5-12 aryl, and said 5-12 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
2 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
3 and R
3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
or R
3 and R
3’ together with the atom to which they attached to form
Y is a bond, oxygen, or - (CR
Y1R
Y2)
n-;
n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
R
Y1 and R
Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
4 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
10 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl.
In some embodiments, provided here is a compound of formula Ia or Ib, and a pharmaceutically acceptable salt thereof or a stereoisomer thereof
In some embodiments of formula I, Ia, or Ib, wherein
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C
1-6 alkyl, -C
2-6 alkenyl, C
2-6 alkynyl, -C
5-12 aryl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-C
5-12 aryl, -5-12 membered heteroaryl, -5-12 membered heterocyclyl, -C
1-6 alkylene-N (C
1-6 alkyl)
2, -C
1-6 alkylene-O-C
1-6 alkyl, -C
1-6 alkylene-CO-NH-C
1-6 alkyl, -C
1-6 alkylene-CO-5-12 membered heterocyclyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl and C
3-8 cycloalkyl-C
5-12 aryl, and wherein said -C
1-6 alkyl, said -C
1-6 alkenyl, said C
1-6 alkynyl, said -C
5-12 aryl, said -C
1-6 alkylene-COO-C
1-6 alkyl, said -C
1-6 alkylene-C
5-12 aryl, said -5-12 membered heteroaryl, said -5-12 membered heterocyclyl, said -C
1-6 alkylene-N (C
1-6 alkyl)
2, said -C
1-6 alkylene-O-C
1-6 alkyl, said -C
1-6 alkylene-CO-NH-C
1-6 alkyl, said -C
1-6 alkylene-CO-5-12 membered heterocyclyl, said -C
1-6 alkylene-SO
2-C
1-6 alkyl, said -C
1-6 alkylene-SO-C
1-6 alkyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl; or
R
1 and R
1’ together with the nitrogen atom to which they are both attached form 4-8 membered heterocyclic ring, and wherein said 4-8 membered heterocyclic ring can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO
2, and said 4-8 membered heterocyclic ring can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
X is selected from the group consisting of hydrogen, deuterium, C
1-6 alkyl, –C (=O) -G, –C (=O) -W- (CR
X1R
X2)
m-G, –C (=O) -W- (CR
X1R
X2)
m-NR
5R
5’, C (=O) -W- (CR
X1R
X2)
m-SR
11, , C (=O) -W- (CR
X1R
X2)
m-SOR
11, C (=O) -W- (CR
X1R
X2)
m-SO
2R
11, –C (=O) -W- (CR
X1R
X2)
m-OR
11, -P (=O) (OR
6)
p (NHR
7)
q, –C (=O) -W- (CR
X1R
X2)
m-G-O-C (=O) -R
8, –C (=O) -W- (CR
X1R
X2)
m-G-O-R
8, –C (=O) -O- (CR
X1R
X2)
m-O-C (=O) -R
9, -C (=O) -O-R
7, –C (=O) -W- (CR
X1R
X2)
m-G-O-C (=O) -G, and –C (=O) -W- (CR
X1R
X2)
m-G-NR
5R
5’;
W is oxygen or a bond;
m is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
p and q are each independently selected from 0, 1 or 2, provided that the sum of p and q is 2;
R
X1 and R
X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C
1-6 alkyl, -C
1-6 alkylene-SH, -C
1-6 alkylene-C
2-6 alkenyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
3-8 cycloalkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-CONH
2,
-C
1-6 alkylene-Se-C
1-6 alkyl, -C
1-6 alkylene-SH, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-CO
2-C
1-6 alkyl, C
5-12aryl, -C
1-6 alkylene-C
5-12 aryl, -C
1-6 alkylene-5-12 membered heteroaryl, -C
1-6 alkylene-5-12 membered heterocyclyl, and 5-12 membered heteroaryl, and wherein said C
1-6 alkyl, said -C
1-6 alkylene-SH, said -C
1-6 alkylene-C
2-6 alkenyl, said -C
3-8 cycloalkyl, said -C
1-6 alkylene-C
3-8 cycloalkyl, said -C
1-6 alkylene-S-C
1-6 alkyl, said -C
1-6 alkylene-CONH
2, said
said
said -C
1-6 alkylene-Se-C
1-6 alkyl, said -C
1-6 alkylene-SH, said -C
1-6 alkylene-SO
2-C
1-6 alkyl, said -C
1-6 alkylene-CO
2-C
1-6 alkyl, said C
5-12aryl, said -C
1-6 alkylene-C
5-12 aryl, said -C
1-6 alkylene-5-12 membered heteroaryl, said -C
1-6 alkylene-5-12 membered heterocyclyl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
or R
X1 and R
X2 together with the carbon atom to which they are attached form 5-10 membered carbocyclic ring, C
3-8 cycloalkyl, C
2-4 alkenyl, 5-10 membered heterocyclic ring, and wherein said 5-10 membered carbocyclic ring, said C
2-4 alkenyl, said 5-10 membered heterocyclic ring can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl; R
5 and R
5’ are each independently selected from the group consisting of hydrogen, deuterium, -C
1-6 alkyl, -C
3-8 cycloalkyl, -C (=O) -C
1-6 alkyl, -C (=O) -C
5-10 carbocyclic, -C (=O) -adamantanyl, -C (=O) -C
3-8 cycloalkyl, and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
or R
X1 and R
5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-12 membered heterocyclic ring, and wherein said 5-12 membered heterocyclic ring can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO
2, and said 5-12 membered heterocyclic ring can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
each of R
6 is independently selected from the group consisting of hydrogen, deuterium, -C
1-6 alkyl, -C
3-8 cycloalkyl, 5-12 membered heterocyclyl ring, -C
1-6 alkenyl, and -C
3-8 cycloalkenyl, and wherein said -C
1-6 alkyl, said -C
3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said -C
1-6 alkenyl, and said -C
3-8 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
or R
6 together with the oxygen atom to which it is attached forms a purine or pyrimidine nucleoside;
each of R
7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, C
3-8 cycloalkyl, 5-12 membered heterocyclyl ring, C
1-6 alkenyl, C
3-8 cycloalkenyl, C
5-12 aryl, and 5-12 membered heteroaryl, and wherein said C
1-6 alkyl, said C
3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said C
1-6 alkenyl, said C
3-8 cycloalkenyl, said C
5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
8 and R
9 are each independently selected from the group consisting of C
1-6 alkyl, C
3-8 cycloalkyl, monosaccharide, acylated monosaccharide, C
5-12 aryl, and 5-12 membered heteroaryl, and wherein said C
1-6 alkyl, said C
3-8 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C
5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
11 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
G is C
5-12 aryl, or 5-12 membered heteroaryl, and wherein said C
5-12 aryl, and said 5-12 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
2 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
3 and R
3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
Y is a bond, oxygen, or - (CR
Y1R
Y2)
n-;
n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
R
Y1 and R
Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
4 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl; or
R
10 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-6 alkyl, and C
1-6 alkoxy, and wherein said C
1-6 alkyl, and said C
1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C
1-3 alkyl, -C
2-3 alkenyl, C
2-3 alkynyl, -C
5-10 aryl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-C
5-10 aryl, -5-10 membered heteroaryl, -5-10 membered heterocyclyl, -C
1-3 alkylene-N (C
1-3 alkyl)
2, -C
1-3 alkylene-O-C
1-3 alkyl, -C
1-3 alkylene-CO-NH-C
1-3 alkyl, -C
1-3 alkylene-CO-5-10 membered heterocyclyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl and C
3-6 cycloalkyl-C
5-10 aryl, and wherein said -C
1-3 alkyl, said -C
2-3 alkenyl, said C
2-3 alkynyl, said -C
5-10 aryl, said -C
1-3 alkylene-COO-C
1-3 alkyl, said -C
1-3 alkylene-C
5-10 aryl, said -5-10 membered heteroaryl, said -5-10 membered heterocyclyl, said -C
1-3 alkylene-N (C
1-3 alkyl)
2, said -C
1-3 alkylene-O-C
1-3 alkyl, said -C
1-3 alkylene-CO-NH-C
1-3 alkyl, said -C
1-3 alkylene-CO-5-10 membered heterocyclyl, said -C
1-3 alkylene-SO
2-C
1-3 alkyl, said C
3-6 cycloalkyl-C
5-10 aryl and said -C
1-3 alkylene-SO-C
1-3 alkyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl; or
R
1 and R
1’ together with the nitrogen atom to which they are both attached form 4-6 membered heterocyclyl, and wherein said 4-6 membered heterocyclyl can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO
2, and said 4-6 membered heterocyclyl can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C
1-3 alkyl, -C
2-3 alkenyl, C
2-3 alkynyl, -C
5-10 aryl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-C
5-10 aryl, -5-10 membered heteroaryl, -5-10 membered heterocyclyl, -C
1-3 alkylene-N (C
1-3 alkyl)
2, -C
1-3 alkylene-O-C
1-3 alkyl, -C
1-3 alkylene-CO-NH-C
1-3 alkyl, -C
1-3 alkylene-CO-5-10 membered heterocyclyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl and C
3-6 cycloalkyl-C
5-10 aryl, and wherein said -C
1-3 alkyl, said -C
2-3 alkenyl, said C
2-3 alkynyl, said -C
5-10 aryl, said -C
1-3 alkylene-COO-C
1-3 alkyl, said -C
1-3 alkylene-C
5-10 aryl, said -5-10 membered heteroaryl, said -5-10 membered heterocyclyl, said -C
1-3 alkylene-N (C
1-3 alkyl)
2, said -C
1-3 alkylene-O-C
1-3 alkyl, said -C
1-3 alkylene-CO-NH-C
1-3 alkyl, said -C
1-3 alkylene-CO-5-10 membered heterocyclyl, said -C
1-3 alkylene-SO
2-C
1-3 alkyl, said C
3-6 cycloalkyl-C
5-10 aryl and said -C
1-3 alkylene-SO-C
1-3 alkyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl; or
R
1 and R
1’ together with the nitrogen atom to which they are both attached form 4-6 membered heterocyclyl, and wherein said 4-6 membered heterocyclyl can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO
2, and said 4-6 membered heterocyclyl can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, vinyl, allyl, ethyne, propyne, C
5 aryl, C
6 aryl, C
7 aryl, C
8 aryl, C
9 aryl, C
10 aryl, -CH
2-COO-CH
3, - (CH
2)
2-COO-CH
3, - (CH
2)
3-COO-CH
3, -CH
2-COO-CH
2CH
3, - (CH
2)
2-COO-CH
2CH
3, - (CH
2)
3-COO-CH
2CH
3, -CH
2-COO-CH
2CH
2CH
3, - (CH
2)
2-COO-CH
2CH
2CH
3, - (CH
2)
3-COO-CH
2CH
2CH
3, -CH
2-COO-CH (CH
3)
2, - (CH
2)
2-COO-CH (CH
3)
2, - (CH
2)
3-COO-CH (CH
3)
2, -CH
2-C
5 aryl, -CH
2-C
6 aryl, - (CH
2)
2-C
6 aryl, - (CH
2)
3-C
6 aryl, -CH
2-C
7 aryl, - (CH
2)
2-C
7 aryl, - (CH
2)
3-C
7 aryl, -CH
2-C
8 aryl, - (CH
2)
2-C
8 aryl, - (CH
2)
3-C
8 aryl, -CH
2-C
9 aryl, - (CH
2)
2-C
9 aryl, - (CH
2)
3-C
9 aryl, -CH
2-C
10 aryl, - (CH
2)
2-C
10 aryl, - (CH
2)
3-C
10 aryl, -5 membered heteroaryl, -6 membered heteroaryl, -7 membered heteroaryl, -8 membered heteroaryl, -9 membered heteroaryl, -10 membered heteroaryl, -5 membered heterocyclyl, -6 membered heterocyclyl, -7 membered heterocyclyl, -8 membered heterocyclyl, -9 membered heterocyclyl, -10 membered heterocyclyl, -CH
2-N (CH
3)
2, - (CH
2)
2-N (CH
3)
2, - (CH
2)
3-N (CH
3)
2, -CH
2-N (CH
2CH
3)
2, - (CH
2)
2-N (CH
2CH
3)
2, - (CH
2)
3-N (CH
2CH
3)
2, -CH
2-N (CH
2CH
2CH
3)
2, - (CH
2)
2-N (CH
2CH
2CH
3)
2, - (CH
2)
3-N (CH
2CH
2CH
3)
2, -CH
2-N (CH (CH
3)
2)
2, - (CH
2)
2-N (CH (CH
3)
2)
2, - (CH
2)
3-N (CH (CH
3)
2)
2, -CH
2-O-CH
3, - (CH
2)
2-O-CH
3, - (CH
2)
3-O-CH
3, -CH
2-O-CH
2CH
3, - (CH
2)
2-O-CH
2CH
3, - (CH
2)
3-O-CH
2CH
3, -CH
2-O-CH
2CH
2CH
3, - (CH
2)
2-O-CH
2CH
2CH
3, - (CH
2)
3-O-CH
2CH
2CH
3, -CH
2-O-CH (CH
3)
2, - (CH
2)
2-O-CH (CH
3)
2, - (CH
2)
3-O-CH (CH
3)
2, -CH
2-CO-NH-CH
3, - (CH
2)
2-CO-NH-CH
3, - (CH
2)
3-CO-NH-CH
3, -CH
2-CO-NH-CH
2CH
3, - (CH
2)
2-CO-NH-CH
2CH
3, - (CH
2)
3-CO-NH-CH
2CH
3, -CH
2-CO-NH-CH
2CH
2CH
3, - (CH
2)
2-CO-NH-CH
2CH
2CH
3, - (CH
2)
3-CO-NH-CH
2CH
2CH
3, -CH
2-CO-NH-CH (CH
3)
2, - (CH
2)
2-CO-NH-CH (CH
3)
2, - (CH
2)
3-CO-NH-CH (CH
3)
2, -CH
2-CO-5 membered heterocyclyl, - (CH
2)
2-CO-5 membered heterocyclyl, - (CH
2)
3-CO-5 membered heterocyclyl, -CH
2-CO-6 membered heterocyclyl, - (CH
2)
2-CO-6 membered heterocyclyl, - (CH
2)
3-CO-6 membered heterocyclyl, -CH
2-CO-7 membered heterocyclyl, - (CH
2)
2-CO-7 membered heterocyclyl, - (CH
2)
3-CO-7 membered heterocyclyl, -CH
2-CO-8 membered heterocyclyl, - (CH
2)
2-CO-8 membered heterocyclyl, - (CH
2)
3-CO-8 membered heterocyclyl, -CH
2-CO-9 membered heterocyclyl, - (CH
2)
2-CO-9 membered heterocyclyl, - (CH
2)
3-CO-9 membered heterocyclyl, -CH
2-CO-10 membered heterocyclyl, - (CH
2)
2-CO-10 membered heterocyclyl, - (CH
2)
3-CO-10 membered heterocyclyl, -CH
2-SO
2-CH
3, - (CH
2)
2-SO
2-CH
3, - (CH
2)
3-SO
2-CH
3, -CH
2-SO
2-CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
3, -CH
2-SO
2-CH
2CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
2CH
3, -CH
2-SO
2-CH (CH
3)
2, - (CH
2)
2-SO
2-CH (CH
3)
2, - (CH
2)
3-SO
2-CH (CH
3)
2, -CH
2-SO-CH
3, - (CH
2)
2-SO-CH
3, - (CH
2)
3-SO-CH
3, -CH
2-SO-CH
2CH
3, - (CH
2)
2-SO-CH
2CH
3, - (CH
2)
3-SO-CH
2CH
3, -CH
2-SO-CH
2CH
2CH
3, - (CH
2)
2-SO-CH
2CH
2CH
3, - (CH
2)
3-SO-CH
2CH
2CH
3, -CH
2-SO-CH (CH
3)
2, - (CH
2)
2-SO-CH (CH
3)
2, and - (CH
2)
3-SO-CH (CH
3)
2, -C
3 cycloalkyl-C
5 aryl, -C
4 cycloalkyl-C
5 aryl, -C
5 cycloalkyl-C
5 aryl, -C
6 cycloalkyl-C
5 aryl, -C
3 cycloalkyl-C
6 aryl, -C
4 cycloalkyl-C
6 aryl, -C
5 cycloalkyl-C
6 aryl, -C
6 cycloalkyl-C
6 aryl, -C
3 cycloalkyl-C
7 aryl, -C
4 cycloalkyl-C
7 aryl, -C
5 cycloalkyl-C
7 aryl, -C
6 cycloalkyl-C
7 aryl, -C
3 cycloalkyl-C
8 aryl, -C
4 cycloalkyl-C
8 aryl, -C
5 cycloalkyl-C
8 aryl, -C
6 cycloalkyl-C
8 aryl, -C
3 cycloalkyl-C
9 aryl, -C
4 cycloalkyl-C
9 aryl, -C
5 cycloalkyl-C
9 aryl, -C
6 cycloalkyl-C
9 aryl, -C
3 cycloalkyl-C
10 aryl, -C
4 cycloalkyl-C
10 aryl, -C
5 cycloalkyl-C
10 aryl, -C
6 cycloalkyl-C
10 aryl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said vinyl, said allyl, said ethyne, said propyne, said C
5 aryl, C
6 aryl, said C
7 aryl, said C
8 aryl, said C
9 aryl, said C
10 aryl, said -CH
2-COO-CH
3, said - (CH
2)
2-COO-CH
3, said - (CH
2)
3-COO-CH
3, said -CH
2-COO-CH
2CH
3, said - (CH
2)
2-COO-CH
2CH
3, said - (CH
2)
3-COO-CH
2CH
3, said -CH
2-COO-CH
2CH
2CH
3, said - (CH
2)
2-COO-CH
2CH
2CH
3, said - (CH
2)
3-COO-CH
2CH
2CH
3, said -CH
2-COO-CH (CH
3)
2, said - (CH
2)
2-COO-CH (CH
3)
2, said - (CH
2)
3-COO-CH (CH
3)
2, said -CH
2-C
5 aryl, said -CH
2-C
6 aryl, said - (CH
2)
2-C
6 aryl, said - (CH
2)
3-C
6 aryl, said -CH
2-C
7 aryl, said - (CH
2)
2-C
7 aryl, said - (CH
2)
3-C
7 aryl, said -CH
2-C
8 aryl, said - (CH
2)
2-C
8 aryl, said - (CH
2)
3-C
8 aryl, said -CH
2-C
9 aryl, said - (CH
2)
2-C
9 aryl, said - (CH
2)
3-C
9 aryl, said -CH
2-C
10 aryl, said - (CH
2)
2-C
10 aryl, said - (CH
2)
3-C
10 aryl, said -5 membered heteroaryl, said -6 membered heteroaryl, said -7 membered heteroaryl, said -8 membered heteroaryl, said -9 membered heteroaryl, said -10 membered heteroaryl, said -5 membered heterocyclyl, said -6 membered heterocyclyl, said -7 membered heterocyclyl, said -8 membered heterocyclyl, said -9 membered heterocyclyl, said -10 membered heterocyclyl, said -CH
2-N (CH
3)
2, said - (CH
2)
2-N (CH
3)
2, said - (CH
2)
3-N (CH
3)
2, said -CH
2-N (CH
2CH
3)
2, said - (CH
2)
2-N (CH
2CH
3)
2, said - (CH
2)
3-N (CH
2CH
3)
2, said -CH
2-N (CH
2CH
2CH
3)
2, said - (CH
2)
2-N (CH
2CH
2CH
3)
2, said - (CH
2)
3-N (CH
2CH
2CH
3)
2, said -CH
2-N (CH (CH
3)
2)
2, said - (CH
2)
2-N (CH (CH
3)
2)
2, said - (CH
2)
3-N (CH (CH
3)
2)
2, said -CH
2-O-CH
3, said - (CH
2)
2-O-CH
3, said - (CH
2)
3-O-CH
3, said -CH
2-O-CH
2CH
3, said - (CH
2)
2-O-CH
2CH
3, said - (CH
2)
3-O-CH
2CH
3, said -CH
2-O-CH
2CH
2CH
3, said - (CH
2)
2-O-CH
2CH
2CH
3, said - (CH
2)
3-O-CH
2CH
2CH
3, said -CH
2-O-CH (CH
3)
2, said - (CH
2)
2-O-CH (CH
3)
2, said - (CH
2)
3-O-CH (CH
3)
2, said -CH
2-CO-NH-CH
3, said - (CH
2)
2-CO-NH-CH
3, said - (CH
2)
3-CO-NH-CH
3, said -CH
2-CO-NH-CH
2CH
3, said - (CH
2)
2-CO-NH-CH
2CH
3, said - (CH
2)
3-CO-NH-CH
2CH
3, said -CH
2-CO-NH-CH
2CH
2CH
3, said - (CH
2)
2-CO-NH-CH
2CH
2CH
3, said - (CH
2)
3-CO-NH-CH
2CH
2CH
3, said -CH
2-CO-NH-CH (CH
3)
2, said - (CH
2)
2-CO-NH-CH (CH
3)
2, said - (CH
2)
3-CO-NH-CH (CH
3)
2, said -CH
2-CO-5 membered heterocyclyl, said - (CH
2)
2-CO-5 membered heterocyclyl, said - (CH
2)
3-CO-5 membered heterocyclyl, said -CH
2-CO-6 membered heterocyclyl, said - (CH
2)
2-CO-6 membered heterocyclyl, said - (CH
2)
3-CO-6 membered heterocyclyl, said -CH
2-CO-7 membered heterocyclyl, said - (CH
2)
2-CO-7 membered heterocyclyl, said - (CH
2)
3-CO-7 membered heterocyclyl, said -CH
2-CO-8 membered heterocyclyl, said - (CH
2)
2-CO-8 membered heterocyclyl, said - (CH
2)
3-CO-8 membered heterocyclyl, said -CH
2-CO-9 membered heterocyclyl, said - (CH
2)
2-CO-9 membered heterocyclyl, said - (CH
2)
3-CO-9 membered heterocyclyl, said -CH
2-CO-10 membered heterocyclyl, said - (CH
2)
2-CO-10 membered heterocyclyl, said - (CH
2)
3-CO-10 membered heterocyclyl, said -CH
2-SO
2-CH
3, said - (CH
2)
2-SO
2-CH
3, said - (CH
2)
3-SO
2-CH
3, said -CH
2-SO
2-CH
2CH
3, said - (CH
2)
2-SO
2-CH
2CH
3, said - (CH
2)
3-SO
2-CH
2CH
3, said -CH
2-SO
2-CH
2CH
2CH
3, said - (CH
2)
2-SO
2-CH
2CH
2CH
3, said - (CH
2)
3-SO
2-CH
2CH
2CH
3, said -CH
2-SO
2-CH (CH
3)
2, said - (CH
2)
2-SO
2-CH (CH
3)
2, said - (CH
2)
3-SO
2-CH (CH
3)
2, said -CH
2-SO-CH
3, said - (CH
2)
2-SO-CH
3, said - (CH
2)
3-SO-CH
3, said -CH
2-SO-CH
2CH
3, said - (CH
2)
2-SO-CH
2CH
3, said - (CH
2)
3-SO-CH
2CH
3, said -CH
2-SO-CH
2CH
2CH
3, said - (CH
2)
2-SO-CH
2CH
2CH
3, said - (CH
2)
3-SO-CH
2CH
2CH
3, said -CH
2-SO-CH (CH
3)
2, said - (CH
2)
2-SO-CH (CH
3)
2, said -C
3 cycloalkyl-C
5 aryl, said -C
4 cycloalkyl-C
5 aryl, said -C
5 cycloalkyl-C
5 aryl, said -C
6 cycloalkyl-C
5 aryl, said -C
3 cycloalkyl-C
6 aryl, said -C
4 cycloalkyl-C
6 aryl, said -C
5 cycloalkyl-C
6 aryl, said -C
6 cycloalkyl-C
6 aryl, said -C
3 cycloalkyl-C
7 aryl, said -C
4 cycloalkyl-C
7 aryl, said -C
5 cycloalkyl-C
7 aryl, said -C
6 cycloalkyl-C
7 aryl, said -C
3 cycloalkyl-C
8 aryl, said -C
4 cycloalkyl-C
8 aryl, said -C
5 cycloalkyl-C
8 aryl, said -C
6 cycloalkyl-C
8 aryl, said -C
3 cycloalkyl-C
9 aryl, said -C
4 cycloalkyl-C
9 aryl, said -C
5 cycloalkyl-C
9 aryl, said -C
6 cycloalkyl-C
9 aryl, said -C
3 cycloalkyl-C
10 aryl, said -C
4 cycloalkyl-C
10 aryl, said -C
5 cycloalkyl-C
10 aryl, and said -C
6 cycloalkyl-C
10 aryl, and said - (CH
2)
3-SO-CH (CH
3)
2, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl; or
R
1 and R
1’ together with the nitrogen atom to which they are both attached form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO
2, and said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, vinyl, allyl, ethyne, propyne, C
5 aryl, C
6 aryl, C
7 aryl, C
8 aryl, C
9 aryl, C
10 aryl, -CH
2-COO-CH
3, - (CH
2)
2-COO-CH
3, - (CH
2)
3-COO-CH
3, -CH
2-COO-CH
2CH
3, - (CH
2)
2-COO-CH
2CH
3, - (CH
2)
3-COO-CH
2CH
3, -CH
2-COO-CH
2CH
2CH
3, - (CH
2)
2-COO-CH
2CH
2CH
3, - (CH
2)
3-COO-CH
2CH
2CH
3, -CH
2-COO-CH (CH
3)
2, - (CH
2)
2-COO-CH (CH
3)
2, - (CH
2)
3-COO-CH (CH
3)
2, -CH
2-C
5 aryl, -CH
2-C
6 aryl, - (CH
2)
2-C
6 aryl, - (CH
2)
3-C
6 aryl, -CH
2-C
7 aryl, - (CH
2)
2-C
7 aryl, - (CH
2)
3-C
7 aryl, -CH
2-C
8 aryl, - (CH
2)
2-C
8 aryl, - (CH
2)
3-C
8 aryl, -CH
2-C
9 aryl, - (CH
2)
2-C
9 aryl, - (CH
2)
3-C
9 aryl, -CH
2-C
10 aryl, - (CH
2)
2-C
10 aryl, - (CH
2)
3-C
10 aryl, -5 membered heteroaryl, -6 membered heteroaryl, -7 membered heteroaryl, -8 membered heteroaryl, -9 membered heteroaryl, -10 membered heteroaryl, -5 membered heterocyclyl, -6 membered heterocyclyl, -7 membered heterocyclyl, -8 membered heterocyclyl, -9 membered heterocyclyl, -10 membered heterocyclyl, -CH
2-N (CH
3)
2, - (CH
2)
2-N (CH
3)
2, - (CH
2)
3-N (CH
3)
2, -CH
2-N (CH
2CH
3)
2, - (CH
2)
2-N (CH
2CH
3)
2, - (CH
2)
3-N (CH
2CH
3)
2, -CH
2-N (CH
2CH
2CH
3)
2, - (CH
2)
2-N (CH
2CH
2CH
3)
2, - (CH
2)
3-N (CH
2CH
2CH
3)
2, -CH
2-N (CH (CH
3)
2)
2, - (CH
2)
2-N (CH (CH
3)
2)
2, - (CH
2)
3-N (CH (CH
3)
2)
2, -CH
2-O-CH
3, - (CH
2)
2-O-CH
3, - (CH
2)
3-O-CH
3, -CH
2-O-CH
2CH
3, - (CH
2)
2-O-CH
2CH
3, - (CH
2)
3-O-CH
2CH
3, -CH
2-O-CH
2CH
2CH
3, - (CH
2)
2-O-CH
2CH
2CH
3, - (CH
2)
3-O-CH
2CH
2CH
3, -CH
2-O-CH (CH
3)
2, - (CH
2)
2-O-CH (CH
3)
2, - (CH
2)
3-O-CH (CH
3)
2, -CH
2-CO-NH-CH
3, - (CH
2)
2-CO-NH-CH
3, - (CH
2)
3-CO-NH-CH
3, -CH
2-CO-NH-CH
2CH
3, - (CH
2)
2-CO-NH-CH
2CH
3, - (CH
2)
3-CO-NH-CH
2CH
3, -CH
2-CO-NH-CH
2CH
2CH
3, - (CH
2)
2-CO-NH-CH
2CH
2CH
3, - (CH
2)
3-CO-NH-CH
2CH
2CH
3, -CH
2-CO-NH-CH (CH
3)
2, - (CH
2)
2-CO-NH-CH (CH
3)
2, - (CH
2)
3-CO-NH-CH (CH
3)
2, -CH
2-CO-5 membered heterocyclyl, - (CH
2)
2-CO-5 membered heterocyclyl, - (CH
2)
3-CO-5 membered heterocyclyl, -CH
2-CO-6 membered heterocyclyl, - (CH
2)
2-CO-6 membered heterocyclyl, - (CH
2)
3-CO-6 membered heterocyclyl, -CH
2-CO-7 membered heterocyclyl, - (CH
2)
2-CO-7 membered heterocyclyl, - (CH
2)
3-CO-7 membered heterocyclyl, -CH
2-CO-8 membered heterocyclyl, - (CH
2)
2-CO-8 membered heterocyclyl, - (CH
2)
3-CO-8 membered heterocyclyl, -CH
2-CO-9 membered heterocyclyl, - (CH
2)
2-CO-9 membered heterocyclyl, - (CH
2)
3-CO-9 membered heterocyclyl, -CH
2-CO-10 membered heterocyclyl, - (CH
2)
2-CO-10 membered heterocyclyl, - (CH
2)
3-CO-10 membered heterocyclyl, -CH
2-SO
2-CH
3, - (CH
2)
2-SO
2-CH
3, - (CH
2)
3-SO
2-CH
3, -CH
2-SO
2-CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
3, -CH
2-SO
2-CH
2CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
2CH
3, -CH
2-SO
2-CH (CH
3)
2, - (CH
2)
2-SO
2-CH (CH
3)
2, - (CH
2)
3-SO
2-CH (CH
3)
2, -CH
2-SO-CH
3, - (CH
2)
2-SO-CH
3, - (CH
2)
3-SO-CH
3, -CH
2-SO-CH
2CH
3, - (CH
2)
2-SO-CH
2CH
3, - (CH
2)
3-SO-CH
2CH
3, -CH
2-SO-CH
2CH
2CH
3, - (CH
2)
2-SO-CH
2CH
2CH
3, - (CH
2)
3-SO-CH
2CH
2CH
3, -CH
2-SO-CH (CH
3)
2, - (CH
2)
2-SO-CH (CH
3)
2, - (CH
2)
3-SO-CH (CH
3)
2, -C
3 cycloalkyl-C
5 aryl, -C
4 cycloalkyl-C
5 aryl, -C
5 cycloalkyl-C
5 aryl, -C
6 cycloalkyl-C
5 aryl, -C
3 cycloalkyl-C
6 aryl, -C
4 cycloalkyl-C
6 aryl, -C
5 cycloalkyl-C
6 aryl, -C
6 cycloalkyl-C
6 aryl, -C
3 cycloalkyl-C
7 aryl, -C
4 cycloalkyl-C
7 aryl, -C
5 cycloalkyl-C
7 aryl, -C
6 cycloalkyl-C
7 aryl, -C
3 cycloalkyl-C
8 aryl, -C
4 cycloalkyl-C
8 aryl, -C
5 cycloalkyl-C
8 aryl, -C
6 cycloalkyl-C
8 aryl, -C
3 cycloalkyl-C
9 aryl, -C
4 cycloalkyl-C
9 aryl, -C
5 cycloalkyl-C
9 aryl, -C
6 cycloalkyl-C
9 aryl, -C
3 cycloalkyl-C
10 aryl, -C
4 cycloalkyl-C
10 aryl, -C
5 cycloalkyl-C
10 aryl, and -C
6 cycloalkyl-C
10 aryl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said vinyl, said allyl, said ethyne, said propyne, said C
5 aryl, C
6 aryl, said C
7 aryl, said C
8 aryl, said C
9 aryl, said C
10 aryl, said -CH
2-COO-CH
3, said - (CH
2)
2-COO-CH
3, said - (CH
2)
3-COO-CH
3, said -CH
2-COO-CH
2CH
3, said - (CH
2)
2-COO-CH
2CH
3, said - (CH
2)
3-COO-CH
2CH
3, said -CH
2-COO-CH
2CH
2CH
3, said - (CH
2)
2-COO-CH
2CH
2CH
3, said - (CH
2)
3-COO-CH
2CH
2CH
3, said -CH
2-COO-CH (CH
3)
2, said - (CH
2)
2-COO-CH (CH
3)
2, said - (CH
2)
3-COO-CH (CH
3)
2, said -CH
2-C
5 aryl, said -CH
2-C
6 aryl, said - (CH
2)
2-C
6 aryl, said - (CH
2)
3-C
6 aryl, said -CH
2-C
7 aryl, said - (CH
2)
2-C
7 aryl, said - (CH
2)
3-C
7 aryl, said -CH
2-C
8 aryl, said - (CH
2)
2-C
8 aryl, said - (CH
2)
3-C
8 aryl, said -CH
2-C
9 aryl, said - (CH
2)
2-C
9 aryl, said - (CH
2)
3-C
9 aryl, said -CH
2-C
10 aryl, said - (CH
2)
2-C
10 aryl, said - (CH
2)
3-C
10 aryl, said -5 membered heteroaryl, said -6 membered heteroaryl, said -7 membered heteroaryl, said -8 membered heteroaryl, said -9 membered heteroaryl, said -10 membered heteroaryl, said -5 membered heterocyclyl, said -6 membered heterocyclyl, said -7 membered heterocyclyl, said -8 membered heterocyclyl, said -9 membered heterocyclyl, said -10 membered heterocyclyl, said -CH
2-N (CH
3)
2, said - (CH
2)
2-N (CH
3)
2, said - (CH
2)
3-N (CH
3)
2, said -CH
2-N (CH
2CH
3)
2, said - (CH
2)
2-N (CH
2CH
3)
2, said - (CH
2)
3-N (CH
2CH
3)
2, said -CH
2-N (CH
2CH
2CH
3)
2, said - (CH
2)
2-N (CH
2CH
2CH
3)
2, said - (CH
2)
3-N (CH
2CH
2CH
3)
2, said -CH
2-N (CH (CH
3)
2)
2, said - (CH
2)
2-N (CH (CH
3)
2)
2, said - (CH
2)
3-N (CH (CH
3)
2)
2, said -CH
2-O-CH
3, said - (CH
2)
2-O-CH
3, said - (CH
2)
3-O-CH
3, said -CH
2-O-CH
2CH
3, said - (CH
2)
2-O-CH
2CH
3, said - (CH
2)
3-O-CH
2CH
3, said -CH
2-O-CH
2CH
2CH
3, said - (CH
2)
2-O-CH
2CH
2CH
3, said - (CH
2)
3-O-CH
2CH
2CH
3, said -CH
2-O-CH (CH
3)
2, said - (CH
2)
2-O-CH (CH
3)
2, said - (CH
2)
3-O-CH (CH
3)
2, said -CH
2-CO-NH-CH
3, said - (CH
2)
2-CO-NH-CH
3, said - (CH
2)
3-CO-NH-CH
3, said -CH
2-CO-NH-CH
2CH
3, said - (CH
2)
2-CO-NH-CH
2CH
3, said - (CH
2)
3-CO-NH-CH
2CH
3, said -CH
2-CO-NH-CH
2CH
2CH
3, said - (CH
2)
2-CO-NH-CH
2CH
2CH
3, said - (CH
2)
3-CO-NH-CH
2CH
2CH
3, said -CH
2-CO-NH-CH (CH
3)
2, said - (CH
2)
2-CO-NH-CH (CH
3)
2, said - (CH
2)
3-CO-NH-CH (CH
3)
2, said -CH
2-CO-5 membered heterocyclyl, said - (CH
2)
2-CO-5 membered heterocyclyl, said - (CH
2)
3-CO-5 membered heterocyclyl, said -CH
2-CO-6 membered heterocyclyl, said - (CH
2)
2-CO-6 membered heterocyclyl, said - (CH
2)
3-CO-6 membered heterocyclyl, said -CH
2-CO-7 membered heterocyclyl, said - (CH
2)
2-CO-7 membered heterocyclyl, said - (CH
2)
3-CO-7 membered heterocyclyl, said -CH
2-CO-8 membered heterocyclyl, said - (CH
2)
2-CO-8 membered heterocyclyl, said - (CH
2)
3-CO-8 membered heterocyclyl, said -CH
2-CO-9 membered heterocyclyl, said - (CH
2)
2-CO-9 membered heterocyclyl, said - (CH
2)
3-CO-9 membered heterocyclyl, said -CH
2-CO-10 membered heterocyclyl, said - (CH
2)
2-CO-10 membered heterocyclyl, said - (CH
2)
3-CO-10 membered heterocyclyl, said -CH
2-SO
2-CH
3, said - (CH
2)
2-SO
2-CH
3, said - (CH
2)
3-SO
2-CH
3, said -CH
2-SO
2-CH
2CH
3, said - (CH
2)
2-SO
2-CH
2CH
3, said - (CH
2)
3-SO
2-CH
2CH
3, said -CH
2-SO
2-CH
2CH
2CH
3, said - (CH
2)
2-SO
2-CH
2CH
2CH
3, said - (CH
2)
3-SO
2-CH
2CH
2CH
3, said -CH
2-SO
2-CH (CH
3)
2, said - (CH
2)
2-SO
2-CH (CH
3)
2, said - (CH
2)
3-SO
2-CH (CH
3)
2, said -CH
2-SO-CH
3, said - (CH
2)
2-SO-CH
3, said - (CH
2)
3-SO-CH
3, said -CH
2-SO-CH
2CH
3, said - (CH
2)
2-SO-CH
2CH
3, said - (CH
2)
3-SO-CH
2CH
3, said -CH
2-SO-CH
2CH
2CH
3, said - (CH
2)
2-SO-CH
2CH
2CH
3, said - (CH
2)
3-SO-CH
2CH
2CH
3, said -CH
2-SO-CH (CH
3)
2, said - (CH
2)
2-SO-CH (CH
3)
2, said - (CH
2)
3-SO-CH (CH
3)
2, said -C
3 cycloalkyl-C
5 aryl, said -C
4 cycloalkyl-C
5 aryl, said -C
5 cycloalkyl-C
5 aryl, said -C
6 cycloalkyl-C
5 aryl, said -C
3 cycloalkyl-C
6 aryl, said -C
4 cycloalkyl-C
6 aryl, said -C
5 cycloalkyl-C
6 aryl, said -C
6 cycloalkyl-C
6 aryl, said -C
3 cycloalkyl-C
7 aryl, said -C
4 cycloalkyl-C
7 aryl, said -C
5 cycloalkyl-C
7 aryl, said -C
6 cycloalkyl-C
7 aryl, said -C
3 cycloalkyl-C
8 aryl, said -C
4 cycloalkyl-C
8 aryl, said -C
5 cycloalkyl-C
8 aryl, said -C
6 cycloalkyl-C
8 aryl, said -C
3 cycloalkyl-C
9 aryl, said -C
4 cycloalkyl-C
9 aryl, said -C
5 cycloalkyl-C
9 aryl, said -C
6 cycloalkyl-C
9 aryl, said -C
3 cycloalkyl-C
10 aryl, said -C
4 cycloalkyl-C
10 aryl, said -C
5 cycloalkyl-C
10 aryl, and said -C
6 cycloalkyl-C
10 aryl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO
2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -CH
2-vinyl, - (CH
2)
2-vinyl, - (CH
2)
3-vinyl, -CH
2-allyl, - (CH
2)
2-allyl, - (CH
2)
3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -CH
2-COO-CH
3, - (CH
2)
2-COO-CH
3, - (CH
2)
3-COO-CH
3, -CH
2-COO-CH
2CH
3, - (CH
2)
2-COO-CH
2CH
3, - (CH
2)
3-COO-CH
2CH
3, -CH
2-COO-CH
2CH
2CH
3, - (CH
2)
2-COO-CH
2CH
2CH
3, - (CH
2)
3-COO-CH
2CH
2CH
3, -CH
2-COO-CH (CH
3)
2, - (CH
2)
2-COO-CH (CH
3)
2, - (CH
2)
3-COO-CH (CH
3)
2, -CH
2-SO
2-CH
3, - (CH
2)
2-SO
2-CH
3, - (CH
2)
3-SO
2-CH
3, -CH
2-SO
2-CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
3, -CH
2-SO
2-CH
2CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
2CH
3, -CH
2-SO
2-CH (CH
3)
2, - (CH
2)
2-SO
2-CH (CH
3)
2, - (CH
2)
3-SO
2-CH (CH
3)
2, -CH
2-SO-CH
3, - (CH
2)
2-SO-CH
3, - (CH
2)
3-SO-CH
3, -CH
2-SO-CH
2CH
3, - (CH
2)
2-SO-CH
2CH
3, - (CH
2)
3-SO-CH
2CH
3, -CH
2-SO-CH
2CH
2CH
3, - (CH
2)
2-SO-CH
2CH
2CH
3, - (CH
2)
3-SO-CH
2CH
2CH
3, -CH
2-SO-CH (CH
3)
2, - (CH
2)
2-SO-CH (CH
3)
2, - (CH
2)
3-SO-CH (CH
3)
2, -CH
2-S-CH
3, - (CH
2)
2-S-CH
3, - (CH
2)
3-S-CH
3, -CH
2-S-CH
2CH
3, - (CH
2)
2-S-CH
2CH
3, - (CH
2)
3-S-CH
2CH
3, -CH
2-S-CH
2CH
2CH
3, - (CH
2)
2-S-CH
2CH
2CH
3, - (CH
2)
3-S-CH
2CH
2CH
3, -CH
2-S-CH (CH
3)
2, - (CH
2)
2-S-CH (CH
3)
2, - (CH
2)
3-S-CH (CH
3)
2, -CH
2-O-CH
3, - (CH
2)
2-O-CH
3, - (CH
2)
3-O-CH
3, -CH
2-O-CH
2CH
3, - (CH
2)
2-O-CH
2CH
3, - (CH
2)
3-O-CH
2CH
3, -CH
2-O-CH
2CH
2CH
3, - (CH
2)
2-O-CH
2CH
2CH
3, - (CH
2)
3-O-CH
2CH
2CH
3, -CH
2-O-CH (CH
3)
2, - (CH
2)
2-O-CH (CH
3)
2, - (CH
2)
3-O-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, -C
5 aryl, -C
6 aryl, -C
7 aryl, -C
8 aryl, -C
9 aryl, -C
10 aryl, -C
5 aryl substituted by F, -C
6 aryl substituted by F, -C
7 aryl substituted by F, -C
8 aryl substituted by F, -C
9 aryl substituted by F, -C
10 aryl substituted by F, -C
5 aryl substituted by Cl, -C
6 aryl substituted by Cl, -C
7 aryl substituted by Cl, -C
8 aryl substituted by Cl, -C
9 aryl substituted by Cl, -C
10 aryl substituted by Cl, -C
1 haloalkyl, -C
2 haloalkyl, and –C
3 haloalkyl; or
R
1 and R
1’ together with the nitrogen atom to which they are both attached form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO
2, and said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO
2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -CH
2-vinyl, - (CH
2)
2-vinyl, - (CH
2)
3-vinyl, -CH
2-allyl, - (CH
2)
2-allyl, - (CH
2)
3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -CH
2-COO-CH
3, - (CH
2)
2-COO-CH
3, - (CH
2)
3-COO-CH
3, -CH
2-COO-CH
2CH
3, - (CH
2)
2-COO-CH
2CH
3, - (CH
2)
3-COO-CH
2CH
3, -CH
2-COO-CH
2CH
2CH
3, - (CH
2)
2-COO-CH
2CH
2CH
3, - (CH
2)
3-COO-CH
2CH
2CH
3, -CH
2-COO-CH (CH
3)
2, - (CH
2)
2-COO-CH (CH
3)
2, - (CH
2)
3-COO-CH (CH
3)
2, -CH
2-SO
2-CH
3, - (CH
2)
2-SO
2-CH
3, - (CH
2)
3-SO
2-CH
3, -CH
2-SO
2-CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
3, -CH
2-SO
2-CH
2CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
2CH
3, -CH
2-SO
2-CH (CH
3)
2, - (CH
2)
2-SO
2-CH (CH
3)
2, - (CH
2)
3-SO
2-CH (CH
3)
2, -CH
2-SO-CH
3, - (CH
2)
2-SO-CH
3, - (CH
2)
3-SO-CH
3, -CH
2-SO-CH
2CH
3, - (CH
2)
2-SO-CH
2CH
3, - (CH
2)
3-SO-CH
2CH
3, -CH
2-SO-CH
2CH
2CH
3, - (CH
2)
2-SO-CH
2CH
2CH
3, - (CH
2)
3-SO-CH
2CH
2CH
3, -CH
2-SO-CH (CH
3)
2, - (CH
2)
2-SO-CH (CH
3)
2, - (CH
2)
3-SO-CH (CH
3)
2, -CH
2-S-CH
3, - (CH
2)
2-S-CH
3, - (CH
2)
3-S-CH
3, -CH
2-S-CH
2CH
3, - (CH
2)
2-S-CH
2CH
3, - (CH
2)
3-S-CH
2CH
3, -CH
2-S-CH
2CH
2CH
3, - (CH
2)
2-S-CH
2CH
2CH
3, - (CH
2)
3-S-CH
2CH
2CH
3, -CH
2-S-CH (CH
3)
2, - (CH
2)
2-S-CH (CH
3)
2, - (CH
2)
3-S-CH (CH
3)
2, -CH
2-O-CH
3, - (CH
2)
2-O-CH
3, - (CH
2)
3-O-CH
3, -CH
2-O-CH
2CH
3, - (CH
2)
2-O-CH
2CH
3, - (CH
2)
3-O-CH
2CH
3, -CH
2-O-CH
2CH
2CH
3, - (CH
2)
2-O-CH
2CH
2CH
3, - (CH
2)
3-O-CH
2CH
2CH
3, -CH
2-O-CH (CH
3)
2, - (CH
2)
2-O-CH (CH
3)
2, - (CH
2)
3-O-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, -C
5 aryl, -C
6 aryl, -C
7 aryl, -C
8 aryl, -C
9 aryl, -C
10 aryl, -C
5 aryl substituted by F, -C
6 aryl substituted by F, -C
7 aryl substituted by F, -C
8 aryl substituted by F, -C
9 aryl substituted by F, -C
10 aryl substituted by F, -C
5 aryl substituted by Cl, -C
6 aryl substituted by Cl, -C
7 aryl substituted by Cl, -C
8 aryl substituted by Cl, -C
9 aryl substituted by Cl, -C
10 aryl substituted by Cl, -C
1 haloalkyl, -C
2 haloalkyl, and –C
3 haloalkyl. In some embodiments of formula I, Ia, or Ib, wherein
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl,
R
1 and R
1’ together with the nitrogen atom to which they are both attached form
said and wherein said
and said
said can be optionally substituted with one or more substituents, said which are independently selected from the group consisting of F, Cl, Br, I, -OH, oxo, -CN, -C
1-4 alkyl, -C
1-4 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -4-6 membered heterocyclyl, -COO-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl. Preferably, R
1 and R
1’ together with the nitrogen atom to which they are both attached form
said and wherein said
and said
said can be optionally substituted with one or more substituents, said which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, -C
5 aryl, -C
6 aryl, -C
7 aryl, -C
8 aryl, -C
9 aryl, -C
10 aryl, -C
5 aryl substituted by F, -C
6 aryl substituted by F, -C
7 aryl substituted by F, -C
8 aryl substituted by F, -C
9 aryl substituted by F, -C
10 aryl substituted by F, -C
5 aryl substituted by Cl, -C
6 aryl substituted by Cl, -C
7 aryl substituted by Cl, -C
8 aryl substituted by Cl, -C
9 aryl substituted by Cl, -C
10 aryl substituted by Cl, -C
1 haloalkyl, -C
2 haloalkyl, and –C
3 haloalkyl. Most preferably, R
1 and R
1’ together with the nitrogen atom to which they are both attached form
In some embodiments of formula I, Ia, or Ib, wherein
X is selected from the group consisting of –C (=O) -W- (CR
X1R
X2)
m-NR
5R
5’, C (=O) -W- (CR
X1R
X2)
m-SR
11, C (=O) -W- (CR
X1R
X2)
m-SOR
11, C (=O) -W- (CR
X1R
X2)
m-SO
2R
11, and –C (=O) -W- (CR
X1R
X2)
m-OR
11;
W is oxygen or a bond;
m is selected from 1, 2, or 3;
R
X1 and R
X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C
1-3 alkyl, -C
1-3 alkylene-SH, -C
1-3alkylene-C
2-3 alkenyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
3-6 cycloalkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-CONH
2,
-C
1-3 alkylene-Se-C
1-3 alkyl, -C
1-3 alkylene-SH, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-CO
2-C
1-3 alkyl, C
5-10aryl, -C
1-3 alkylene-C
5-10 aryl, -C
1-3 alkylene-5-10 membered heteroaryl, -C
1-3 alkylene-5-10 membered heterocyclyl, and 5-10 membered heteroaryl, and wherein said C
1-3 alkyl, said -C
1-3 alkylene-SH, said -C
1-3alkylene-C
2-3 alkenyl, said -C
3-6 cycloalkyl, said -C
1-3 alkylene-C
3-6 cycloalkyl, said -C
1-3 alkylene-S-C
1-3 alkyl, said -C
1-3 alkylene-CONH
2, said
said
said -C
1-3 alkylene-Se-C
1-3 alkyl, said -C
1-3 alkylene-SH, said -C
1-3 alkylene-SO
2-C
1-3 alkyl, said -C
1-3 alkylene-CO
2-C
1-3 alkyl, said C
5-10aryl, said -C
1-3 alkylene-C
5-10 aryl, said -C
1-3 alkylene-5-10 membered heteroaryl, said -C
1-3 alkylene-5-10 membered heterocyclyl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
or R
X1 and R
X2 together with the carbon atom to which they are attached form 5-8 membered carbocyclic ring, C
3-6 cycloalkyl, C
2-3 alkenyl, 5-8 membered heterocyclyl, and wherein said 5-8 membered carbocyclic ring, said C
3-6 cycloalkyl, said C
2-3 alkenyl, and said 5-8 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
5 and R
5’ are each independently selected from the group consisting of hydrogen, deuterium, -C
1-3 alkyl, -C
3-6cycloalkyl, -C (=O) -C
1-3 alkyl, -C (=O) -5-10 membered heterocyclyl, -C (=O) -5-10 membered carbocyclic, -C (=O) -adamantanyl, -C (=O) -C
1-3 alkylene-O-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-NH-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-N (C
1-3 alkyl)
2, -C (=O) -C
3-6 cycloalkyl, and wherein said -C
1-3 alkyl, said -C
3-6 cycloalkyl, -C (=O) -5-10 membered heterocyclyl, -C (=O) -5-10 membered carbocyclic, -C (=O) -C
1-3 alkylene-O-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-NH-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-N (C
1-3 alkyl)
2, said -C (=O) -C
1-3 alkyl, and said -C (=O) -C
3-6 cycloalkyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
or R
X1 and R
5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-10 membered heterocyclyl, and wherein said 5-10 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO
2, and said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl;
R
11 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl.
In some embodiments, the compound of formula I or Ia, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, wherein
X is selected from the group consisting of –C (=O) -W- (CR
X1R
X2)
m-NR
5R
5’, C (=O) -W- (CR
X1R
X2)
m-SR
11, C (=O) -W- (CR
X1R
X2)
m-SOR
11, C (=O) -W- (CR
X1R
X2)
m-SO
2R
11, and –C (=O) -W- (CR
X1R
X2)
m-OR
11;
W is oxygen or a bond;
m is selected from 1, 2, or 3;
R
X1 and R
X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C
1-3 alkyl, -C
0-3 alkylene-SH, -C
0-3alkylene-C
2-3 alkenyl, -C
3-6 cycloalkyl, -C
0-3 alkylene-C
3-6 cycloalkyl, -C
0-3 alkylene-S-C
1-3 alkyl, -C
0-3 alkylene-CONH
2,
-C
0-3 alkylene-Se-C
1-3 alkyl, -C
0-3 alkylene-SH, -C
0-3 alkylene-SO
2-C
1-3 alkyl, -C
0-3 alkylene-CO
2-C
1-3 alkyl, C
5-10aryl, -C
0-3 alkylene-C
5-10 aryl, -C
0-3 alkylene-5-10 membered heteroaryl, -C
0-3 alkylene-5-10 membered heterocyclyl, and 5-10 membered heteroaryl, and wherein said C
1-3 alkyl, said –C
0-3 alkylene-SH, said –C
0-3alkylene-C
2-3 alkenyl, said -C
3-6 cycloalkyl, said –C
0-3 alkylene-C
3-6 cycloalkyl, said –C
0-3 alkylene-S-C
1-3 alkyl, said –C
0-3 alkylene-CONH
2, said
said
said –C
0-3 alkylene-Se-C
1-3 alkyl, said –C
0-3 alkylene-SH, said –C
0-3 alkylene-SO
2-C
1-3 alkyl, said –C
0-3 alkylene-CO
2-C
1-3 alkyl, said C
5-10aryl, said -C
1-3 alkylene-C
5-10 aryl, said –C
0-3 alkylene-5-10 membered heteroaryl, said –C
0-3 alkylene-5-10 membered heterocyclyl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-4 alkenyl, -C
2-4 alkynyl, -C
3-6 cycloalkyl, -C
1-4 alkylene-C
2-4 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-4 alkylene-COO-C
1-3 alkyl, -C
1-4alkylene-SO
2-C
1-3 alkyl, -C
1-4 alkylene-SO-C
1-3 alkyl, -C
1-4 alkylene-S-C
1-3 alkyl, -C
1-4 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3haloalkyl;
or R
X1 and R
X2 together with the carbon atom to which they are attached form 5-8 membered carbocyclic ring, C
3-6 cycloalkyl, C
2-3 alkenyl, 5-8 membered heterocyclyl, and wherein said 5-8 membered carbocyclic ring, said C
3-6 cycloalkyl, said C
2-3 alkenyl, and said 5-8 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-4 alkenyl, -C
2-4 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-4 alkylene-COO-C
1-3 alkyl, -C
1-4alkylene-SO
2-C
1-3 alkyl, -C
1-4alkylene-SO-C
1-3 alkyl, -C
1-4 alkylene-S-C
1-3 alkyl, -C
1-4 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl;
R
5 and R
5’ are each independently selected from the group consisting of hydrogen, deuterium, -C
1-3 alkyl, -C
3-6cycloalkyl, -C (=O) -C
1-3 alkyl, -C (=O) -5-10 membered heterocyclyl, -C (=O) -5-10 membered carbocyclic, -C (=O) -adamantanyl, -C (=O) -C
1-3 alkylene-O-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-NH-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-N (C
1-3 alkyl)
2, -C (=O) -C
3-1 cycloalkyl, and wherein said -C
1-3 alkyl, said -C
3-6 cycloalkyl, -C (=O) -5-10 membered heterocyclyl, -C (=O) -5-10 membered carbocyclic, -C (=O) -C
1-3 alkylene-O-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-NH-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-N (C
1-3 alkyl)
2, said -C (=O) -C
1-3 alkyl, and said -C (=O) -C
3-6 cycloalkyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-4 alkenyl, -C
2-4 alkynyl, -C
3-6 cycloalkyl, -C
1-4 alkylene-C
2-4 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-4 alkylene-COO-C
1-3 alkyl, -C
1-4alkylene-SO
2-C
1-3 alkyl, -C
1-4alkylene-SO-C
1-3 alkyl, -C
1-4 alkylene-S-C
1-3 alkyl, -C
1-4 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3haloalkyl;
or R
X1 and R
5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-10 membered heterocyclyl, and wherein said 5-10 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO
2, and said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3alkoxy, -C
2-4 alkenyl, -C
2-4 alkynyl, -C
3-6 cycloalkyl, -C
1-4 alkylene-C
2-4alkenyl, -4-10 membered heterocyclyl, -COO-C
1-3alkyl, -C
1-4 alkylene-COO-C
1-3 alkyl, -C
1-4 alkylene-SO
2-C
1-3 alkyl, -C
1-4alkylene-SO-C
1-3alkyl, -C
1-4 alkylene-S-C
1-3 alkyl, -C
1-4 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-6 haloalkyl;
R
11 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-4alkenyl, -C
2-4 alkynyl, -C
3-6cycloalkyl, -C
1-4 alkylene-C
2-4alkenyl, -4-10 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-4alkylene-COO-C
1-3 alkyl, -C
1-4alkylene-SO
2-C
1-3alkyl, -C
1-4 alkylene-SO-C
1-3 alkyl, -C
1-4 alkylene-S-C
1-3 alkyl, -C
1-4 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
X is selected from the group consisting of –C (=O) -W- (CR
X1R
X2)
m-NR
5R
5’, C (=O) -W- (CR
X1R
X2)
m-SR
11 , C (=O) -W- (CR
X1R
X2)
m-SOR
11, C (=O) -W- (CR
X1R
X2)
m-SO
2R
11, and –C (=O) -W- (CR
X1R
X2)
m-OR
11;
W is a bond;
m is 1;
R
X1 and R
X2 are each independently selected from the group consisting from hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl,
-CO-CH
3, -SO-CH
3, -SO
2-CH
3, -NH-CO-CH
3,
and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -CO-CH
3, -NH-CO-CH
3, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, -C
5 aryl, -C
6 aryl, -C
7 aryl, -C
8 aryl, -C
9 aryl, -C
10 aryl, -C
5 aryl substituted by F, -C
6 aryl substituted by F, -C
7 aryl substituted by F, -C
8 aryl substituted by F, -C
9 aryl substituted by F, -C
10 aryl substituted by F, -C
5 aryl substituted by Cl, -C
6 aryl substituted by Cl, -C
7 aryl substituted by Cl, -C
8 aryl substituted by Cl, -C
9 aryl substituted by Cl, -C
10 aryl substituted by Cl, -C
1 haloalkyl, -C
2 haloalkyl, and –C
3 haloalkyl;
or R
X1 and R
X2 together with the carbon atom to which they are attached form
5 membered carbocyclic ring, 6 membered carbocyclic ring, 7 membered carbocyclic ring, 8 membered carbocyclic ring, C
3 cycloalkyl, C
4 cycloalkyl, C
5 cycloalkyl, C
6 cycloalkyl, C
2 alkenyl, C
3 alkenyl, C
4 alkenyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, and wherein said 5 membered carbocyclic ring, said 6 membered carbocyclic ring, said 7 membered carbocyclic ring, said 8 membered carbocyclic ring, said C
3 cycloalkyl, said C
4 cycloalkyl, said C
5 cycloalkyl, said C
6 cycloalkyl, said C
2 alkenyl, said C
3 alkenyl, said C
4 alkenyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO
2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -CH
2-vinyl, - (CH
2)
2-vinyl, - (CH
2)
3-vinyl, -CH
2-allyl, - (CH
2)
2-allyl, - (CH
2)
3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -CH
2-COO-CH
3, - (CH
2)
2-COO-CH
3, - (CH
2)
3-COO-CH
3, -CH
2-COO-CH
2CH
3, - (CH
2)
2-COO-CH
2CH
3, - (CH
2)
3-COO-CH
2CH
3, -CH
2-COO-CH
2CH
2CH
3, - (CH
2)
2-COO-CH
2CH
2CH
3, - (CH
2)
3-COO-CH
2CH
2CH
3, -CH
2-COO-CH (CH
3)
2, - (CH
2)
2-COO-CH (CH
3)
2, - (CH
2)
3-COO-CH (CH
3)
2, -CH
2-SO
2-CH
3, - (CH
2)
2-SO
2-CH
3, - (CH
2)
3-SO
2-CH
3, -CH
2-SO
2-CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
3, -CH
2-SO
2-CH
2CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
2CH
3, -CH
2-SO
2-CH (CH
3)
2, - (CH
2)
2-SO
2-CH (CH
3)
2, - (CH
2)
3-SO
2-CH (CH
3)
2, -CH
2-SO-CH
3, - (CH
2)
2-SO-CH
3, - (CH
2)
3-SO-CH
3, -CH
2-SO-CH
2CH
3, - (CH
2)
2-SO-CH
2CH
3, - (CH
2)
3-SO-CH
2CH
3, -CH
2-SO-CH
2CH
2CH
3, - (CH
2)
2-SO-CH
2CH
2CH
3, - (CH
2)
3-SO-CH
2CH
2CH
3, -CH
2-SO-CH (CH
3)
2, - (CH
2)
2-SO-CH (CH
3)
2, - (CH
2)
3-SO-CH (CH
3)
2, -CH
2-S-CH
3, - (CH
2)
2-S-CH
3, - (CH
2)
3-S-CH
3, -CH
2-S-CH
2CH
3, - (CH
2)
2-S-CH
2CH
3, - (CH
2)
3-S-CH
2CH
3, -CH
2-S-CH
2CH
2CH
3, - (CH
2)
2-S-CH
2CH
2CH
3, - (CH
2)
3-S-CH
2CH
2CH
3, -CH
2-S-CH (CH
3)
2, - (CH
2)
2-S-CH (CH
3)
2, - (CH
2)
3-S-CH (CH
3)
2, -CH
2-O-CH
3, - (CH
2)
2-O-CH
3, - (CH
2)
3-O-CH
3, -CH
2-O-CH
2CH
3, - (CH
2)
2-O-CH
2CH
3, - (CH
2)
3-O-CH
2CH
3, -CH
2-O-CH
2CH
2CH
3, - (CH
2)
2-O-CH
2CH
2CH
3, - (CH
2)
3-O-CH
2CH
2CH
3, -CH
2-O-CH (CH
3)
2, - (CH
2)
2-O-CH (CH
3)
2, - (CH
2)
3-O-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, -C
5 aryl, -C
6 aryl, -C
7 aryl, -C
8 aryl, -C
9 aryl, -C
10 aryl, -C
5 aryl substituted by F, -C
6 aryl substituted by F, -C
7 aryl substituted by F, -C
8 aryl substituted by F, -C
9 aryl substituted by F, -C
10 aryl substituted by F, -C
5 aryl substituted by Cl, -C
6 aryl substituted by Cl, -C
7 aryl substituted by Cl, -C
8 aryl substituted by Cl, -C
9 aryl substituted by Cl, -C
10 aryl substituted by Cl, -C
1 haloalkyl, -C
2 haloalkyl, and –C
3 haloalkyl; R
5 and R
5’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C (=O) -CH
3, -C (=O) -CH
2CH
3, -C (=O) -CH
2CH
2CH
3, -C (=O) -CH (CH
3)
2,
-C(=O) -5 membered heterocyclyl, -C (=O) -6 membered heterocyclyl, -C (=O) -7 membered heterocyclyl, -C (=O) -8 membered heterocyclyl, -C (=O) -9 membered heterocyclyl, -C (=O) -10 membered heterocyclyl, -C (=O) -5 membered carbocyclic, -C (=O) -6 membered carbocyclic, -C (=O) -7 membered carbocyclic, -C (=O) -8 membered carbocyclic, -C (=O) -9 membered carbocyclic, -C (=O) -10 membered carbocyclic, -C (=O) -adamantanyl, -C (=O) -CH
2-O-CH
3, -C (=O) - (CH
2)
2-O-CH
3, -C (=O) - (CH
2)
3-O-CH
3, -C (=O) -CH
2-O-CH
2CH
3, -C (=O) - (CH
2)
2-O-CH
2CH
3, -C (=O) - (CH
2)
3-O-CH
2CH
3, -C (=O) -CH
2-O-CH
2CH
2CH
3, -C (=O) - (CH
2)
2-O-CH
2CH
2CH
3, -C (=O) - (CH
2)
3-O-CH
2CH
2CH
3, -C (=O) -CH
2-O-CH (CH
3)
2, -C (=O) - (CH
2)
2-O-CH (CH
3)
2, -C (=O) - (CH
2)
3-O-CH (CH
3)
2, -C (=O) -CH
2-NH-CH
3, -C (=O) - (CH
2)
2-NH-CH
3, -C (=O) - (CH
2)
3-NH-CH
3, -C (=O) -CH
2-NH-CH
2CH
3, -C (=O) - (CH
2)
2-NH-CH
2CH
3, -C (=O) - (CH
2)
3-NH-CH
2CH
3, -C (=O) -CH
2-NH-CH
2CH
2CH
3, -C (=O) - (CH
2)
2-NH-CH
2CH
2CH
3, -C (=O) - (CH
2)
3-NH-CH
2CH
2CH
3, -C (=O) -CH
2-NH-CH (CH
3)
2, -C (=O) - (CH
2)
2-NH-CH (CH
3)
2, -C (=O) - (CH
2)
3-NH-CH (CH
3)
2, -C (=O) -CH
2-N (CH
3)
2, -C (=O) - (CH
2)
2-N (CH
3)
2, -C (=O) - (CH
2)
3-N (CH
3)
2, -C (=O) -CH
2-N (CH
2CH
3)
2, -C (=O) - (CH
2)
2-N (CH
2CH
3)
2, -C (=O) - (CH
2)
3-N (CH
2CH
3)
2, -C (=O) -CH
2-N (CH
2CH
2CH
3)
2, -C (=O) - (CH
2)
2-N (CH
2CH
2CH
3)
2, -C (=O) - (CH
2)
3-N (CH
2CH
2CH
3)
2, -C (=O) -CH
2-N (CH (CH
3)
2)
2, -C (=O) - (CH
2)
2-N (CH (CH
3)
2)
2, -C (=O) - (CH
2)
3-N (CH (CH
3)
2)
2, -C (=O) -C
3 cycloalkyl, -C (=O) -C
4 cycloalkyl, -C (=O) -C
5 cycloalkyl, and -C (=O) -C
6 cycloalkyl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said -C (=O) -CH
3, said -C (=O) -CH
2CH
3, said -C (=O) -CH
2CH
2CH
3, said -C (=O) -CHCH
3)
2, said -C (=O) -5 membered heterocyclyl, said -C (=O) -6 membered heterocyclyl, said -C (=O) -7 membered heterocyclyl, said -C (=O) -8 membered heterocyclyl, said -C (=O) -9 membered heterocyclyl, said -C (=O) -10 membered heterocyclyl, said -C (=O) -5 membered carbocyclic, said -C (=O) -6 membered carbocyclic, said -C (=O) -7 membered carbocyclic, said -C (=O) -8 membered carbocyclic, said -C (=O) -9 membered carbocyclic, said -C (=O) -10 membered carbocyclic, said -C (=O) -CH
2-O-CH
3, said -C (=O) - (CH
2)
2-O-CH
3, said -C (=O) - (CH
2)
3-O-CH
3, said -C (=O) -CH
2-O-CH
2CH
3, said -C (=O) - (CH
2)
2-O-CH
2CH
3, said -C (=O) - (CH
2)
3-O-CH
2CH
3, said -C (=O) -CH
2-O-CH
2CH
2CH
3, said -C (=O) - (CH
2)
2-O-CH
2CH
2CH
3, said -C (=O) - (CH
2)
3-O-CH
2CH
2CH
3, said -C (=O) -CH
2-O-CH (CH
3)
2, said -C (=O) - (CH
2)
2-O-CH (CH
3)
2, said -C (=O) - (CH
2)
3-O-CH (CH
3)
2, said -C (=O) -CH
2-NH-CH
3, said -C (=O) - (CH
2)
2-NH-CH
3, said -C (=O) - (CH
2)
3-NH-CH
3, said -C (=O) -CH
2-NH-CH
2CH
3, said -C (=O) - (CH
2)
2-NH-CH
2CH
3, said -C (=O) - (CH
2)
3-NH-CH
2CH
3, said -C (=O) -CH
2-NH-CH
2CH
2CH
3, said -C (=O) - (CH
2)
2-NH-CH
2CH
2CH
3, said -C (=O) - (CH
2)
3-NH-CH
2CH
2CH
3, said -C (=O) -CH
2-NH-CH (CH
3)
2, said -C (=O) - (CH
2)
2-NH-CH (CH
3)
2, said -C (=O) - (CH
2)
3-NH-CH (CH
3)
2, said -C (=O) -CH
2-N (CH
3)
2, said -C (=O) - (CH
2)
2-N (CH
3)
2, said -C (=O) - (CH
2)
3-N (CH
3)
2, said -C (=O) -CH
2-N (CH
2CH
3)
2, said -C (=O) - (CH
2)
2-N (CH
2CH
3)
2, said -C (=O) - (CH
2)
3-N (CH
2CH
3)
2, said -C (=O) -CH
2-N (CH
2CH
2CH
3)
2, said -C (=O) - (CH
2)
2-N (CH
2CH
2CH
3)
2, said -C (=O) - (CH
2)
3-N (CH
2CH
2CH
3)
2, said -C (=O) -CH
2-N (CH (CH
3)
2)
2, said -C (=O) - (CH
2)
2-N (CH (CH
3)
2)
2, said -C (=O) - (CH
2)
3-N (CH (CH
3)
2)
2, said -C (=O) -C
3 cycloalkyl, said -C (=O) -C
4 cycloalkyl, said -C (=O) -C
5 cycloalkyl, and said -C (=O) -C
6 cycloalkyl, can be optional substituted with one or more substituents, said which are independently selected from the group consisting of can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, -C
5 aryl, -C
6 aryl, -C
7 aryl, -C
8 aryl, -C
9 aryl, -C
10 aryl, -C
5 aryl substituted by F, -C
6 aryl substituted by F, -C
7 aryl substituted by F, -C
8 aryl substituted by F, -C
9 aryl substituted by F, -C
10 aryl substituted by F, -C
5 aryl substituted by Cl, -C
6 aryl substituted by Cl, -C
7 aryl substituted by Cl, -C
8 aryl substituted by Cl, -C
9 aryl substituted by Cl, -C
10 aryl substituted by Cl, -C
1 haloalkyl, -C
2 haloalkyl, and –C
3 haloalkyl; or R
X1 and R
5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, and wherein said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO
2, and said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO
2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -CH
2-vinyl, - (CH
2)
2-vinyl, - (CH
2)
3- vinyl, -CH
2-allyl, - (CH
2)
2-allyl, - (CH
2)
3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -CH
2-COO-CH
3, - (CH
2)
2-COO-CH
3, - (CH
2)
3-COO-CH
3, -CH
2-COO-CH
2CH
3, - (CH
2)
2-COO-CH
2CH
3, - (CH
2)
3-COO-CH
2CH
3, -CH
2-COO-CH
2CH
2CH
3, - (CH
2)
2-COO-CH
2CH
2CH
3, - (CH
2)
3-COO-CH
2CH
2CH
3, -CH
2-COO-CH (CH
3)
2, - (CH
2)
2-COO-CH (CH
3)
2, - (CH
2)
3-COO-CH (CH
3)
2, -CH
2-SO
2-CH
3, - (CH
2)
2-SO
2-CH
3, - (CH
2)
3-SO
2-CH
3, -CH
2-SO
2-CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
3, -CH
2-SO
2-CH
2CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
2CH
3, -CH
2-SO
2-CH (CH
3)
2, - (CH
2)
2-SO
2-CH (CH
3)
2, - (CH
2)
3-SO
2-CH (CH
3)
2, -CH
2-SO-CH
3, - (CH
2)
2-SO-CH
3, - (CH
2)
3-SO-CH
3, -CH
2-SO-CH
2CH
3, - (CH
2)
2-SO-CH
2CH
3, - (CH
2)
3-SO-CH
2CH
3, -CH
2-SO-CH
2CH
2CH
3, - (CH
2)
2-SO-CH
2CH
2CH
3, - (CH
2)
3-SO-CH
2CH
2CH
3, -CH
2-SO-CH (CH
3)
2, - (CH
2)
2-SO-CH (CH
3)
2, - (CH
2)
3-SO-CH (CH
3)
2, -CH
2-S-CH
3, - (CH
2)
2-S-CH
3, - (CH
2)
3-S-CH
3, -CH
2-S-CH
2CH
3, - (CH
2)
2-S-CH
2CH
3, - (CH
2)
3-S-CH
2CH
3, -CH
2-S-CH
2CH
2CH
3, - (CH
2)
2-S-CH
2CH
2CH
3, - (CH
2)
3-S-CH
2CH
2CH
3, -CH
2-S-CH (CH
3)
2, - (CH
2)
2-S-CH (CH
3)
2, - (CH
2)
3-S-CH (CH
3)
2, -CH
2-O-CH
3, - (CH
2)
2-O-CH
3, - (CH
2)
3-O-CH
3, -CH
2-O-CH
2CH
3, - (CH
2)
2-O-CH
2CH
3, - (CH
2)
3-O-CH
2CH
3, -CH
2-O-CH
2CH
2CH
3, - (CH
2)
2-O-CH
2CH
2CH
3, - (CH
2)
3-O-CH
2CH
2CH
3, -CH
2-O-CH (CH
3)
2, - (CH
2)
2-O-CH (CH
3)
2, - (CH
2)
3-O-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, -C
5 aryl, -C
6 aryl, -C
7 aryl, -C
8 aryl, -C
9 aryl, -C
10 aryl, -C
5 aryl substituted by F, -C
6 aryl substituted by F, -C
7 aryl substituted by F, -C
8 aryl substituted by F, -C
9 aryl substituted by F, -C
10 aryl substituted by F, -C
5 aryl substituted by Cl, -C
6 aryl substituted by Cl, -C
7 aryl substituted by Cl, -C
8 aryl substituted by Cl, -C
9 aryl substituted by Cl, -C
10 aryl substituted by Cl, -C
1 haloalkyl, -C
2 haloalkyl, and –C
3 haloalkyl; R
11 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl,
methoxy, ethoxy, propoxy, isopropoxy; and each of which is optional substituted with one or more substituents, which are independently selected from deuterium, halogen, -OH, oxo, -CN, -NO
2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy -C
2-4alkenyl, -C
2-4 alkynyl, -C
1-4 alkylene-C
2-4alkenyl,
-NH-CO-C
1-3alkyl, -CO-NH-C
1-3alkyl, -CO-N (CH
3)
2, -COO-C
1-3 alkyl, -C
1-4alkylene-COO-C
1-3 alkyl, -C
1-4alkylene-SO
2-C
1-3alkyl, -C
1-4 alkylene-SO-C
1-3 alkyl, -C
1-4 alkylene-S-C
1-3 alkyl, -C
1-4 alkylene-O-C
1-3alkyl, -NH
2, -NHmethyl, -NHethyl, -NHpropyl, -NHisopropyl, -N (CH
3)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein X is selected from the group consisting of –C (=O) -W- (CR
X1R
X2)
m-NR
5R
5’, C (=O) -W- (CR
X1R
X2)
m-SR
11 , C (=O) -W- (CR
X1R
X2)
m-SOR
11, C (=O) -W- (CR
X1R
X2)
m-SO
2R
11, and –C (=O) -W- (CR
X1R
X2)
m-OR
11;
W is a bond;
m is 1;
R
X1 and R
X2 are each independently selected from the group consisting from hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl,
-CO-CH
3, -SO-CH
3, -SO
2-CH
3, -NH-CO-CH
3,
and each of which can be optional substituted with one or more substituents, said which are independently selected from the group consisting of can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl
or R
X1 and R
X2 together with the carbon atom to which they are attached form
5 membered carbocyclic ring, 6 membered carbocyclic ring, 7 membered carbocyclic ring, 8 membered carbocyclic ring, C
3cycloalkyl, C
4 cycloalkyl, C
5 cycloalkyl, C
6 cycloalkyl, C
2 alkenyl, C
3 alkenyl, C
4 alkenyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, and wherein said 5 membered carbocyclic ring, said 6 membered carbocyclic ring, said 7 membered carbocyclic ring, said 8 membered carbocyclic ring, said C
3 cycloalkyl, said C
4 cycloalkyl, said C
5 cycloalkyl, said C
6 cycloalkyl, said C
2 alkenyl, said C
3 alkenyl, said C
4 alkenyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO
2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -CH
2-vinyl, - (CH
2)
2-vinyl, - (CH
2)
3-vinyl, -CH
2-allyl, - (CH
2)
2-allyl, - (CH
2)
3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -CH
2-COO-CH
3, - (CH
2)
2-COO-CH
3, - (CH
2)
3-COO-CH
3, -CH
2-COO-CH
2CH
3, - (CH
2)
2-COO-CH
2CH
3, - (CH
2)
3-COO-CH
2CH
3, -CH
2-COO-CH
2CH
2CH
3, - (CH
2)
2-COO-CH
2CH
2CH
3, - (CH
2)
3-COO-CH
2CH
2CH
3, -CH
2-COO-CH (CH
3)
2, - (CH
2)
2-COO-CH (CH
3)
2, - (CH
2)
3-COO-CH (CH
3)
2, -CH
2-SO
2-CH
3, - (CH
2)
2-SO
2-CH
3, - (CH
2)
3-SO
2-CH
3, -CH
2-SO
2-CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
3, -CH
2-SO
2-CH
2CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
2CH
3, -CH
2-SO
2-CH (CH
3)
2, - (CH
2)
2-SO
2-CH (CH
3)
2, - (CH
2)
3-SO
2-CH (CH
3)
2, -CH
2-SO-CH
3, - (CH
2)
2-SO-CH
3, - (CH
2)
3-SO-CH
3, -CH
2-SO-CH
2CH
3, - (CH
2)
2-SO-CH
2CH
3, - (CH
2)
3-SO-CH
2CH
3, -CH
2-SO-CH
2CH
2CH
3, - (CH
2)
2-SO-CH
2CH
2CH
3, - (CH
2)
3-SO-CH
2CH
2CH
3, -CH
2-SO-CH (CH
3)
2, - (CH
2)
2-SO-CH (CH
3)
2, - (CH
2)
3-SO-CH (CH
3)
2, -CH
2-S-CH
3, - (CH
2)
2-S-CH
3, - (CH
2)
3-S-CH
3, -CH
2-S-CH
2CH
3, - (CH
2)
2-S-CH
2CH
3, - (CH
2)
3-S-CH
2CH
3, -CH
2-S-CH
2CH
2CH
3, - (CH
2)
2-S-CH
2CH
2CH
3, - (CH
2)
3-S-CH
2CH
2CH
3, -CH
2-S-CH (CH
3)
2, - (CH
2)
2-S-CH (CH
3)
2, - (CH
2)
3-S-CH (CH
3)
2, -CH
2-O-CH
3, - (CH
2)
2-O-CH
3, - (CH
2)
3-O-CH
3, -CH
2-O-CH
2CH
3, - (CH
2)
2-O-CH
2CH
3, - (CH
2)
3-O-CH
2CH
3, -CH
2-O-CH
2CH
2CH
3, - (CH
2)
2-O-CH
2CH
2CH
3, - (CH
2)
3-O-CH
2CH
2CH
3, -CH
2-O-CH (CH
3)
2, - (CH
2)
2-O-CH (CH
3)
2, - (CH
2)
3-O-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, -C
5 aryl, -C
6 aryl, -C
7 aryl, -C
8 aryl, -C
9 aryl, -C
10 aryl, -C
5 aryl substituted by F, -C
6 aryl substituted by F, -C
7 aryl substituted by F, -C
8 aryl substituted by F, -C
9 aryl substituted by F, -C
10 aryl substituted by F, -C
5 aryl substituted by Cl, -C
6 aryl substituted by Cl, -C
7 aryl substituted by Cl, -C
8 aryl substituted by Cl, -C
9 aryl substituted by Cl, -C
10 aryl substituted by Cl, -C
1 haloalkyl, -C
2 haloalkyl, and –C
3 haloalkyl; R
5 and R
5’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C (=O) -CH
3, -C (=O) -CH
2CH
3, -C (=O) -CH
2CH
2CH
3, -C (=O) -CH (CH
3)
2,
-C (=O) -5 membered heterocyclyl, -C (=O) -6 membered heterocyclyl, -C (=O) -7 membered heterocyclyl, -C (=O) -8 membered heterocyclyl, -C (=O) -9 membered heterocyclyl, -C (=O) -10 membered heterocyclyl, -C (=O) -5 membered carbocyclic, -C (=O) -6 membered carbocyclic, -C (=O) -7 membered carbocyclic, -C (=O) -8 membered carbocyclic, -C (=O) -9 membered carbocyclic, -C (=O) -10 membered carbocyclic, -C (=O) -adamantanyl, -C (=O) -CH
2-O-CH
3, -C (=O) - (CH
2)
2-O-CH
3, -C (=O) - (CH
2)
3-O-CH
3, -C (=O) -CH
2-O-CH
2CH
3, -C (=O) - (CH
2)
2-O-CH
2CH
3, -C (=O) - (CH
2)
3-O-CH
2CH
3, -C (=O) -CH
2-O-CH
2CH
2CH
3, -C (=O) - (CH
2)
2-O-CH
2CH
2CH
3, -C (=O) - (CH
2)
3-O-CH
2CH
2CH
3, -C (=O) -CH
2-O-CH (CH
3)
2, -C (=O) - (CH
2)
2-O-CH (CH
3)
2, -C (=O) - (CH
2)
3-O-CH (CH
3)
2, -C (=O) -CH
2-NH-CH
3, -C (=O) - (CH
2)
2-NH-CH
3, -C (=O) - (CH
2)
3-NH-CH
3, -C (=O) -CH
2-NH-CH
2CH
3, -C (=O) - (CH
2)
2-NH-CH
2CH
3, -C (=O) - (CH
2)
3-NH-CH
2CH
3, -C (=O) -CH
2-NH-CH
2CH
2CH
3, -C (=O) - (CH
2)
2-NH-CH
2CH
2CH
3, -C (=O) - (CH
2)
3-NH-CH
2CH
2CH
3, -C (=O) -CH
2-NH-CH (CH
3)
2, -C (=O) - (CH
2)
2-NH-CH (CH
3)
2, -C (=O) - (CH
2)
3-NH-CH (CH
3)
2, -C (=O) -CH
2-N (CH
3)
2, -C (=O) - (CH
2)
2-N (CH
3)
2, -C (=O) - (CH
2)
3-N (CH
3)
2, -C (=O) -CH
2-N (CH
2CH
3)
2, -C (=O) - (CH
2)
2-N (CH
2CH
3)
2, -C (=O) - (CH
2)
3-N (CH
2CH
3)
2, -C (=O) -CH
2-N (CH
2CH
2CH
3)
2, -C (=O) - (CH
2)
2-N (CH
2CH
2CH
3)
2, -C (=O) - (CH
2)
3-N (CH
2CH
2CH
3)
2, -C (=O) -CH
2-N (CH (CH
3)
2)
2, -C (=O) - (CH
2)
2-N (CH (CH
3)
2)
2, -C (=O) - (CH
2)
3-N (CH (CH
3)
2)
2, -C (=O) -C
3 cycloalkyl, -C (=O) -C
4 cycloalkyl, -C (=O) -C
5 cycloalkyl, and -C (=O) -C
6 cycloalkyl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said -C (=O) -CH
3, said -C (=O) -CH
2CH
3, said -C (=O) -CH
2CH
2CH
3, said -C (=O) -CHCH
3)
2, said -C (=O) -5 membered heterocyclyl, said -C (=O) -6 membered heterocyclyl, said -C (=O) -7 membered heterocyclyl, said -C (=O) -8 membered heterocyclyl, said -C (=O) -9 membered heterocyclyl, said -C (=O) -10 membered heterocyclyl, said -C (=O) -5 membered carbocyclic, said -C (=O) -6 membered carbocyclic, said -C (=O) -7 membered carbocyclic, said -C (=O) -8 membered carbocyclic, said -C (=O) -9 membered carbocyclic, said -C (=O) -10 membered carbocyclic, said -C (=O) -CH
2-O-CH
3, said -C (=O) - (CH
2)
2-O-CH
3, said -C (=O) - (CH
2)
3-O-CH
3, said -C (=O) -CH
2-O-CH
2CH
3, said -C (=O) - (CH
2)
2-O-CH
2CH
3, said -C (=O) - (CH
2)
3-O-CH
2CH
3, said -C (=O) -CH
2-O-CH
2CH
2CH
3, said -C (=O) - (CH
2)
2-O-CH
2CH
2CH
3, said -C (=O) - (CH
2)
3-O-CH
2CH
2CH
3, said -C (=O) -CH
2-O-CH (CH
3)
2, said -C (=O) - (CH
2)
2-O-CH (CH
3)
2, said -C (=O) - (CH
2)
3-O-CH (CH
3)
2, said -C (=O) -CH
2-NH-CH
3, said -C (=O) - (CH
2)
2-NH-CH
3, said -C (=O) - (CH
2)
3-NH-CH
3, said -C (=O) -CH
2-NH-CH
2CH
3, said -C (=O) - (CH
2)
2-NH-CH
2CH
3, said -C (=O) - (CH
2)
3-NH-CH
2CH
3, said -C (=O) -CH
2-NH-CH
2CH
2CH
3, said -C (=O) - (CH
2)
2-NH-CH
2CH
2CH
3, said -C (=O) - (CH
2)
3-NH-CH
2CH
2CH
3, said -C (=O) -CH
2-NH-CH (CH
3)
2, said -C (=O) - (CH
2)
2-NH-CH (CH
3)
2, said -C (=O) - (CH
2)
3-NH-CH (CH
3)
2, said -C (=O) -CH
2-N (CH
3)
2, said -C (=O) - (CH
2)
2-N (CH
3)
2, said -C (=O) - (CH
2)
3-N (CH
3)
2, said -C (=O) -CH
2-N (CH
2CH
3)
2, said -C (=O) - (CH
2)
2-N (CH
2CH
3)
2, said -C (=O) - (CH
2)
3-N (CH
2CH
3)
2, said -C (=O) -CH
2-N (CH
2CH
2CH
3)
2, said -C (=O) - (CH
2)
2-N (CH
2CH
2CH
3)
2, said -C (=O) - (CH
2)
3-N (CH
2CH
2CH
3)
2, said -C (=O) -CH
2-N (CH (CH
3)
2)
2, said -C (=O) - (CH
2)
2-N (CH (CH
3)
2)
2, said -C (=O) - (CH
2)
3-N (CH (CH
3)
2)
2, said -C (=O) -C
3 cycloalkyl, said -C (=O) -C
4 cycloalkyl, said -C (=O) -C
5 cycloalkyl, and said -C (=O) -C
6 cycloalkyl, can be optional substituted with one or more substituents, and said substituents are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, phenyl, phenyl substituted by F, phenyl substituted by Cl;
or R
X1 and R
5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, and wherein said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO
2, and said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO
2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -CH
2-vinyl, - (CH
2)
2-vinyl, - (CH
2)
3-vinyl, -CH
2-allyl, - (CH
2)
2-allyl, - (CH
2)
3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -CH
2-COO-CH
3, - (CH
2)
2-COO-CH
3, - (CH
2)
3-COO-CH
3, -CH
2-COO-CH
2CH
3, - (CH
2)
2-COO-CH
2CH
3, - (CH
2)
3-COO-CH
2CH
3, -CH
2-COO-CH
2CH
2CH
3, - (CH
2)
2-COO-CH
2CH
2CH
3, - (CH
2)
3-COO-CH
2CH
2CH
3, -CH
2-COO-CH (CH
3)
2, - (CH
2)
2-COO-CH (CH
3)
2, - (CH
2)
3-COO-CH (CH
3)
2, -CH
2-SO
2-CH
3, - (CH
2)
2-SO
2-CH
3, - (CH
2)
3-SO
2-CH
3, -CH
2-SO
2-CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
3, -CH
2-SO
2-CH
2CH
2CH
3, - (CH
2)
2-SO
2-CH
2CH
2CH
3, - (CH
2)
3-SO
2-CH
2CH
2CH
3, -CH
2-SO
2-CH (CH
3)
2, - (CH
2)
2-SO
2-CH (CH
3)
2, - (CH
2)
3-SO
2-CH (CH
3)
2, -CH
2-SO-CH
3, - (CH
2)
2-SO-CH
3, - (CH
2)
3-SO-CH
3, -CH
2-SO-CH
2CH
3, - (CH
2)
2-SO-CH
2CH
3, - (CH
2)
3-SO-CH
2CH
3, -CH
2-SO-CH
2CH
2CH
3, - (CH
2)
2-SO-CH
2CH
2CH
3, - (CH
2)
3-SO-CH
2CH
2CH
3, -CH
2-SO-CH (CH
3)
2, - (CH
2)
2-SO-CH (CH
3)
2, - (CH
2)
3-SO-CH (CH
3)
2, -CH
2-S-CH
3, - (CH
2)
2-S-CH
3, - (CH
2)
3-S-CH
3, -CH
2-S-CH
2CH
3, - (CH
2)
2-S-CH
2CH
3, - (CH
2)
3-S-CH
2CH
3, -CH
2-S-CH
2CH
2CH
3, - (CH
2)
2-S-CH
2CH
2CH
3, - (CH
2)
3-S-CH
2CH
2CH
3, -CH
2-S-CH (CH
3)
2, - (CH
2)
2-S-CH (CH
3)
2, - (CH
2)
3-S-CH (CH
3)
2, -CH
2-O-CH
3, - (CH
2)
2-O-CH
3, - (CH
2)
3-O-CH
3, -CH
2-O-CH
2CH
3, - (CH
2)
2-O-CH
2CH
3, - (CH
2)
3-O-CH
2CH
3, -CH
2-O-CH
2CH
2CH
3, - (CH
2)
2-O-CH
2CH
2CH
3, - (CH
2)
3-O-CH
2CH
2CH
3, -CH
2-O-CH (CH
3)
2, - (CH
2)
2-O-CH (CH
3)
2, - (CH
2)
3-O-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, phenyl, phenyl substituted by F, phenyl substituted by Cl; or
R
11 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl,
methoxy, ethoxy, propoxy, isopropoxy; and each of which is optional substituted with one or more substituents, which are independently selected from deuterium, halogen, -OH, oxo, -CN, -NO
2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy -C
2-4alkenyl, -C
2-4 alkynyl, -C
1-4 alkylene-C
2-4alkenyl,
-NH-CO-CH
3, -CO-NH-CH
3, -CO-N (CH
3)
2, -COO-CH
3, -CH
2-COO-CH
3, -CH
2-SO
2-CH
3, -CH
2e-SO-CH
3, -CH
2-S-CH
3, -CH
2-O-CH
3, -NH
2, -NHmethyl, -NHethyl, -NHpropyl, -NHisopropyl, -N (CH
3)
2, carboxyl, phenyl, phenyl substituted by halogen . the halogen is F, Cl, or Br.
In some embodiments of formula I, Ia, or Ib, wherein
R
2 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
2 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein R
2 is hydrogen, or deuterium.
In some embodiments of formula I, Ia, or Ib, wherein
R
3 and R
3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
3 and R
3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
3 and R
3’ are each independently hydrogen, or deuterium.
In some embodiments of formula I, Ia, or Ib, wherein
Y is - (CR
Y1R
Y2)
n-;
n is selected from 1, 2, or 3;
R
Y1 and R
Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
Y is - (CR
Y1R
Y2)
n-;
n is 1;
R
Y1 and R
Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
Y is - (CR
Y1R
Y2)
n-;
n is 1;
R
Y1 and R
Y2 are each independently hydrogen or deuterium.
In some embodiments of formula I, Ia, or Ib, wherein
R
4 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
4 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
4 is hydrogen or deuterium.
In some embodiments of formula I, Ia, or Ib, wherein
R
10 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-6 alkyl, -C
1-6 alkoxy, -C
2-6 alkenyl, -C
2-6 alkynyl, -C
3-8 cycloalkyl, -C
1-6 alkylene-C
2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-6 alkyl, -C
1-6 alkylene-COO-C
1-6 alkyl, -C
1-6 alkylene-SO
2-C
1-6 alkyl, -C
1-6 alkylene-SO-C
1-6 alkyl, -C
1-6 alkylene-S-C
1-6 alkyl, -C
1-6 alkylene-O-C
1-6 alkyl, -NH
2, -NH (C
1-6 alkyl) , -N (C
1-6alkyl)
2, carboxyl, -C
5-12 aryl, -C
5-12 aryl substituted by halogen and -C
1-6 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
10 is selected from the group consisting of hydrogen, deuterium, halogen, C
1-3 alkyl, and C
1-3 alkoxy, and wherein said C
1-3 alkyl, and said C
1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments, the compound of formula I, Ia, Ib or Ic, a pharmaceutically acceptable salt thereof or a stereoisomer thereof, wherein
R
10 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C
1-4 alkyl, -C
1-4 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -C
3-6 cycloalkyl, -4-6 membered heterocyclyl, -COO-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein
R
10 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C
3 cycloalkyl, -C
4 cycloalkyl, -C
5 cycloalkyl, -C
6 cycloalkyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH
3, -COO-CH
2CH
3, -COO-CH
2CH
2CH
3, -COO-CH (CH
3)
2, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl, -C
5 aryl, -C
6 aryl, -C
7 aryl, -C
8 aryl, -C
9 aryl, -C
10 aryl, -C
5 aryl substituted by F, -C
6 aryl substituted by F, -C
7 aryl substituted by F, -C
8 aryl substituted by F, -C
9 aryl substituted by F, -C
10 aryl substituted by F, -C
5 aryl substituted by Cl, -C
6 aryl substituted by Cl, -C
7 aryl substituted by Cl, -C
8 aryl substituted by Cl, -C
9 aryl substituted by Cl, -C
10 aryl substituted by Cl, -C
1 haloalkyl, -C
2 haloalkyl, and –C
3 haloalkyl.
In some embodiments of formula I, Ia, or Ib, wherein R
10 is hydrogen or deuterium.
In some embodiments, provided here is a compound of formula Ia-1-3, Ib-1-3 or Ic-1-2, and a pharmaceutically acceptable salt thereof or a stereoisomer thereof
In some embodiments of the compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof defined herein, wherein the configuration of the chiral atom in the compound represented by the general formula I, Ia, Ib, Ia-1, Ia-2, Ia-3, Ib-1, Ib-2, Ib-3, Ic-1, Ic-2, is S-or R-configuration.
In some embodiments, provided here is a compound of formula Id-1-4, Ie-1-4, If 1-4. Ig 1-4, Ih 1-4, Ii 1-4, Ij 1-4, or Ik 1-4, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, the tautomer thereof
In some embodiments of formula I, Ia, or Ib, the compound is of formula Ia-3, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof:
wherein Y, R
1, R
1’, R
X1, R
X2, R
5, R
5’ and m is the same as defined herein.
In another aspect, provided herein is a compound of formula II, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, the tautomer thereof
wherein m is 1or 2; R
1, R
1’, R
X1, R
X2, R
5, and R
5’ is the same as defined herein.
In some embodiments of formula II, wherein
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C
1-3 alkyl, -C
2-3 alkenyl, C
2-3 alkynyl, -C
5-10 aryl, -C
1-3 alkylene-COO-C
1-3 alkyl, -C
1-3 alkylene-C
5-10 aryl, -5-10 membered heteroaryl, -5-10 membered heterocyclyl, -C
1-3 alkylene-N (C
1-3 alkyl)
2, -C
1-3 alkylene-O-C
1-3 alkyl, -C
1-3 alkylene-CO-NH-C
1-3 alkyl, -C
1-3 alkylene-CO-5-10 membered heterocyclyl, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-SO-C
1-3 alkyl and C
3-6 cycloalkyl-C
5-10 aryl; each of which can be optionally substituted with one or more substituents, and said substituents are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-3 alkenyl, -C
2-3 alkynyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl;
R
X1 and R
X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C
1-3 alkyl, -C
1-3 alkylene-SH, -C
1-3alkylene-C
2-3 alkenyl, -C
3-6 cycloalkyl, -C
1-3 alkylene-C
3-6 cycloalkyl, -C
1-3 alkylene-S-C
1-3 alkyl, -C
1-3 alkylene-CONH
2,
-C
1-3 alkylene-Se-C
1-3 alkyl, -C
1-3 alkylene-SH, -C
1-3 alkylene-SO
2-C
1-3 alkyl, -C
1-3 alkylene-CO
2-C
1-3 alkyl, C
5-10aryl, -C
1-3 alkylene-C
5-10 aryl, -C
1-3 alkylene-5-10 membered heteroaryl, -C
1-3 alkylene-5-10 membered heterocyclyl, and 5-10 membered heteroaryl, each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -C
2-4 alkenyl, -C
2-4 alkynyl, -C
3-6 cycloalkyl, -C
1-4 alkylene-C
2-4 alkenyl, -4-10 membered heterocyclyl, -COO-C
1-3 alkyl, -C
1-4 alkylene-COO-C
1-3 alkyl, -C
1-4alkylene-SO
2-C
1-3 alkyl, -C
1-4 alkylene-SO-C
1-3 alkyl, -C
1-4 alkylene-S-C
1-3 alkyl, -C
1-4 alkylene-O-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl, -C
5-10 aryl, -C
5-10 aryl substituted by halogen and -C
1-3haloalkyl; or
R
5 and R
5’ are each independently selected from the group consisting of hydrogen, deuterium, -C
1-3 alkyl, -C
3-6cycloalkyl, -C (=O) -C
1-3 alkyl, -C (=O) -5-10 membered heterocyclyl, -C (=O) -5-10 membered carbocyclic, -C (=O) -adamantanyl, -C (=O) -C
1-3 alkylene-O-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-NH-C
1-3 alkyl, -C (=O) -C
1-3 alkylene-N (C
1-3 alkyl)
2, -C (=O) -C
3-6 cycloalkyl, each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO
2, -C
1-3 alkyl, -C
1-3 alkoxy, -COO-C
1-3 alkyl, -NH
2, -NH (C
1-3 alkyl) , -N (C
1-3alkyl)
2, carboxyl.
In some embodiments of formula II, wherein
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, vinyl, allyl, ethyne, propyne, C
5 aryl, C
6 aryl, C
7 aryl, C
8 aryl, C
9 aryl, C
10 aryl, -CH
2-COO-CH
3, - (CH
2)
2-COO-CH
3, - (CH
2)
3-COO-CH
3, -CH
2-COO-CH
2CH
3, - (CH
2)
2-COO-CH
2CH
3, - (CH
2)
3-COO-CH
2CH
3, -CH
2-COO-CH
2CH
2CH
3, - (CH
2)
2-COO-CH
2CH
2CH
3, - (CH
2)
3-COO-CH
2CH
2CH
3, -CH
2-COO-CH (CH
3)
2, - (CH
2)
2-COO-CH (CH
3)
2, - (CH
2)
3-COO-CH (CH
3)
2, -CH
2-C
5 aryl, -CH
2-C
6 aryl, - (CH
2)
2-C
6 aryl, - (CH
2)
3-C
6 aryl, -CH
2-C
7 aryl, - (CH
2)
2-C
7 aryl, - (CH
2)
3-C
7 aryl, -CH
2-C
8 aryl, - (CH
2)
2-C
8 aryl, - (CH
2)
3-C
8 aryl, -CH
2-C
9 aryl, - (CH
2)
2-C
9 aryl, - (CH
2)
3-C
9 aryl, -CH
2-C
10 aryl, - (CH
2)
2-C
10 aryl, - (CH
2)
3-C
10 aryl, -5 membered heteroaryl, -6 membered heteroaryl, -7 membered heteroaryl, -8 membered heteroaryl, -9 membered heteroaryl, -10 membered heteroaryl, each of which can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO
2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl;
R
X1 and R
X2 are each independently selected from the group consisting from hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl,
-CO-CH
3, -SO-CH
3, -SO
2-CH
3, -NH-CO-CH
3,
and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; or
R
5 and R
5’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C (=O) -CH
3, -C (=O) -CH
2CH
3, -C (=O) -CH
2CH
2CH
3, -C (=O) -CH (CH
3)
2,
-C (=O) -CH
2-O-CH
3, -C (=O) - (CH
2)
2-O-CH
3, -C (=O) - (CH
2)
3-O-CH
3, -C (=O) -CH
2-O-CH
2CH
3, -C (=O) -CH
2-NH-CH
3, -C (=O) - (CH
2)
2-NH-CH
3, -C (=O) - (CH
2)
3-NH-CH
3, -C (=O) -CH
2-NH-CH
2CH
3, -C (=O) -CH
2-N (CH
3)
2, -C (=O) - (CH
2)
2-N (CH
3)
2, -C (=O) - (CH
2)
3-N (CH
3)
2, -C (=O) -CH
2-N (CH
2CH
3)
2, each of which can be optional substituted with one or more substituents, and said substituents are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -COO-CH
3, -COO-CH
2CH
3, -NH
2, -NHCH
3, -NHCH
2CH
3, -NHCH
2CH
2CH
3, -NHCH (CH
3)
2, -N (CH
3)
2, -N (CH
2CH
3)
2, -N (CH
2CH
2CH
3)
2, -N (CH (CH
3)
2)
2, carboxyl.
In some embodiments of formula II, wherein
R
1 and R
1’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, tert-butyl,
R
X1 and R
X2 are each independently selected from the group consisting from hydrogen, deuterium methyl, ethyl, propyl, isopropyl, tert-butyl,
R
5 and R
5’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C (=O) -CH
3, -C (=O) -CH
2CH
3, -C (=O) -CH
2CH
2CH
3, -C (=O) -CH (CH
3)
2,
In another aspect, provided here is a compound of formula III, IV, V, VI or VII, and a pharmaceutically acceptable salt thereof or a stereoisomer thereof
wherein Z, R
1, R
1’, R
4, R
10, R
3, R
3’, R
X1, R
X2, R
11, are as defined herein.
In some embodiments of formula I, Ia, Ib, Ia-1, Ia-2, Ia-3, Ib-1, Ib-2, Ib-3, Ic-1, Ic-2, Id-1-4, Ie-1-4, If 1-4. Ig 1-4, Ih 1-4, Ii 1-4, Ij 1-4, Ik 1-4, II, III, IV, V, VI, or VII, wherein the compound is selected from:
In another embodiment, provided here are the following compounds or pharmaceutically acceptable salt thereof of the invention:
In another aspect, provided here is a pharmaceutical composition comprising the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention; and a pharmaceutically acceptable carrier, diluent or excipient.
In yet another aspect, provided here is a method of treating a subject having a cancer, said method comprising administering to the subject a therapeutically effective amount of the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention; or the pharmaceutical composition of the present invention. In still other aspects, the presently disclosed subject matter provides the use of a compound of the present invention, or a pharmaceutical composition thereof, for treating a disease or condition. In some embodiments, the disease or condition is selected from the group consisting of an infection, cancer, an autoimmune disease, an inflammatory disease, and a neurodegenerative or neurological disease.
As used herein, a "cancer" in a patient refers to the presence of cells possessing characteristics typical of cancer-causing cells, for example, uncontrolled proliferation, loss of specialized functions, immortality, significant metastatic potential, significant increase in anti-apoptotic activity, rapid growth and proliferation rate, and certain characteristic morphology and cellular markers. In some circumstances, cancer cells will be in the form of a tumor; such cells may exist locally within an animal, or circulate in the blood stream as independent cells, for example, leukemic cells. A "tumor, " as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. A "solid tumor, " as used herein, is an abnormal mass of tissue that generally does not contain cysts or liquid areas. A solid tumor may be in the brain, colon, breasts, prostate, liver, kidneys, lungs, esophagus, head and neck, ovaries, cervix, stomach, colon, rectum, bladder, uterus, testes, and pancreas, as non-limiting examples. In some embodiments, the solid tumor regresses or its growth is slowed or arrested after the solid tumor is treated with the presently disclosed methods. In other embodiments, the solid tumor is malignant. In some embodiments, the cancer comprises Stage 0 cancer. In some embodiments, the cancer comprises Stage I cancer. In some embodiments, the cancer comprises Stage II cancer. In some embodiments, the cancer comprises Stage III cancer. In some embodiments, the cancer comprises Stage IV cancer. In some embodiments, the cancer is refractory and/or metastatic. For example, the cancer may be refractory to treatment with radiotherapy, chemotherapy or monotreatment with immunotherapy. Cancer as used herein includes newly diagnosed or recurrent cancers, including without limitation, acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, breast carcinoma, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, colorectal carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, head and neck squamous cell carcinoma, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung carcinoma, Lewis lung carcinoma, lymphoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premenopausal breast cancer, prostate cancer, rhabdomyosarcoma, reticulum cell sarcoma, sarcoma, small cell lung cancer, a solid tumor, stomach cancer, testicular cancer, and uterine carcinoma.
In some embodiments, the cancer is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, colon cancer, leukemia, glioblastoma or head and neck cancer.
In another aspect, provided here is use of the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention; or the pharmaceutical composition of the present invention for the manufacture of a medicament for the treatment of a cancer.
In some embodiments, the cancer is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, colon cancer, leukemia, glioblastoma or head and neck cancer.
In some embodiments, the medicament is used as a glutamine antagonist.
As used herein, the term "glutamine antagonist" refers to a glutamine analog that interfers with a glutamine metabolic pathway, e.g., the inhibition or blocking of a metabolic pathway downstream of glutamine in which glutamine acts as a precursor of one or more non-glutamine compounds. Examples of such metabolic pathways are well known (see, e.g., Hensley et al, "Glutamine and cancer: cell biology, physiology, and clinical opportunities" J Clin Invest. 2013; 123 (9) : 3678-3684; DeBerardinis et al, "Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer" Oncogene. 2009; 29 (3) : 313-324; and Medina et al, "Relevance of glutamine metabolism to tumor cell growth" Mol Cell Biochem. 1992; 113 (1) : 1 -15) . In some contexts, the term glutamine antagonist also includes glutamine analogs that inhibit glutamine uptake by cells, thereby reducing its biological activity. Diseases or conditions wherein excess and/or aberrant glutamine.
In yet another aspect, provided here is the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention; or the pharmaceutical composition of the present invention, for use in treating the disease or condition. In some embodiments, the disease or condition is selected from the group consisting of an infection, cancer, an autoimmune disease, an inflammatory disease, and a neurodegenerative or neurological disease.
In yet another aspect, provided here is the compound, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention; or the pharmaceutical composition of the present invention for use in therapy.
In yet another aspect, provided here is the compound, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention; or the pharmaceutical composition of the present invention for use as a medicament.
In yet another aspect, provided here is the compound, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention; or the pharmaceutical composition of the present invention, for use in treating the disease or condition. In some embodiments, the disease or condition is selected from the group consisting of an infection, cancer, an autoimmune disease, an inflammatory disease, and a neurodegenerative or neurological disease.
In yet another aspect, there is provided the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of the present invention; or the pharmaceutical composition of the present invention for use in the treatment of a cancer.
In some embodiments, the cancer is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, colon cancer, leukemia, glioblastoma or head and neck cancer.
FIG. 1 is a graph showing the concentrations of DON and reference compound over time after IV infusion.
FIG. 2 is a graph showing the concentrations of DON and compound 2 over time after IV infusion.
FIG. 3 is a graph showing the concentrations of DON and compound 1 over time after IV infusion.
FIG. 4 is a bar graph showing the stability of compounds after incubation for 60 minutes in the presence of human microsomes.
FIG. 5 is a bar graph showing the stability of compounds after incubation for 60 minutes in the presence of human microsomes.
FIG. 6 is a graph showing the body weight changes of the mice in the different groups.
FIG. 7 is a graph showing anti-tumor activity of test compounds in MC38 syngeneic model.
Definition
The term “halogen” or “halo” , as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo. The preferred halogen groups include -F, -Cl and -Br.
The term “alkyl” , as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl. Similary, C
1-6, as in C
1-6alkyl is defined to identify the group as having 1, 2, 3, 4, 5 or 6 carbon atoms in a linear or branched arrangement.
The term “alkylene” means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. For example, methylene (i.e., -CH
2-) , ethylene (i.e., -CH
2-CH
2-or -CH (CH
3) -) and propylene (i.e., -CH
2-CH
2-CH
2-, -CH (-CH
2-CH
3) -or -CH
2-CH (CH
3) -) .
The term “alkenyl” means a straight or branch-chained hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms in length. For example, “C
2-6alkenyl” contains from 2 to 6 carbon atoms. Alkenyl group include, but are not limited to, for example, ethenyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, hepetenyl, octenyl and the like.
The term “alkynyl” contains a straight or branch-chained hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms in length. For example, “C
2-6alkynyl” contains from 2 to 6 carbon atoms. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
The term “alkoxy” radicals are oxygen ethers formed from the previously described alkyl groups.
The term “aryl” , as used herein, unless otherwise indicated, refers to an unsubstituted or substituted mono or polycyclic aromatic ring system containing carbon ring atoms. The preferred aryls are mono cyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls.
The term “heterocyclyl” , as used herein, unless otherwise indicated, refers to unsubstituted and substituted mono or polycyclic non-aromatic ring system containing one or more heteroatoms, which comprising moncyclic heterocyclyl, bicyclic heterocyclyl, bridged heterocyclyl, fused heterocyclyl or sipro heterocyclyl. Preferred heteroatoms include N, O, and S, including N-oxides, sulfur oxides, and dioxides. Preferably the ring is three to ten membered and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, preferably one, two or three, are included within the present definition. Examples of such heterocyclic groups include, but are not limited to azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone and oxadiazolyl.
The term “heteroaryl” , as used herein, unless otherwise indicated, represents an aromatic ring system containing carbon (s) and at least one heteroatom. Heteroaryl may be monocyclic or polycyclic, substituted or unsubstituted. A monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms. A polycyclic heteroaryl ring may contain fused, spiro or bridged ring junction, for example, bycyclic heteroaryl is a polycyclic heteroaryl. Bicyclic heteroaryl rings may contain from 8 to 12 member atoms. Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (cabons and heteroatoms) . Examples of heteroaryl groups include, but are not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adeninyl, quinolinyl or isoquinolinyl.
The term “cycloalkyl” refers to a substituted or unsubstituted monocyclic ring, bicyclic ring bridged ring, fused ring, sipiro ring non-aromatic ring system onle containing carbon atoms. Examplary “cycloalkyl” groups includes but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and so on.
The term “carbocycle” refers to a substituted or unsubstituted monocyclic ring, bicyclic ring bridged ring, fused ring, sipiro ring non-aromatic ring system only containing carbon atoms ( (i.e., C
3-14 ) . Non-limiting exemplary carbocycle groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, and cyclopentenyl, cyclohexenyl.
For the purpose of the present disclosure, the term "carbocycle " as used by itself or as part of another group means that the carbocycle as defined above substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino) alkyl, (carboxamido) alkyl, mercaptoalkyl, and (heterocyclo) alkyl. In one embodiment, the optionally substituted cycloalkyl is substituted with two substituents. In another embodiment, the optionally substituted cycloalkyl is substituted with one substituent.
As used herein, the term "fused ring" refers to a cyclic group formed by substituents on separate atoms in a straight or branched alkane, or to a cyclic group formed by substituents on separate atoms in another ring.
As used herein, the term "spirocycle" or "spirocyclic ring" refers to a pendant cyclic group formed by substituents on a single atom.
As used herein, "optional" or "optionally, " may mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" may encompass both "aryl" and "substituted aryl" as defined herein. It will be understood by those ordinarily skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible, and/or inherently unstable.
The term “composition” , as used herein, is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
The compounds of the present invention may also be present in the form of pharmaceutically acceptable salt (s) . For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salt (s) " . The pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts. The pharmaceutically acceptable acidic/anionic salt generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid. Representative organic or inorganic acids include hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic. Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.
The present invention includes within its scope the prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds that are readily converted in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs" , ed. H. Bundgaard, Elsevier, 1985.
It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques know in the art as well as those methods set forth herein.
The present invention includes compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof.
The present invention includes all stereoisomers of the compound and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.
The term “stereoisomer” as used in the present invention refers to an isomer in which atoms or groups of atoms in the molecule are connected to each other in the same order but differ in spatial arrangement, including conformational isomers and conformational isomers. The configuration isomers include geometric isomers and optical isomers, and optical isomers mainly include enantiomers and diastereomers. The invention includes all possible stereoisomers of the compound.
The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. The isotopes of hydrogen can be denoted as
1H (hydrogen) ,
2H (deuterium) and
3H (tritium) . They are also commonly denoted as D for deuterium and T for tritium. In the application, CD
3 denotes a methyl group wherein all of the hydrogen atomsare deuterium. Isotopes of carbon include
13C and
14C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent.
When a tautomer of the compound exists, the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
When the compound and pharmaceutically acceptable salts thereof exist in the form of solvates or polymorphic forms, the present invention includes any possible solvates and polymorphic forms. A type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone or the like can be used.
The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Since the compounds are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60%pure, more suitably at least 75%pure, especially at least 98%pure (%are on a weight for weight basis) .
The pharmaceutical compositions of the present invention comprise a compound (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
In practice, the compounds or a prodrug or a metabolite or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous) . Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound or a pharmaceutically acceptable salt thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt. The compounds or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
The pharmaceutical carrier employed can be, for example, a solid, liquid or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen. In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.
A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient. For example, a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 0.05 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 0.0lmg to about 2g of the active ingredient, typically 0.01mg, 0.02mg, 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg or l000mg.
Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound of this invention or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 0.05wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.
Generally, dosage levels on the order of from about 0.001mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions or alternatively about 0.05mg to about 7g per patient per day. For example, inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS) , may be effectively treated by the administration of from about 0.001 to 50mg of the compound per kilogram of body weight per day or alternatively about 0.05mg to about 3.5g per patient per day.
It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
These and other aspects will become apparent from the following written description of the invention.
Examples
The following examples are provided to better illustrate the present invention. All parts and percentages are by weight and all temperatures are degrees Celsius, unless explicitly stated otherwise. The following abbreviations have been used in the examples:
SERIES 1-COMPOUNDS OF Formula I or IaIntermediate A1
Intermediate A1 was prepared refering to the compound 3 in WO2017023774 in Scheme 1 at page 82.
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Intermediate B1
Step a: To a solution of (S) -2- (l2-azaneyl) butanoic acid (1023 mg, 9.9205 mmol) in acetic acid (10 mL) was added acetic anhydride (1769 mg, 17.3281 mmol) . The mixture was stirred for 2h at 100 ℃. The reaction mixture was concentrated under reduced pressure. The residue was stirred in EA, then filtered and the solid was collected to afford (S) -2-acetamidobutanoic acid (628 mg, 4.3264 mmol) . MS: m/z 144 (M-H)
-
Step b: To a solution of (S) -2-acetamidobutanoic acid (0.628 g, 4.3264 mmol) and methyl (S) -2-amino-6-diazo-5-oxohexanoate (498 mg, 2.6893 mmol) in DCM (5 mL) was added ethyl cyanoglyoxylate-2-oxime (624 mg, 4.3909 mmol) , N, N'-Diisopropylcarbodiimide (539 mg, 4.2710 mmol) and 2, 4, 6-Collidine (679 mg, 5.6033 mmol) at 0 ℃. The mixture was stirred at RT for 1 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by FLASH. The product’s solution was concentrated under reduced pressure to afford methyl (S) -2- ( (S) -2-acetamidobutanamido) -6-diazo-5-oxohexanoate (1269 mg, 4.0631 mmol) . MS: m/z 313 (M+H)
+
Step c: To a solution of methyl (S) -2- ( (S) -2-acetamidobutanamido) -6-diazo-5-oxohexanoate (1.269 g, 4.0631 mmol) in THF (10 mL) added LiOH (156.2 mg, 6.5224 mmol) in water (5 mL) at 0℃. The mixture was stirred for 1h at RT and the reaction mixture was purified by FLASH (MeCN/H2O, 0~10%) . The product’s solution was concentrated under reduced pressure and the residue was further purified by pre-HPLC. The product’s solution was concentrated under reduced pressure to afford (S) -2- ( (S) -2-acetamidobutanamido) -6-diazo-5-oxohexanoic acid (101 mg, 338.5917 μmol) . MS: m/z 299 (M+H)
+
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Intermediate B2
Intermediate B2 was prepared from known patent, WO2020150639, where it was as compound 3 in Scheme 1 at page 121.
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Intermediate B3
Step a: To a solution of DL-Serine (1.64 g, 15.6054 mmol) , 5-Fluoroindole (1.01 g, 7.4738 mmol) was added acetic anhydride (5 mL) and acetic acid (20mL) under N
2 protection. The mixture was stirred at 80 ℃ for 3 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC. The product’s solution was concentrated under reduced pressure to afford 2-acetamido-3- (5-fluoro-1H-indol-3-yl) propanoic acid (2044 mg, 7.7350 mmol) . MS: m/z 265 (M+H)
+,
Step b: Referenced B2
The following compound was synthesized using the above procedure or modification procedure with the corresponding starting materials.
Intermediate C1
Step a: To a solution of Nalpha-Fmoc-L-Tryptophan (1348 mg, 3.161 mmol) , isopropyl (S) -2-amino-6-diazo-5-oxohexanoate (452 mg, 2.120 mmol) and 4-Methylmorpholine (666 mg, 6.584 mmol) in DMF (10 mL) was added HATU (1226 mg, 3.224 mmol) at 0℃. The mixture was stirred for 3h at 0 ℃~RT, then to the mixture was added water (10 mL) and DCM (10 mL) . The reaction mixture was filtered and the organic phase was collected. The aqueous solution was extracted with DCM (10 mL×2) and the organic phase was combined. The combined organic phase was washed with brine (10 mL×3) and dried over anhydrous Na
2SO
4. The resulting mixture was concentrated under reduced pressure. The residue was purified by FLASH (MeCN/H2O, 0~60%) and the product’s solution was concentrated under reduced pressure to afford isopropyl (S) -2- ( (S) -2- ( ( ( (9H-fluoren-9-yl) methoxy) carbonyl) amino) -3- (1H-indol-3-yl) propanamido) -6-diazo-5-ox ohexanoate (742 mg, 1.194 mmol, 56.306%yield) . MS: m/z 622 (M+H)
+
Step b: To a solution of isopropyl (S) -2- ( (S) -2- ( ( ( (9H-fluoren-9-yl) methoxy) carbonyl) amino) -3- (1H-indol-3-yl) propanamido) -6-diazo-5-ox ohexanoate (469 mg, 754.406 μmol) in DCM (50 mL) was added piperidine (224 mg, 2.631 mmol) at 0 ℃. The mixture was stirred for 6h at 0 ℃~RT. The reaction mixture was concentrated under reduced pressure. The residue was purified by FLASH (MeCN/H2O, 0~100%) and the product’s solution was concentrated under reduced pressure to afford isopropyl (S) -2- ( (S) -2-amino-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoate (189 mg, 473.159 μmol, 62.719%yield) . MS: m/z 400 (M+H)
+
Step c: To a solution of isobutyric acid (0.0813 g, 922.765 μmol) , N, N'-Diisopropylcarbodiimide (0.1202 g, 952.464 μmol) 2, 4, 6-Collidine (0.1642 g, 1.355 mmol) and Ethyl cyanoglyoxylate-2-oxi (0.1876 g, 1.320 mmol) in DMF (5 mL) was added isopropyl (S) -2- ( (S) -2-amino-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoate (0.0938 g, 234.827 μmol) at 0 ℃. The mixture was stirred for 5 h at 0 ℃~RT and to the mixture was added water (10 mL) and DCM (10 mL) , then the reaction mixture was filtered and the organic phase was collected. The aqueous solution was extracted with DCM (10 mL×2) and the organic phase was combined. The combined organic phase washed with brine (10 mL×3) and dried over anhydrous Na
2SO
4. The resulting mixture was concentrated under reduced pressure. The residue was purified by FLASH (MeCN/H2O, 0~45%) and the product’s solution was concentrated under reduced pressure to afford Isopropyl (S) -2- ( (S) -3- (1H-indol-3-yl) -2-isobutyramidopropanamido) -6-diazo-5-oxohexanoate (100 mg, 212.978 μmol, 90.696%yield) . MS: m/z 470 (M+H)
+
Step d: To a solution of
Isopropyl (S) -2- ( (S) -3- (1H-indol-3-yl) -2-isobutyramidopropanamido) -6-diazo-5-oxohexanoate (98 mg, 208.718 μmol) in THF (6 mL) was added NaOH (25 mg, 625.045 μmol) in water (2mL) at 0 ℃. The mixture was stirred for 1 h at RT. The reaction mixture was purified by FLASH (MeCN/H2O, 0~10%) and the product’s solution was concentrated under reduced pressure to afford
(S) -2- ( (S) -3- (1H-indol-3-yl) -2-isobutyramidopropanamido) -6-diazo-5-oxohexanoic acid (90 mg, 210.550 μmol) . MS: m/z 428 (M+H)
+
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Intermediate D1 and D2
Step a: To a solution of Indole (2.33 g, 19.889 mmol) and Ytterbium (III) triflate hydrate (1.79 g, 2.804 mmol) in Ethylene chloride (15 mL) under nitrogen atmosphere was added (2S) -Methylglycidate (1.02 g, 9.991 mmol) . The mixture was heated to 85℃, stirred for 3 h at this temperature. After cooling to RT, the reaction mixture was concentrated under reduced pressure. The residue was purified by FLASH (eluting with MeCN : H
2O=0-80%, v/v) . The product’s solution was concentrated under reduced pressure to remove MeCN. The product mixture was diluted with EA, dried over anhydrous Na
2SO
4, filtered and concentrated under reduced pressure to give methyl (S) -2-hydroxy-3- (1H-indol-3-yl) propanoate, Intermediate D1, (779 mg, 3.553 mmol) . MS: m/z 220 (M+H)
+.
Step b: To a 0℃ solution of methyl (S) -2-hydroxy-3- (1H-indol-3-yl) propanoate (0.283g, 1.291 mmol) in DCM (3 mL) was added TEA (498 mg, 4.921 mmol) , then 4-methylbenzenesulfonyl chloride was added dropwise. The mixture was stirred for 1 h at this temperature and the reaction mixture was quenched with NaHCO
3 (aq) (10 mL) . The aqueous layer was separated and extracted with DCM (2×10 mL) . The combined organic layers were dried over anhydrous Na
2SO
4, filtered and concentrated under reduced pressure to give methyl (S) -3- (1H-indol-3-yl) -2- (tosyloxy) propanoate (482 mg) which was used in next step without any further purification. MS: m/z (374)
+.
Step c: To a 0℃ solution of ethanethiol (327 mg, 5.263 mmol) and MeONa (286 mg, 5.294 mmol) in MeOH (3 mL) under nitrogen atmosphere was added methyl (S) -3- (1H-indol-3-yl) -2- (tosyloxy) propanoate (482. mg, 1.291 mmol) in MeOH (2 mL) dropwise. Then the resulting solution was stirred for 2 hours at room temperature. HCl (4M solution in EA, 3 mL) was added, the solid was filtered through a pad of Celite followed by MeOH washing and the filtrate was concentrated under reduced pressure. The residue was purified by FLASH (eluting with MeCN : H
2O=0-80%, v/v) . The product’s solution was concentrated under reduced pressure to give methyl (R) -2- (ethylthio) -3- (1H-indol-3-yl) propanoate (126 mg, 478.442 μmol) . MS: m/z (264)
+.
Step d: To a solution of methyl (R) -2- (ethylthio) -3- (1H-indol-3-yl) propanoate (125 mg, 474.644 μmol) in THF (2 mL) was added LiOH (2M solution in water, 1 mL) . The mixture was stirred for 2 h at room temperature. After citric acid (solid) was added, the reaction was diluted with water (5mL) and extracted with EA (2×10 mL) . The combined organic layers were dried over anhydrous Na
2SO
4, filtered, and concentrated under reduced pressure to give (R) -2- (ethylthio) -3- (1H-indol-3-yl) propanoic acid, Intermediate D2 (118 mg) . MS: m/z (250)
+.
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Intermediate D3
Step a: To a solution of methyl (S) -2-hydroxy-3- (1H-indol-3-yl) propanoate (2 g, 9.123 mmol) in DCM (20 mL) was added Imidazole (2061 mg, 30.274 mmol) and TBDMS-Cl (2980 mg, 19.772 mmol) . The mixture was stirred for overnight at RT. The reaction mixture was quenched with Water (10 mL) and extracted with DCM (10 mL) . The reaction mixture was separated and organic extracts were collected. The aqueous solution was extracted with DCM (2×10 mL) . The residue was purified by wet column chromatography with EA/Hex (0-20%) . The product’s solution was concentrated under reduced pressure. The methyl (2S) -2- [tert-butyl (dimethyl) silyl] oxy-3- (1H-indol-3-yl) propanoate (3099 mg) was obtained. MS: m/z 334 (M+H)
+.
Step b: To a -78℃ solution of methyl (S) -2- ( (tert-butyldimethylsilyl) oxy) -3- (1H-indol-3-yl) propanoate (3.099g, 9.292 mmol) in THF (30 mL) was added LiHMDS (10.5 mL, 10.491 mmol) . The mixture was stirred for 30min at -78℃. Then Carbobenzyloxy chloride (4623 mg, 27.100 mmol) was dropped into the mixture at -78℃. The reaction mixture was stirred for 1h at this temperature. The reaction was quenched with sat. NH
4Cl, and the aqueous solution was extracted with EA (2×10 mL) . The combined organic extracts were washed with brine (3×10 mL) , dried over anhydrous Na
2SO
4. The organic phase was concentrated under reduced pressure. The benzyl (S) -3- (2- ( (tert-butyldimethylsilyl) oxy) -3-methoxy-3-oxopropyl) -1H-indole-1-carboxylate (4345 mg) was obtained. MS: m/z 468 (M+H)
+.
Step c: To a solution of benzyl (S) -3- (2- ( (tert-butyldimethylsilyl) oxy) -3-methoxy-3-oxopropyl) -1H-indole-1-carboxylate (4.345 g, 9.292 mmol) in THF (30 mL) was added Tetrabutylammonium fluoride (5 mL) . The mixture was stirred for overnight at RT. The reaction mixture was concentrated under reduced pressure. The residue was purified by FLASH with EA/Hex (0-60%) . The product’s solution was concentrated under reduced pressure. The benzyl 3- [ (2S) -2-hydroxy-3-methoxy-3-oxo-propyl] indole-1-carboxylate (2.21 g) was obtained. MS: m/z 354 (M+H)
+.
Step d: To a solution of benzyl 3- [ (2S) -2-hydroxy-3-methoxy-3-oxo-propyl] indole-1-carboxylate (103 mg, 291.481 μmol) , and 4A molecular sieve in CH
3I (1mL) was added Silver oxide (216 mg, 932.098 μmol) . The mixture was stirred for overnight at RT. The reaction mixture was concentrated under reduced pressure. The reaction mixture was diluted with EA (5mL) and filtered, the filtrate was concentrated to afford benzyl (S) -3- (2, 3-dimethoxy-3-oxopropyl) -1H-indole-1-carboxylate (107.088 mg, 100.000%yield) . MS: m/z 368 (M+H)
+.
Step e: To a solution of benzyl (S) -3- (2, 3-dimethoxy-3-oxopropyl) -1H-indole-1-carboxylate (0.107g, 291.240 μmol) in THF (5 mL) and MeOH (5mL) was added NaOH (3mL, 3M/L) . The mixture was stirred for 1h at RT. The reaction mixture was adjusted the pH to 3 with 1M HCl. The aqueous solution was extracted with EA (2×10 mL) . The combined organic extracts were washed with brine (3×10 mL) , dried over anhydrous Na
2SO
4. The organic phase was concentrated under reduced pressure and (S) -3- (1H-indol-3-yl) -2-methoxypropanoic acid (71 mg) was obtained. MS: m/z 220 (M+H)
+.
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Other Intermediates
EXAMPLE 1
(S) -2- ( (S) -2-acetamido-3-phenylpropanamido) -6-diazo-N- (4-fluorobenzyl) -5-oxohexanamide (compound 1)
To a solution of (2S) -2- [ [ (2S) -2-acetamido-3-phenyl-propanoyl] amino] -6-diazo-5-oxo-hexanoic acid (174 mg, 482.8451 μmol) , 4-Fluorobenzylamine (208 mg, 1.6621 mmol) and NMM (178 mg, 1.7598 mmol) in DMF (10 mL) was added HATU (292 mg, 767.9577μmol) at 0 ℃. The mixture was stirred at RT for 1 h. The reaction mixture was purified by FLASH. The residue was further purified by pre-HPLC and the product’s solution was concentrated under reduced pressure to afford (S) -2- ( (S) -2-acetamido-3-phenylpropanamido) -6-diazo-N- (4-fluorobenzyl) -5-oxohexanamide (0.1525 g, 326.2090 μmol) by lyophilization. MS: m/z 468 (M+H)
+,
1H NMR (400 MHz, CD
3OD) δδ 7.31 –7.26 (m, 2H) , 7.26 –7.21 (m, 4H) , 7.21 –7.15 (m, 1H) , 7.09 –6.97 (m, 2H) , 4.55 (dd, J = 8.8, 6 .0 Hz, 1H) , 4.38 –4.21 (m, 3H) , 3.10 (dd, J = 13.9, 6.0 Hz, 1H) , 2.89 (dd, J = 13.9, 8.8 Hz, 1H) , 2.37 (s, 2 H) , 2.17 –2.03 (m, 1H) , 1.97 –1.84 (m, 4H) .
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Example 2
(S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -N-benzyl-6-diazo-5-oxohexanamide (compound 494)
To a solution of (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoic acid (0.0713 g, 178.518 μmol) , Benzylamine (0.0491 g, 458.225 μmol) and NMM (0.0589 g, 582.321 μmol) in DMF (5 mL) was added HATU (0.1462 g, 384.505 μmol) . The mixture was stirred at RT for 3 h. And the mixture was added water (10 mL) and DCM (10 mL) . The reaction mixture was filtered and the organic extracts were collected. The aqueous solution was extracted with DCM (10 mL×2) . The combined organic extracts were washed with brine (10 mL×3) and dried over anhydrous Na
2SO
4. The resulting mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC. The product’s solution was concentrated under reduced pressure. The (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -N-benzyl-6-diazo-5-oxohexanamide (0.0507 g, 103.779 μmol) was obtained by lyophilization. MS: m/z 489 (M+H)
+,
1H NMR (400 MHz, CD
3OD) δ 7.58 (d, J = 7.9 Hz, 1H) , 7.34 –7.26 (m, 3H) , 7.25 –7.18 (m, 3H) , 7.14 (s, 1H) , 7.12 –7.05 (m, 1H) , 7.06 –6.98 (m, 1H) , 4.58 (t, J = 6.8 Hz, 1H) , 4.34 –4.16 (m, 3H) , 3.20 (ddd, J = 33.1, 14.5, 6.8 Hz, 2H) , 2.26 –2.07 (m, 2H) , 2.06 –1.96 (m, 1H) , 1.94 (s, 3H) , 1.87 –1.75 (m, 1H) .
EXAMPLE 3
Ethyl ( (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoyl) -L-valinate (compound 495)
To a solution of (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoic acid (202 mg, 505.7856 μmol) , Ethyl L-valinate hydrochloride (215 mg, 1.1835 mmol) and NMM (168 mg,1.6609 mmol) in DMF (10 mL) was added HATU (408 mg, 1.073 mmol) at 0 ℃. The mixture was stirred at RT for 16 h. The reaction mixture was purified by FLASH. The residue was further purified by pre-HPLC. The product’s solution was concentrated under reduced pressure. Ethyl ( (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoyl) -L-valinate (52.7 mg,100.0791 μmol) was obtained by lyophilization. MS: m/z 527 (M+H)
+,
1H NMR (400 MHz, CDCl3) δ 8.22 (s, 1H) , 7.69 (d, J = 7.9 Hz, 1H) , 7.38 (d, J = 8.0 Hz, 1H) , 7.23 (dd, J = 16.4, 8.6 Hz, 2H) , 7.15 (t, J = 7.5 Hz, 1H) , 7.10 (s, 1H) , 6.16 (d, J = 7.5 Hz, 1H) , 4.77 (m, J = 6.0 Hz, 1H) , 4.43 –4.37 (m, 1H) , 4.35 (m, J = 6.1 Hz, 1H) , 4.25 –4.16 (m, 2H) , 3.41 (m, J = 14.9 Hz, 1H) , 3.22 –3.09 (m, 1H) , 2.51 –2.34 (m, 1H) , 2.31 –2.15 (m, 2H) , 2.02 (s, J = 7.4 Hz, 3H) , 1.98 –1.84 (m, 2H) , 1.30 (t, J = 7.1 Hz, 3H) , 0.97 (t, J = 7.3 Hz, 6H) .
EXAMPLE 4
(S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-N- (4-fluorobenzyl) -5-oxohexanamide (compound 496)
To a solution of (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoic acid (203mg, 508.2628μmol) , (4-fluorophenyl) methanamine (128 mg, 1.0228mmol) and 1-Methylimidazole (141mg, 1.7173mmol) in DMF (2 mL) was added TCFH (219mg, 780.5288 μmol) . The mixture was stirred at RT for 16 h. The reaction mixture was purified by FLASH. The residue was further purified by pre-HPLC. The product’s solution was concentrated under reduced pressure. The (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-N- (4-fluorobenzyl) -5-oxohexanamide (52 mg, 102.6597 μmol) was obtained by lyophilization. MS: m/z 507 (M+H)
+,
1H NMR (400 MHz, CDCl
3) δ 7.99 (s, 1H) , 7.61 –7.51 (m, 1H) , 7.28 (d, J = 8.1 Hz, 1H) , 7.13 (d, J = 7.2 Hz, 2H) , 6.98 (ddd, J = 24.6, 15.6, 7.8 Hz, 3H) , 6.77 –6.62 (m, 1H) , 5.97 (d, J = 5.5 Hz, 1H) , 4.53 (dd, J = 11.2, 5.6 Hz, 1H) , 4.18 (d, J = 22.1 Hz, 2H) , 3.76 (s, 1H) , 3.30 (dd, J = 14.6, 5.3 Hz, 1H) , 3.17 –3.01 (m, 1H) , 2.27 (s, 1H) , 2.11 (d, J = 17.1 Hz, 1H) , 1.88 (s, 1H) , 1.79 (s, 1H) , 1.48 (s, 3H) .
EXAMPLE 5
2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxo-N- (4- (trifluoromethyl) phenyl) hexanamide (compound 497)
(S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoic acid (150 mg, 375.5636 μmol) , tetrahydrofura (3 mL) were added to a vial. Then to the mixture was added 4- (trifluoromethyl) aniline (124.8 mg, 774.5578 μmol) , XtalFluor-E (133 mg, 580.7990 μmol) at an ice water bath. The mixture was cloudy. The ice water bath was removed and the mixture was stirred at room temperature for overnight. DMF (0.75 ml, 5V) was added into the vial, and the mixture was clean. Then the mixture was stirred overnight at room temperature. The reaction mixture was purified by flash (MeCN/H
2O=0%~70%) , and the product fractions were collected and concentrated. 2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxo-N- (4- (trifluoromethyl) phenyl) hexana mide (4.9 mg, 9.0321 μmol) was obtained by lyophilization as a white solid. MS: m/z 543 (M+H)
+,
1H NMR (400 MHz, CD
3OD ) δ 7.88 (d, J = 8.5 Hz, 1H) , 7.75 (d, J = 8.5 Hz, 1H) , 7.58 (t, J = 8.5 Hz, 3H) , 7.32 (dd, J = 36.1, 8.0 Hz, 1H) , 7.16 (d, J = 2.0 Hz, 1H) , 7.08 –7.01 (m, 1H) , 7.01 –6.95 (m, 1H) , 4.70 –4.41 (m, 1H) , 4.36 –4.06 (m, 1H) , 3.26 –3.05 (m, 2H) , 2.22 –2.02 (m, 1H) , 2.00 (d, J = 7.7 Hz, 3H) , 1.96 –1.79 (m, 1H) , 1.53 (m, J = 51.9 Hz, 1H) , 1.29 (m, 1H) .
EXAMPLE 6
methyl ( (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoyl) glycinate (compound 498)
To a solution of (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoic acid (0.1526 g, 382.0734 μmol) in DMF (5mL) was added N, N'-Diisopropylcarbodiimide (0.0741 g, 587.1679 μmol) , 2, 4, 6-Collidine (0.0951g, 784.7881μmol)
Ethyl cyanoglyoxylate-2-oxime (0.1079 g, 759.2576μmol) and Glycine methyl ester hydrochloride (0.1582 g, 1.2600mmol) at 0 ℃. The mixture was stirred at 0 ℃~RT for 3h. The aqueous solution was extracted with DCM (10 mL×2) . The combined organic extracts were washed with brine (10 mL×3) and dried over anhydrous Na
2SO
4. The reaction mixture was purified by FLASH. The residue was further purified by pre-HPLC. The product’s solution was concentrated under reduced pressure to afford methyl ( (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoyl) glycinate (0.0622 g, 132.2061 μmol, 34.6023%yield) . MS: m/z 471 (M+H)
+ ,
1H NMR (400 MHz, CD
3OD) δ 7.58 (d, J = 7.9 Hz, 1H) , 7.33 (d, J = 8.1 Hz, 1H) , 7.16 (s, 1H) , 7.12 –7.06 (m, 1H) , 7.02 (m, 1H) , 4.59 (t, J = 7.0 Hz, 1H) , 4.27 (dd, J = 8.9, 4.8 Hz, 1H) , 3.76 (d, J = 10.8 Hz, 2H) , 3.70 (s, 3H) , 3.20 (ddd, J = 39.2, 14.5, 6.8 Hz, 2H) , 2.29 (m, 2H) , 2.10 –1.99 (m, 1H) , 1.97 (s, 3H) , 1.82 (m, 1H) .
The following compounds were synthesized using the above procedure (example 2 to example 6) or modification procedure with the corresponding starting materials.
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
EXAMPLE 7
S-isopropyl
2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanethioate
To a solution of (S) -2- ( (S) -2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoic acid (190 mg, 475.714 μmol) , propane-2-thiol (76 mg, 997.895 μmol) and DIPEA (197 mg, 1.524 mmol) in DMF (5 mL) was added BOP (237 mg,535.860 μmol) . The mixture was stirred at RT for 2.5 h. Water (30 mL) and EA (30 mL×2) were added. The reaction mixture was filtered and the organic extracts were collected. The combined organic extracts were washed with brine (30 mL×2) . The reaction mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC. The product’s solution was concentrated under reduced pressure. The S-isopropyl 2- (2-acetamido-3- (1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanethioate (28.3 mg, 61.852 μmol) was obtained by lyophilization. MS: m/z 458 (M+H)
+,
1H NMR (400 MHz, CDCl
3) δ 8.09 (d, J = 19.0 Hz, 1H) , 7.60 (d, J = 5.6 Hz, 1H) , 7.29 (d, J = 7.9 Hz, 1H) , 7.16 –7.10 (m, 1H) , 7.10 –7.01 (m, 2H) , 6.09 (s, 1H) , 6.00 (s, 1H) , 5.02 (s, 1H) , 4.76 –4.63 (m, 1H) , 4.46 –4.34 (m, 1H) , 3.49 (dd, J = 13.1, 6.8 Hz, 2H) , 3.30 –3.20 (m, 1H) , 3.17 –3.06 (m, 1H) , 2.10 (dd, J = 25.3, 17.9 Hz, 2H) , 1.93 (t, J = 3.6 Hz, 3H) , 1.81 (d, J = 13.2 Hz, 2H) , 1.18 (d, J = 6.9 Hz, 6H) .
The following compounds were synthesized by using the above procedure or modification procedure with the corresponding starting materials.
EXAMPLE 8
Isopropyl (S) -2- ( (S) -2-acetamido-3- (7-fluoro-1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoate and isopropyl (S) -2- ( (R) -2-acetamido-3- (7-fluoro-1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoate
Step a: A flame-dried round bottom flask was charged with a solution of 7-fluoro-1H-indole (202 mg, 1.495 mmol) , serine (347 mg, 3.302 mmol) and acetic anhydride (0.8 mL) in acetic acid (5 mL) . The mixture was stirred at 80℃ under nitrogen atmosphere for 3 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel plate (eluting with DCM : MeOH=10: 1, v/v) to give 2-acetamido-3- (7-fluoro-1H-indol-3-yl) propanoic acid (122 mg, 461.681 μmol) . MS: m/z 265 (M+H)
+.
Step b: To a solution of 2-acetamido-3- (7-fluoro-1H-indol-3-yl) propanoic acid (0.122 g,461.681 μmol) , isopropyl (S) -2-amino-6-diazo-5-oxohexanoate (101 mg, 473.660 μmol) and DIPEA (164 mg, 1.269 mmol) in DCM was added HATU (182 mg, 478.659μmol) . The mixture was stirred at RT for one night. The reaction mixture was concentrated under reduced pressure. The residue was purified by chiral separation (CHIRALPAK IA column, 2.12cm×15cm id, 5 μm particle size) to give the previous point (1.878min, 13.1 mg, 28.511μmol) , MS: m/z 460(M+H)
+,
1H NMR (400 MHz, CDCl
3) δ 8.30 (s, 1H) , 7.45 (t, J = 8.1 Hz, 1H) , 7.21 –7.14 (m, 1H) , 7.11 –7.00 (m, 1H) , 6.92 (dd, J = 11.1, 7.8 Hz, 1H) , 6.26 (d, J = 7.3 Hz, 1H) , 6.18 (d, J = 7.2 Hz, 1H) , 4.96 (dt, J = 18.7, 6.2 Hz, 1H) , 4.79 –4.65 (m, 1H) , 4.41 –4.31 (m, 1H) , 3.33 (ddd, J = 14.6, 9.2, 5.0 Hz, 1H) , 3.22 –3.11 (m, 1H) , 2.67 –2.43 (m, 2H) , 2.16 (ddd, J = 11.5, 6.1, 3.4 Hz, 2H) , 2.03 (d, J = 6.3 Hz, 3H) , 1.26 (dd, J = 6.3, 2.6 Hz, 3H) , 1.23 (dd, J = 6.2, 2.3 Hz, 3H) , and the back point (2.625min, 14.7 mg, 31.993μmol) ; MS: m/z 460 (M+H)
+,
1H NMR (400 MHz, CDCl
3) δ 8.25 (s, 1H) , 7.37 (d, J = 8.0 Hz, 1H) , 7.08 (s, 1H) , 6.99 (td, J = 7.9, 4.7 Hz, 1H) , 6.88 –6.81 (m, 1H) , 6.29 (d, J = 7.2 Hz, 1H) , 6.04 (d, J = 7.7 Hz, 1H) , 4.90 (dt, J = 15.8, 6.3 Hz, 1H) , 4.70 (dd, J = 13.1, 7.9 Hz, 1H) , 4.34 –4.23 (m, 1H) , 3.23 (dd, J = 14.6, 5.7 Hz, 1H) , 3.10 (dd, J = 14.6, 8.1 Hz, 1H) , 2.22 (td, J = 23.0, 15.8 Hz, 2H) , 2.12 –1.74 (m, 5H) , 1.20 –1.12 (m, 6H) .
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Synthesis of Control Compounds:
Compound 47 of WO2017023774 (named “reference compound 1” ) was obtained according to the synthesis route and operation steps of compound 47 on Page 115-116 in WO2017023774.
Example 9 Dog pharmacokinetic study
Reference compound, compound 1 and compound 2 were provided for Dog pharmacokinetic study, and they were shown as below:
The dog pharmacokinetic study was conducted in accordance with the guidelines recommended in Guide for the Care and Use of Laboratory Animals and approved by the Beijing Piroma Biotech Inc. Reference compound, compound 2 and compound 1 were administered intravenously to a male and a female beagle dogs (n=2/group) at a dose of 500 nmoL/kg respectively. Blood sample were collected at 0min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 24h, post dose, in tubes with EDTA-K2. Blood samples were centrifuged at a temperature of 4 ℃ at 3000g for 10 min. All samples were kept chilled throughout processing. Plasma samples were collected in polypropylene tubes and stored at -80 ℃ until bioanalysis.
For quantifying intact compounds and DON in the pharmacokinetic samples, plasma samples (50 μL) were processed using a single liquid extraction method by addition of 200 μL of acetonitrile containing internal standard (Dexamethasone 100 ng/mL) , followed by vortex-mixing for 30 s and then centrifugation at 15000g for 5 min at 4 ℃. 100 μL of the supernatant was diluted with 100 μL of water and transferred to a 250 μL polypropylene vial sealed with a Teflon cap. Prodrug and DON disappearance was monitored over time using a liquid chromatography and tandem mass spectrometry (LC-MS/MS) .
For LC-MS/MS analysis, intact compounds were analyzed on an ExionLC system coupled to Accela open autosampler on a Phenomenex Kinetex 5 μm C18 100A (2.1*50) mm UPLC column. The temperature of autosampler was controlled and the autosampler was operated at 4 ℃. The mobile phase used for the chromatographic separation was composed of acetonitrile/water containing 0.1%formic acid and will run at a flow rate of 0.6 mL/min for 3.5 min using gradient elution. The column effluent was monitored using TSQ Vantage triple-quadrupole mass-spectrometric detector, equipped with an electrospray probe set in the positive ionization mode. Samples were introduced into the ionization source through a heated nebulized probe (450 ℃) . Disappearance of prodrugs will be measured from ratio of peak areas of analyte to IS (internal standard) .
DON was analyzed on an ExionLC system coupled with a REF Triple Quad 5500+ mass spectrometer. Separation was achieved at 25 ℃ using an HALO Penta-HILIC 2.7 μM 90A (2.1x100 mm) . The mobile phase consisted of 100%Water (5MM ammonium formate PH=3.0) and 100%Acetonitrile. Pumps were operated at a flow rate of 0.6 mL/min for 5.0 min using gradientelution. The mass spectrometer controlled by Analyst software 1.6.3 was operated with a heated ESI ionsource in positive ionization mode.
Reference compound, compound 2 and compound 1 were administrated intravenously to a beagle dog respectively. FIG. 1 is a graph showing the concentrations of DON and reference compound over time after IV infusion (intravenous infusion) . FIG. 2 is a graph showing the concentrations of DON and compound 2 over time after IV infusion. FIG. 3 is a graph showing the concentrations of DON and compound 1 over time after IV infusion. The pharmacokinetic data was shown in the following Table 1.
Table 1. Pharmacokinetic parameters intact compounds administration
Example 10 Metabolic stability in human plasma and microsomes
Reference compound, reference compound 1, compound 494, compound 495, compound 499, compound 501, compound 527 and compound 530 were provided for metabolic stability in human plasma and microsomes, and they were shown as below:
For metabolic stability analysis, microsomes from human was used. Reference compound, reference compound 1, compound 494, compound 495, compound 499, compound 501, compound 527 and compound 530 (the concentration of the each compound was 1 μM) were spiked in each microsomes matrix and incubated in an orbital shaker at 37 ℃ respectively. At predetermined times (0 and 60 min) , 50 μL aliquots of the mixture in duplicate were obtained, and 200 μL of ice cold acetonitrile spiked with the internal standard (Dexamethasone 100 ng/mL) was added into the obtained mixture to quench the reaction of the obtained mixture. The samples were vortexed for 30 s and centrifuged at 15000g for 5 min. 100 μL of the supernatant was diluted with 100 μL of water and transferred to a 250 μL polypropylene vial sealed with a Teflon cap. Prodrug disappearance was monitored over time using a liquid chromatography and tandem mass spectrometry (LC-MS/MS) .
For LC-MS/MS analysis, intact compounds were analyzed on an ExionLC system coupled to Accela open autosampler on a Phenomenex Kinetex 5 μm C18 100A (2.1*50) mm UPLC column. The temperature of autosampler was controlled and the autosampler was operated at 4 ℃. The mobile phase used for the chromatographic separation was composed of acetonitrile/water containing 0.1%formic acid and at a flow rate of 0.5 mL/min for 3.5 min using gradient elution. The column effluent was monitored using TSQ Vantage triple-quadrupole mass-pectrometric detector, equipped with an electrospray probe set in the positive ionization mode. Samples were introduced into the ionization source through a heated nebulized probe (450 ℃) . Disappearance of the compounds will be measured from ratio of peak areas of analyte to IS (internal standard) .
FIG. 4 and FIG. 5 is a bar graph showing the stability of compounds after incubation for 60 minutes in the presence of human microsomes.
Example 11 Anti-tumor Efficacy of compound 496 and compound 527 the anti-tumor Efficacy in MC38 Syngeneics in CES1c -/-mouse
Compound 496, compound 527 and reference compound were provided for anti-tumor efficacy in MC38 Syngeneics in CES1c -/-mouse, and they were shown as below:
Animal species: Mus musculus; Strain: C57BL/6-Ces1c
em1Smoc; Age: 6-8 weeks; Sex: female. (Shanghai Model Organisms)
The MC38 tumor cells were maintained in vitro in DMEM medium supplemented with 10%FBS at 37 ℃, 5%CO
2. The cells growing in an exponential growth phase were harvested and counted for tumor inoculation. The culture MC38 were harvested, re-suspended in PBS containing 50%Matrigel at a density of 1×10
7 cells/mL. Each mouse was inoculated subcutaneously in the right flank region with 1×10
6 cells in 0.1 mL of PBS containing 50%Matrigel for tumor development.
The treatments were started when the mean tumor size reached 46-132mm
3 (average tumor size 95 mm
3) . Each group contained 5 tumor bearing mice. Group 1 was treated with Vehicle (10%DMSO + 90%Saline) , S.C., QD (Subcutaneous injection, quaque die) . Group 2 was given treatments with reference compound at 2 μmol/kg, S.C., QD. Group 3 was given treatments with compound 35 at 2 μmol/kg, S.C., QD. Group 4 was given treatments with compound 3 at 2 μmol/kg, S.C., QD. The administration of different compounds in each study group was shown in the following Table 2.
In vivo efficacy was examined according to absolute tumor growth inhibition (TGI) and the safety was evaluated according to weight change and survival in mice.
Table 2. Groups and treatments for efficacy study
Group | Treatment | Dose (μmol/kg) | | Schedule | |
1 | |
2 | S.C. | QD×21 |
2 | |
2 | S.C. | QD×21 |
3 | |
2 | S.C. | QD×21 |
4 | |
2 | S.C. | QD×21 |
Body Weight
Group treated with reference compound showed some body weight loss, but the group treated with vehicle, the group treated with compound 505 and the group treated with compound 474 were well-tolerated by the tumor-bearing mice. The results of the body weight changes in the tumor-bearing mice are shown in Table 3, FIG. 6.
Table 3. The body weight changes (%) of the mice in different groups
Tumor Volumes
The results of tumor sizes in different groups at different time points post tumor inoculation were shown in Table 4 and FIG. 7. The tumor growth inhibition was summarized in Table 5. The result showed that all treatment groups had significant anti-tumor effect when compared to the vehicle group. Statistical analysis of difference in tumor volume among the groups was performed using one-way ANOVA followed by individual comparisons using Games-Howell post-hoc test (equal variance not assumed) . All data was analyzed using SPSS 22.0 software.
Table 4. Mean tumor volume in the different treatment groups
Table 5: Anti-tumor activity of test compounds in MC38 syngeneic model
Claims (25)
- A compound of formula I, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, the tautomer thereofWherein,Z is (OR 1) 1-2, (C (R 1) 2) 1-6, (N (R 1) ) 1-2 R 1’, or (SR 1) 1-2;R 1 and R 1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C 1-6 alkyl, -C 2-6 alkenyl, C 2-6 alkynyl, -C 5-12 aryl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-C 5-12 aryl, -5-12 membered heteroaryl, -5-12 membered heterocyclyl, -C 1-6 alkylene-N (C 1-6 alkyl) 2, -C 1-6 alkylene-O-C 1-6 alkyl, -C 1-6 alkylene-CO-NH-C 1-6 alkyl, -C 1-6 alkylene-CO-5-12 membered heterocyclyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, and wherein said -C 1-6 alkyl, said -C 1-6 alkenyl, said C 1-6 alkynyl, said -C 5-12 aryl, said -C 1-6 alkylene-COO-C 1-6 alkyl, said -C 1-6 alkylene-C 5-12 aryl, said -5-12 membered heteroaryl, said -5-12 membered heterocyclyl, said -C 1-6 alkylene-N (C 1-6 alkyl) 2, said -C 1-6 alkylene-O-C 1-6 alkyl, said -C 1-6 alkylene-CO-NH-C 1-6 alkyl, said -C 1-6 alkylene-CO-5-12 membered heterocyclyl, said -C 1-6 alkylene-SO 2-C 1-6 alkyl, said -C 1-6 alkylene-SO-C 1-6 alkyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl; orR 1 and R 1’ together with the nitrogen atom to which they are both attached form 4-8 membered heterocyclyl, and wherein said 4-8 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2, and said 4-8 membered heterocyclyl can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;X is selected from the group consisting of hydrogen, deuterium, C 1-6 alkyl, –C (=O) -G, –C (=O) -W- (CR X1R X2) m-G, –C (=O) -W- (CR X1R X2) m-NR 5R 5’ , C (=O) -W- (CR X1R X2) m-SR 11, , C (=O) -W- (CR X1R X2) m-SOR 11, C (=O) -W- (CR X1R X2) m-SO 2R 11, –C (=O) -W- (CR X1R X2) m-OR 11, -P (=O) (OR 6) p (NHR 7) q, -P (=O) (OG) p, –C (=O) -W- (CR X1R X2) m-G-O-C (=O) -R 8, –C (=O) -W- (CR X1R X2) m-G-O-R 8, –C (=O) -O- (CR X1R X2) m-O-C (=O) -R 9, -C (=O) -O-R 7, –C (=O) -W- (CR X1R X2) m-G-O-C (=O) -G, and –C (=O) -W- (CR X1R X2) m-G-NR 5R 5’;W is oxygen, CO or a bond;m is selected from 1, 2, 3, 4, 5, 6, 7 or 8;p and q are each independently selected from 0, 1 or 2, provided that the sum of p and q is 2;R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C 1-6 alkyl, -C 1-6 alkylene-SH, -C 1-6 alkylene-C 2-6 alkenyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 3-8 cycloalkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-CONH 2, -C 1-6 alkylene-Se-C 1-6 alkyl, -C 1-6 alkylene-SH, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-CO 2-C 1-6 alkyl, C 5-12aryl, -C 1-6 alkylene-C 5-12 aryl, -C 1-6 alkylene-5-12 membered heteroaryl, -C 1-6 alkylene-5-12 membered heterocyclyl, and 5-12 membered heteroaryl, and wherein said C 1-6 alkyl, said -C 1-6 alkylene-SH, said -C 1-6 alkylene-C 2-6 alkenyl, said -C 3-8 cycloalkyl, said -C 1-6 alkylene-C 3-8 cycloalkyl, said -C 1-6 alkylene-S-C 1-6 alkyl, said -C 1-6 alkylene-CONH 2, said said said -C 1-6 alkylene-Se-C 1-6 alkyl, said -C 1-6 alkylene-SH, said -C 1-6 alkylene-SO 2-C 1-6 alkyl, said -C 1-6 alkylene-CO 2-C 1-6 alkyl, said C 5-12aryl, said -C 1-6 alkylene-C 5-12 aryl, said -C 1-6 alkylene-5-12 membered heteroaryl, said -C 1-6 alkylene-5-12 membered heterocyclyl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;or R X1 and R X2 together with the carbon atom to which they are attached form 5-10 membered carbocyclic ring, C 3-8 cycloalkyl, C 2-4 alkenyl, 5-10 membered heterocyclyl, and wherein said 5-10 membered carbocyclic ring, said C 2-4 alkenyl, said 5-10 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 5 and R 5’ are each independently selected from the group consisting of hydrogen, deuterium, -C 1-6 alkyl, -C 3-8 cycloalkyl, -C (=O) -C 1-6 alkyl, -C (=O) -C 5-10 carbocyclic, -C (=O) -adamantanyl, -C (=O) -C 3-6 cycloalkyl, and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;or R X1 and R 5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-12 membered heterocyclyl, and wherein said 5-12 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2, and said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;each of R 6 is independently selected from the group consisting of hydrogen, deuterium, -C 1-6 alkyl, -C 3-8 cycloalkyl, 5-12 membered heterocyclyl, -C 1-6 alkenyl, and -C 3-8 cycloalkenyl, and wherein said -C 1-6 alkyl, said -C 3-8 cycloalkyl, said 5-12 membered heterocyclyl, said -C 1-6 alkenyl, and said -C 3-8 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;or R 6 together with the oxygen atom to which it is attached forms a purine or pyrimidine nucleoside;each of R 7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, 5-12 membered heterocyclyl, C 1-6 alkenyl, C 3-8 cycloalkenyl, C 5-12 aryl, and 5-12 membered heteroaryl, and wherein said C 1-6 alkyl, said C 3-8 cycloalkyl, said 5-12 membered heterocyclyl, said C 1-6 alkenyl, said C 3-8 cycloalkenyl, said C 5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 8 and R 9 are each independently selected from the group consisting of C 1-6 alkyl, C 3-8 cycloalkyl, monosaccharide, acylated monosaccharide, C 5-12 aryl, and 5-12 membered heteroaryl, and wherein said C 1-6 alkyl, said C 3-8 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C 5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 11 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;G is C 5-12 aryl, or 5-12 membered heteroaryl, and wherein said C 5-12 aryl, and said 5-12 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 3 and R 3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;Y is a bond, oxygen, or - (CR Y1R Y2) n-;n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of claim 1 or 2, whereinR 1 and R 1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C 1-3 alkyl, -C 2-3 alkenyl, C 2-3 alkynyl, -C 5-10 aryl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-C 5-10 aryl, -5-10 membered heteroaryl, -5-10 membered heterocyclyl, -C 1-3 alkylene-N (C 1-3 alkyl) 2, -C 1-3 alkylene-O-C 1-3 alkyl, -C 1-3 alkylene-CO-NH-C 1-3 alkyl, -C 1-3 alkylene-CO-5-10 membered heterocyclyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, and -C 1-3 alkylene-SO-C 1-3 alkyl, and wherein said -C 1-3 alkyl, said -C 2-3 alkenyl, said C 2-3 alkynyl, said -C 5-10 aryl, said -C 1-3 alkylene-COO-C 1-3 alkyl, said -C 1-3 alkylene-C 5-10 aryl, said -5-10 membered heteroaryl, said -5-10 membered heterocyclyl, said -C 1-3 alkylene-N (C 1-3 alkyl) 2, said -C 1-3 alkylene-O-C 1-3 alkyl, said -C 1-3 alkylene-CO-NH-C 1-3 alkyl, said -C 1-3 alkylene-CO-5-10 membered heterocyclyl, said -C 1-3 alkylene-SO 2-C 1-3 alkyl, and said -C 1-3 alkylene-SO-C 1-3 alkyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl; orR 1 and R 1’ together with the nitrogen atom to which they are both attached form 4-6 membered heterocyclyl, and wherein said 4-6 membered heterocyclyl can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO 2, and said 4-6 membered heterocyclyl can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any of claims 1-3, whereinR 1 and R 1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C 1-3 alkyl, -C 2-3 alkenyl, C 2-3 alkynyl, -C 5-10 aryl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-C 5-10 aryl, -5-10 membered heteroaryl, -5-10 membered heterocyclyl, -C 1-3 alkylene-N (C 1-3 alkyl) 2, -C 1-3 alkylene-O-C 1-3 alkyl, -C 1-3 alkylene-CO-NH-C 1-3 alkyl, -C 1-3 alkylene-CO-5-10 membered heterocyclyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, and -C 1-3 alkylene-SO-C 1-3 alkyl, and wherein said -C 1-3 alkyl, said -C 2-3 alkenyl, said C 2-3 alkynyl, said -C 5-10 aryl, said -C 1-3 alkylene-COO-C 1-3 alkyl, said -C 1-3 alkylene-C 5-10 aryl, said -5-10 membered heteroaryl, said -5-10 membered heterocyclyl, said -C 1-3 alkylene-N (C 1-3 alkyl) 2, said -C 1-3 alkylene-O-C 1-3 alkyl, said -C 1-3 alkylene-CO-NH-C 1-3 alkyl, said -C 1-3 alkylene-CO-5-10 membered heterocyclyl, said -C 1-3 alkylene-SO 2-C 1-3 alkyl, and said -C 1-3 alkylene-SO-C 1-3 alkyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl; orR 1 and R 1’ together with the nitrogen atom to which they are both attached form 4-6 membered heterocyclyl, and wherein said 4-6 membered heterocyclyl can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO 2, and said 4-6 membered heterocyclyl can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any one of claims 1-4, whereinR 1 and R 1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, vinyl, allyl, ethyne, propyne, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, -CH 2-COO-CH 3, - (CH 2) 2-COO-CH 3, - (CH 2) 3-COO-CH 3, -CH 2-COO-CH 2CH 3, - (CH 2) 2-COO-CH 2CH 3, - (CH 2) 3-COO-CH 2CH 3, -CH 2-COO-CH 2CH 2CH 3, - (CH 2) 2-COO-CH 2CH 2CH 3, - (CH 2) 3-COO-CH 2CH 2CH 3, -CH 2-COO-CH (CH 3) 2, - (CH 2) 2-COO-CH (CH 3) 2, - (CH 2) 3-COO-CH (CH 3) 2, -CH 2-C 5 aryl, -CH 2-C 6 aryl, - (CH 2) 2-C 6 aryl, - (CH 2) 3-C 6 aryl, -CH 2-C 7 aryl, - (CH 2) 2-C 7 aryl, - (CH 2) 3-C 7 aryl, -CH 2-C 8 aryl, - (CH 2) 2-C 8 aryl, - (CH 2) 3-C 8 aryl, -CH 2-C 9 aryl, - (CH 2) 2-C 9 aryl, - (CH 2) 3-C 9 aryl, -CH 2-C 10 aryl, - (CH 2) 2-C 10 aryl, - (CH 2) 3-C 10 aryl, -5 membered heteroaryl, -6 membered heteroaryl, -7 membered heteroaryl, -8 membered heteroaryl, -9 membered heteroaryl, -10 membered heteroaryl, -5 membered heterocyclyl, -6 membered heterocyclyl, -7 membered heterocyclyl, -8 membered heterocyclyl, -9 membered heterocyclyl, -10 membered heterocyclyl, -CH 2-N (CH 3) 2, - (CH 2) 2-N (CH 3) 2, - (CH 2) 3-N (CH 3) 2, -CH 2-N (CH 2CH 3) 2, - (CH 2) 2-N (CH 2CH 3) 2, - (CH 2) 3-N (CH 2CH 3) 2, -CH 2-N (CH 2CH 2CH 3) 2, - (CH 2) 2-N (CH 2CH 2CH 3) 2, - (CH 2) 3-N (CH 2CH 2CH 3) 2, -CH 2-N (CH (CH 3) 2) 2, - (CH 2) 2-N (CH (CH 3) 2) 2, - (CH 2) 3-N (CH (CH 3) 2) 2, -CH 2-O-CH 3, - (CH 2) 2-O-CH 3, - (CH 2) 3-O-CH 3, -CH 2-O-CH 2CH 3, - (CH 2) 2-O-CH 2CH 3, - (CH 2) 3-O-CH 2CH 3, -CH 2-O-CH 2CH 2CH 3, - (CH 2) 2-O-CH 2CH 2CH 3, - (CH 2) 3-O-CH 2CH 2CH 3, -CH 2-O-CH (CH 3) 2, - (CH 2) 2-O-CH (CH 3) 2, - (CH 2) 3-O-CH (CH 3) 2, -CH 2-CO-NH-CH 3, - (CH 2) 2-CO-NH-CH 3, - (CH 2) 3-CO-NH-CH 3, -CH 2-CO-NH-CH 2CH 3, - (CH 2) 2-CO-NH-CH 2CH 3, - (CH 2) 3-CO-NH-CH 2CH 3, -CH 2-CO-NH-CH 2CH 2CH 3, - (CH 2) 2-CO-NH-CH 2CH 2CH 3, - (CH 2) 3-CO-NH-CH 2CH 2CH 3, -CH 2-CO-NH-CH (CH 3) 2, - (CH 2) 2-CO-NH-CH (CH 3) 2, - (CH 2) 3-CO-NH-CH (CH 3) 2, -CH 2-CO-5 membered heterocyclyl, - (CH 2) 2-CO-5 membered heterocyclyl, - (CH 2) 3-CO-5 membered heterocyclyl, -CH 2-CO-6 membered heterocyclyl, - (CH 2) 2-CO-6 membered heterocyclyl, - (CH 2) 3-CO-6 membered heterocyclyl, -CH 2-CO-7 membered heterocyclyl, - (CH 2) 2-CO-7 membered heterocyclyl, - (CH 2) 3-CO-7 membered heterocyclyl, -CH 2-CO-8 membered heterocyclyl, - (CH 2) 2-CO-8 membered heterocyclyl, - (CH 2) 3-CO-8 membered heterocyclyl, -CH 2-CO-9 membered heterocyclyl, - (CH 2) 2-CO-9 membered heterocyclyl, - (CH 2) 3-CO-9 membered heterocyclyl, -CH 2-CO-10 membered heterocyclyl, - (CH 2) 2-CO-10 membered heterocyclyl, - (CH 2) 3-CO-10 membered heterocyclyl, -CH 2-SO 2-CH 3, - (CH 2) 2-SO 2-CH 3, - (CH 2) 3-SO 2-CH 3, -CH 2-SO 2-CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 3, -CH 2-SO 2-CH 2CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 2CH 3, -CH 2-SO 2-CH (CH 3) 2, - (CH 2) 2-SO 2-CH (CH 3) 2, - (CH 2) 3-SO 2-CH (CH 3) 2, -CH 2-SO-CH 3, - (CH 2) 2-SO-CH 3, - (CH 2) 3-SO-CH 3, -CH 2-SO-CH 2CH 3, - (CH 2) 2-SO-CH 2CH 3, - (CH 2) 3-SO-CH 2CH 3, -CH 2-SO-CH 2CH 2CH 3, - (CH 2) 2-SO-CH 2CH 2CH 3, - (CH 2) 3-SO-CH 2CH 2CH 3, -CH 2-SO-CH (CH 3) 2, - (CH 2) 2-SO-CH (CH 3) 2, and - (CH 2) 3-SO-CH (CH 3) 2, and wherein said methyl, said ethyl, said propyl, said isopropyl, said vinyl, said allyl, said ethyne, said propyne, said C 5 aryl, C 6 aryl, said C 7 aryl, said C 8 aryl, said C 9 aryl, said C 10 aryl, said -CH 2-COO-CH 3, said - (CH 2) 2-COO-CH 3, said - (CH 2) 3-COO-CH 3, said -CH 2-COO-CH 2CH 3, said - (CH 2) 2-COO-CH 2CH 3, said - (CH 2) 3-COO-CH 2CH 3, said -CH 2-COO-CH 2CH 2CH 3, said - (CH 2) 2-COO-CH 2CH 2CH 3, said - (CH 2) 3-COO-CH 2CH 2CH 3, said -CH 2-COO-CH (CH 3) 2, said - (CH 2) 2-COO-CH (CH 3) 2, said - (CH 2) 3-COO-CH (CH 3) 2, said -CH 2-C 5 aryl, said -CH 2-C 6 aryl, said - (CH 2) 2-C 6 aryl, said - (CH 2) 3-C 6 aryl, said -CH 2-C 7 aryl, said - (CH 2) 2-C 7 aryl, said - (CH 2) 3-C 7 aryl, said -CH 2-C 8 aryl, said - (CH 2) 2-C 8 aryl, said - (CH 2) 3-C 8 aryl, said -CH 2-C 9 aryl, said - (CH 2) 2-C 9 aryl, said - (CH 2) 3-C 9 aryl, said -CH 2-C 10 aryl, said - (CH 2) 2-C 10 aryl, said - (CH 2) 3-C 10 aryl, said -5 membered heteroaryl, said -6 membered heteroaryl, said -7 membered heteroaryl, said -8 membered heteroaryl, said -9 membered heteroaryl, said -10 membered heteroaryl, said -5 membered heterocyclyl, said -6 membered heterocyclyl, said -7 membered heterocyclyl, said -8 membered heterocyclyl, said -9 membered heterocyclyl, said -10 membered heterocyclyl, said -CH 2-N (CH 3) 2, said - (CH 2) 2-N (CH 3) 2, said - (CH 2) 3-N (CH 3) 2, said -CH 2-N (CH 2CH 3) 2, said - (CH 2) 2-N (CH 2CH 3) 2, said - (CH 2) 3-N (CH 2CH 3) 2, said -CH 2-N (CH 2CH 2CH 3) 2, said - (CH 2) 2-N (CH 2CH 2CH 3) 2, said - (CH 2) 3-N (CH 2CH 2CH 3) 2, said -CH 2-N (CH (CH 3) 2) 2, said - (CH 2) 2-N (CH (CH 3) 2) 2, said - (CH 2) 3-N (CH (CH 3) 2) 2, said -CH 2-O-CH 3, said - (CH 2) 2-O-CH 3, said - (CH 2) 3-O-CH 3, said -CH 2-O-CH 2CH 3, said - (CH 2) 2-O-CH 2CH 3, said - (CH 2) 3-O-CH 2CH 3, said -CH 2-O-CH 2CH 2CH 3, said - (CH 2) 2-O-CH 2CH 2CH 3, said - (CH 2) 3-O-CH 2CH 2CH 3, said -CH 2-O-CH (CH 3) 2, said - (CH 2) 2-O-CH (CH 3) 2, said - (CH 2) 3-O-CH (CH 3) 2, said -CH 2-CO-NH-CH 3, said - (CH 2) 2-CO-NH-CH 3, said - (CH 2) 3-CO-NH-CH 3, said -CH 2-CO-NH-CH 2CH 3, said - (CH 2) 2-CO-NH-CH 2CH 3, said - (CH 2) 3-CO-NH-CH 2CH 3, said -CH 2-CO-NH-CH 2CH 2CH 3, said - (CH 2) 2-CO-NH-CH 2CH 2CH 3, said - (CH 2) 3-CO-NH-CH 2CH 2CH 3, said -CH 2-CO-NH-CH (CH 3) 2, said - (CH 2) 2-CO-NH-CH (CH 3) 2, said - (CH 2) 3-CO-NH-CH (CH 3) 2, said -CH 2-CO-5 membered heterocyclyl, said - (CH 2) 2-CO-5 membered heterocyclyl, said - (CH 2) 3-CO-5 membered heterocyclyl, said -CH 2-CO-6 membered heterocyclyl, said - (CH 2) 2-CO-6 membered heterocyclyl, said - (CH 2) 3-CO-6 membered heterocyclyl, said -CH 2-CO-7 membered heterocyclyl, said - (CH 2) 2-CO-7 membered heterocyclyl, said - (CH 2) 3-CO-7 membered heterocyclyl, said -CH 2-CO-8 membered heterocyclyl, said - (CH 2) 2-CO-8 membered heterocyclyl, said - (CH 2) 3-CO-8 membered heterocyclyl, said -CH 2-CO-9 membered heterocyclyl, said - (CH 2) 2-CO-9 membered heterocyclyl, said - (CH 2) 3-CO-9 membered heterocyclyl, said -CH 2-CO-10 membered heterocyclyl, said - (CH 2) 2-CO-10 membered heterocyclyl, said - (CH 2) 3-CO-10 membered heterocyclyl, said -CH 2-SO 2-CH 3, said - (CH 2) 2-SO 2-CH 3, said - (CH 2) 3-SO 2-CH 3, said -CH 2-SO 2-CH 2CH 3, said - (CH 2) 2-SO 2-CH 2CH 3, said - (CH 2) 3-SO 2-CH 2CH 3, said -CH 2-SO 2-CH 2CH 2CH 3, said - (CH 2) 2-SO 2-CH 2CH 2CH 3, said - (CH 2) 3-SO 2-CH 2CH 2CH 3, said -CH 2-SO 2-CH (CH 3) 2, said - (CH 2) 2-SO 2-CH (CH 3) 2, said - (CH 2) 3-SO 2-CH (CH 3) 2, said -CH 2-SO-CH 3, said - (CH 2) 2-SO-CH 3, said - (CH 2) 3-SO-CH 3, said -CH 2-SO-CH 2CH 3, said - (CH 2) 2-SO-CH 2CH 3, said - (CH 2) 3-SO-CH 2CH 3, said -CH 2-SO-CH 2CH 2CH 3, said - (CH 2) 2-SO-CH 2CH 2CH 3, said - (CH 2) 3-SO-CH 2CH 2CH 3, said -CH 2-SO-CH (CH 3) 2, said - (CH 2) 2-SO-CH (CH 3) 2, and said - (CH 2) 3-SO-CH (CH 3) 2, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl; orR 1 and R 1’ together with the nitrogen atom to which they are both attached form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO 2, and said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any one of claims 1-5, whereinR 1 and R 1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, vinyl, allyl, ethyne, propyne, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, -CH 2-COO-CH 3, - (CH 2) 2-COO-CH 3, - (CH 2) 3-COO-CH 3, -CH 2-COO-CH 2CH 3, - (CH 2) 2-COO-CH 2CH 3, - (CH 2) 3-COO-CH 2CH 3, -CH 2-COO-CH 2CH 2CH 3, - (CH 2) 2-COO-CH 2CH 2CH 3, - (CH 2) 3-COO-CH 2CH 2CH 3, -CH 2-COO-CH (CH 3) 2, - (CH 2) 2-COO-CH (CH 3) 2, - (CH 2) 3-COO-CH (CH 3) 2, -CH 2-C 5 aryl, -CH 2-C 6 aryl, - (CH 2) 2-C 6 aryl, - (CH 2) 3-C 6 aryl, -CH 2-C 7 aryl, - (CH 2) 2-C 7 aryl, - (CH 2) 3-C 7 aryl, -CH 2-C 8 aryl, - (CH 2) 2-C 8 aryl, - (CH 2) 3-C 8 aryl, -CH 2-C 9 aryl, - (CH 2) 2-C 9 aryl, - (CH 2) 3-C 9 aryl, -CH 2-C 10 aryl, - (CH 2) 2-C 10 aryl, - (CH 2) 3-C 10 aryl, -5 membered heteroaryl, -6 membered heteroaryl, -7 membered heteroaryl, -8 membered heteroaryl, -9 membered heteroaryl, -10 membered heteroaryl, -5 membered heterocyclyl, -6 membered heterocyclyl, -7 membered heterocyclyl, -8 membered heterocyclyl, -9 membered heterocyclyl, -10 membered heterocyclyl, -CH 2-N (CH 3) 2, - (CH 2) 2-N (CH 3) 2, - (CH 2) 3-N (CH 3) 2, -CH 2-N (CH 2CH 3) 2, - (CH 2) 2-N (CH 2CH 3) 2, - (CH 2) 3-N (CH 2CH 3) 2, -CH 2-N (CH 2CH 2CH 3) 2, - (CH 2) 2-N (CH 2CH 2CH 3) 2, - (CH 2) 3-N (CH 2CH 2CH 3) 2, -CH 2-N (CH (CH 3) 2) 2, - (CH 2) 2-N (CH (CH 3) 2) 2, - (CH 2) 3-N (CH (CH 3) 2) 2, -CH 2-O-CH 3, - (CH 2) 2-O-CH 3, - (CH 2) 3-O-CH 3, -CH 2-O-CH 2CH 3, - (CH 2) 2-O-CH 2CH 3, - (CH 2) 3-O-CH 2CH 3, -CH 2-O-CH 2CH 2CH 3, - (CH 2) 2-O-CH 2CH 2CH 3, - (CH 2) 3-O-CH 2CH 2CH 3, -CH 2-O-CH (CH 3) 2, - (CH 2) 2-O-CH (CH 3) 2, - (CH 2) 3-O-CH (CH 3) 2, -CH 2-CO-NH-CH 3, - (CH 2) 2-CO-NH-CH 3, - (CH 2) 3-CO-NH-CH 3, -CH 2-CO-NH-CH 2CH 3, - (CH 2) 2-CO-NH-CH 2CH 3, - (CH 2) 3-CO-NH-CH 2CH 3, -CH 2-CO-NH-CH 2CH 2CH 3, - (CH 2) 2-CO-NH-CH 2CH 2CH 3, - (CH 2) 3-CO-NH-CH 2CH 2CH 3, -CH 2-CO-NH-CH (CH 3) 2, - (CH 2) 2-CO-NH-CH (CH 3) 2, - (CH 2) 3-CO-NH-CH (CH 3) 2, -CH 2-CO-5 membered heterocyclyl, - (CH 2) 2-CO-5 membered heterocyclyl, - (CH 2) 3-CO-5 membered heterocyclyl, -CH 2-CO-6 membered heterocyclyl, - (CH 2) 2-CO-6 membered heterocyclyl, - (CH 2) 3-CO-6 membered heterocyclyl, -CH 2-CO-7 membered heterocyclyl, - (CH 2) 2-CO-7 membered heterocyclyl, - (CH 2) 3-CO-7 membered heterocyclyl, -CH 2-CO-8 membered heterocyclyl, - (CH 2) 2-CO-8 membered heterocyclyl, - (CH 2) 3-CO-8 membered heterocyclyl, -CH 2-CO-9 membered heterocyclyl, - (CH 2) 2-CO-9 membered heterocyclyl, - (CH 2) 3-CO-9 membered heterocyclyl, -CH 2-CO-10 membered heterocyclyl, - (CH 2) 2-CO-10 membered heterocyclyl, - (CH 2) 3-CO-10 membered heterocyclyl, -CH 2-SO 2-CH 3, - (CH 2) 2-SO 2-CH 3, - (CH 2) 3-SO 2-CH 3, -CH 2-SO 2-CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 3, -CH 2-SO 2-CH 2CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 2CH 3, -CH 2-SO 2-CH (CH 3) 2, - (CH 2) 2-SO 2-CH (CH 3) 2, - (CH 2) 3-SO 2-CH (CH 3) 2, -CH 2-SO-CH 3, - (CH 2) 2-SO-CH 3, - (CH 2) 3-SO-CH 3, -CH 2-SO-CH 2CH 3, - (CH 2) 2-SO-CH 2CH 3, - (CH 2) 3-SO-CH 2CH 3, -CH 2-SO-CH 2CH 2CH 3, - (CH 2) 2-SO-CH 2CH 2CH 3, - (CH 2) 3-SO-CH 2CH 2CH 3, -CH 2-SO-CH (CH 3) 2, - (CH 2) 2-SO-CH (CH 3) 2, and - (CH 2) 3-SO-CH (CH 3) 2, and wherein said methyl, said ethyl, said propyl, said isopropyl, said vinyl, said allyl, said ethyne, said propyne, said C 5 aryl, C 6 aryl, said C 7 aryl, said C 8 aryl, said C 9 aryl, said C 10 aryl, said -CH 2-COO-CH 3, said - (CH 2) 2-COO-CH 3, said - (CH 2) 3-COO-CH 3, said -CH 2-COO-CH 2CH 3, said - (CH 2) 2-COO-CH 2CH 3, said - (CH 2) 3-COO-CH 2CH 3, said -CH 2-COO-CH 2CH 2CH 3, said - (CH 2) 2-COO-CH 2CH 2CH 3, said - (CH 2) 3-COO-CH 2CH 2CH 3, said -CH 2-COO-CH (CH 3) 2, said - (CH 2) 2-COO-CH (CH 3) 2, said - (CH 2) 3-COO-CH (CH 3) 2, said -CH 2-C 5 aryl, said -CH 2-C 6 aryl, said - (CH 2) 2-C 6 aryl, said - (CH 2) 3-C 6 aryl, said -CH 2-C 7 aryl, said - (CH 2) 2-C 7 aryl, said - (CH 2) 3-C 7 aryl, said -CH 2-C 8 aryl, said - (CH 2) 2-C 8 aryl, said - (CH 2) 3-C 8 aryl, said -CH 2-C 9 aryl, said - (CH 2) 2-C 9 aryl, said - (CH 2) 3-C 9 aryl, said -CH 2-C 10 aryl, said - (CH 2) 2-C 10 aryl, said - (CH 2) 3-C 10 aryl, said -5 membered heteroaryl, said -6 membered heteroaryl, said -7 membered heteroaryl, said -8 membered heteroaryl, said -9 membered heteroaryl, said -10 membered heteroaryl, said -5 membered heterocyclyl, said -6 membered heterocyclyl, said -7 membered heterocyclyl, said -8 membered heterocyclyl, said -9 membered heterocyclyl, said -10 membered heterocyclyl, said -CH 2-N (CH 3) 2, said - (CH 2) 2-N (CH 3) 2, said - (CH 2) 3-N (CH 3) 2, said -CH 2-N (CH 2CH 3) 2, said - (CH 2) 2-N (CH 2CH 3) 2, said - (CH 2) 3-N (CH 2CH 3) 2, said -CH 2-N (CH 2CH 2CH 3) 2, said - (CH 2) 2-N (CH 2CH 2CH 3) 2, said - (CH 2) 3-N (CH 2CH 2CH 3) 2, said -CH 2-N (CH (CH 3) 2) 2, said - (CH 2) 2-N (CH (CH 3) 2) 2, said - (CH 2) 3-N (CH (CH 3) 2) 2, said -CH 2-O-CH 3, said- (CH 2) 2-O-CH 3, said - (CH 2) 3-O-CH 3, said -CH 2-O-CH 2CH 3, said - (CH 2) 2-O-CH 2CH 3, said - (CH 2) 3-O-CH 2CH 3, said -CH 2-O-CH 2CH 2CH 3, said - (CH 2) 2-O-CH 2CH 2CH 3, said - (CH 2) 3-O-CH 2CH 2CH 3, said -CH 2-O-CH (CH 3) 2, said - (CH 2) 2-O-CH (CH 3) 2, said - (CH 2) 3-O-CH (CH 3) 2, said -CH 2-CO-NH-CH 3, said - (CH 2) 2-CO-NH-CH 3, said - (CH 2) 3-CO-NH-CH 3, said -CH 2-CO-NH-CH 2CH 3, said - (CH 2) 2-CO-NH-CH 2CH 3, said - (CH 2) 3-CO-NH-CH 2CH 3, said -CH 2-CO-NH-CH 2CH 2CH 3, said - (CH 2) 2-CO-NH-CH 2CH 2CH 3, said - (CH 2) 3-CO-NH-CH 2CH 2CH 3, said -CH 2-CO-NH-CH (CH 3) 2, said - (CH 2) 2-CO-NH-CH (CH 3) 2, said - (CH 2) 3-CO-NH-CH (CH 3) 2, said -CH 2-CO-5 membered heterocyclyl, said - (CH 2) 2-CO-5 membered heterocyclyl, said - (CH 2) 3-CO-5 membered heterocyclyl, said -CH 2-CO-6 membered heterocyclyl, said - (CH 2) 2-CO-6 membered heterocyclyl, said - (CH 2) 3-CO-6 membered heterocyclyl, said -CH 2-CO-7 membered heterocyclyl, said - (CH 2) 2-CO-7 membered heterocyclyl, said - (CH 2) 3-CO-7 membered heterocyclyl, said -CH 2-CO-8 membered heterocyclyl, said - (CH 2) 2-CO-8 membered heterocyclyl, said - (CH 2) 3-CO-8 membered heterocyclyl, said -CH 2-CO-9 membered heterocyclyl, said - (CH 2) 2-CO-9 membered heterocyclyl, said - (CH 2) 3-CO-9 membered heterocyclyl, said -CH 2-CO-10 membered heterocyclyl, said - (CH 2) 2-CO-10 membered heterocyclyl, said - (CH 2) 3-CO-10 membered heterocyclyl, said -CH 2-SO 2-CH 3, said - (CH 2) 2-SO 2-CH 3, said - (CH 2) 3-SO 2-CH 3, said -CH 2-SO 2-CH 2CH 3, said - (CH 2) 2-SO 2-CH 2CH 3, said - (CH 2) 3-SO 2-CH 2CH 3, said -CH 2-SO 2-CH 2CH 2CH 3, said - (CH 2) 2-SO 2-CH 2CH 2CH 3, said - (CH 2) 3-SO 2-CH 2CH 2CH 3, said -CH 2-SO 2-CH (CH 3) 2, said - (CH 2) 2-SO 2-CH (CH 3) 2, said - (CH 2) 3-SO 2-CH (CH 3) 2, said -CH 2-SO-CH 3, said - (CH 2) 2-SO-CH 3, said - (CH 2) 3-SO-CH 3, said -CH 2-SO-CH 2CH 3, said - (CH 2) 2-SO-CH 2CH 3, said - (CH 2) 3-SO-CH 2CH 3, said -CH 2-SO-CH 2CH 2CH 3, said - (CH 2) 2-SO-CH 2CH 2CH 3, said - (CH 2) 3-SO-CH 2CH 2CH 3, said -CH 2-SO-CH (CH 3) 2, said - (CH 2) 2-SO-CH (CH 3) 2, and said - (CH 2) 3-SO-CH (CH 3) 2, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO 2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -CH 2-vinyl, - (CH 2) 2-vinyl, - (CH 2) 3-vinyl, -CH 2-allyl, - (CH 2) 2-allyl, - (CH 2) 3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH 3, -COO-CH 2CH 3, -COO-CH 2CH 2CH 3, -COO-CH (CH 3) 2, -CH 2-COO-CH 3, - (CH 2) 2-COO-CH 3, - (CH 2) 3-COO-CH 3, -CH 2-COO-CH 2CH 3, - (CH 2) 2-COO-CH 2CH 3, - (CH 2) 3-COO-CH 2CH 3, -CH 2-COO-CH 2CH 2CH 3, - (CH 2) 2-COO-CH 2CH 2CH 3, - (CH 2) 3-COO-CH 2CH 2CH 3, -CH 2-COO-CH (CH 3) 2, - (CH 2) 2-COO-CH (CH 3) 2, - (CH 2) 3-COO-CH (CH 3) 2, -CH 2-SO 2-CH 3, - (CH 2) 2-SO 2-CH 3, - (CH 2) 3-SO 2-CH 3, -CH 2-SO 2-CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 3, -CH 2-SO 2-CH 2CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 2CH 3, -CH 2-SO 2-CH (CH 3) 2, - (CH 2) 2-SO 2-CH (CH 3) 2, - (CH 2) 3-SO 2-CH (CH 3) 2, -CH 2-SO-CH 3, - (CH 2) 2-SO-CH 3, - (CH 2) 3-SO-CH 3, -CH 2-SO-CH 2CH 3, - (CH 2) 2-SO-CH 2CH 3, - (CH 2) 3-SO-CH 2CH 3, -CH 2-SO-CH 2CH 2CH 3, - (CH 2) 2-SO-CH 2CH 2CH 3, - (CH 2) 3-SO-CH 2CH 2CH 3, -CH 2-SO-CH (CH 3) 2, - (CH 2) 2-SO-CH (CH 3) 2, - (CH 2) 3-SO-CH (CH 3) 2, -CH 2-S-CH 3, - (CH 2) 2-S-CH 3, - (CH 2) 3-S-CH 3, -CH 2-S-CH 2CH 3, - (CH 2) 2-S-CH 2CH 3, - (CH 2) 3-S-CH 2CH 3, -CH 2-S-CH 2CH 2CH 3, - (CH 2) 2-S-CH 2CH 2CH 3, - (CH 2) 3-S-CH 2CH 2CH 3, -CH 2-S-CH (CH 3) 2, - (CH 2) 2-S-CH (CH 3) 2, - (CH 2) 3-S-CH (CH 3) 2, -CH 2-O-CH 3, - (CH 2) 2-O-CH 3, - (CH 2) 3-O-CH 3, -CH 2-O-CH 2CH 3, - (CH 2) 2-O-CH 2CH 3, - (CH 2) 3-O-CH 2CH 3, -CH 2-O-CH 2CH 2CH 3, - (CH 2) 2-O-CH 2CH 2CH 3, - (CH 2) 3-O-CH 2CH 2CH 3, -CH 2-O-CH (CH 3) 2, - (CH 2) 2-O-CH (CH 3) 2, - (CH 2) 3-O-CH (CH 3) 2, -NH 2, -NHCH 3, -NHCH 2CH 3, -NHCH 2CH 2CH 3, -NHCH (CH 3) 2, -N (CH 3) 2, -N (CH 2CH 3) 2, -N (CH 2CH 2CH 3) 2, -N (CH (CH 3) 2) 2, carboxyl, -C 5 aryl, -C 6 aryl, -C 7 aryl, -C 8 aryl, -C 9 aryl, -C 10 aryl, -C 5 aryl substituted by F, -C 6 aryl substituted by F, -C 7 aryl substituted by F, -C 8 aryl substituted by F, -C 9 aryl substituted by F, -C 10 aryl substituted by F, -C 5 aryl substituted by Cl, -C 6 aryl substituted by Cl, -C 7 aryl substituted by Cl, -C 8 aryl substituted by Cl, -C 9 aryl substituted by Cl, -C 10 aryl substituted by Cl, -C 1 haloalkyl, -C 2 haloalkyl, and –C 3 haloalkyl; orR 1 and R 1’ together with the nitrogen atom to which they are both attached form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can further contains 1, or 2 heteroatoms selected from N, O, S, SO or SO 2, and said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO 2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -CH 2-vinyl, - (CH 2) 2-vinyl, - (CH 2) 3-vinyl, -CH 2-allyl, - (CH 2) 2-allyl, - (CH 2) 3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH 3, -COO-CH 2CH 3, -COO-CH 2CH 2CH 3, -COO-CH (CH 3) 2, -CH 2-COO-CH 3, - (CH 2) 2-COO-CH 3, - (CH 2) 3-COO-CH 3, -CH 2-COO-CH 2CH 3, - (CH 2) 2-COO-CH 2CH 3, - (CH 2) 3-COO-CH 2CH 3, -CH 2-COO-CH 2CH 2CH 3, - (CH 2) 2-COO-CH 2CH 2CH 3, - (CH 2) 3-COO-CH 2CH 2CH 3, -CH 2-COO-CH (CH 3) 2, - (CH 2) 2-COO-CH (CH 3) 2, - (CH 2) 3-COO-CH (CH 3) 2, -CH 2-SO 2-CH 3, - (CH 2) 2-SO 2-CH 3, - (CH 2) 3-SO 2-CH 3, -CH 2-SO 2-CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 3, -CH 2-SO 2-CH 2CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 2CH 3, -CH 2-SO 2-CH (CH 3) 2, - (CH 2) 2-SO 2-CH (CH 3) 2, - (CH 2) 3-SO 2-CH (CH 3) 2, -CH 2-SO-CH 3, - (CH 2) 2-SO-CH 3, - (CH 2) 3-SO-CH 3, -CH 2-SO-CH 2CH 3, - (CH 2) 2-SO-CH 2CH 3, - (CH 2) 3-SO-CH 2CH 3, -CH 2-SO-CH 2CH 2CH 3, - (CH 2) 2-SO-CH 2CH 2CH 3, - (CH 2) 3-SO-CH 2CH 2CH 3, -CH 2-SO-CH (CH 3) 2, - (CH 2) 2-SO-CH (CH 3) 2, - (CH 2) 3-SO-CH (CH 3) 2, -CH 2-S-CH 3, - (CH 2) 2-S-CH 3, - (CH 2) 3-S-CH 3, -CH 2-S-CH 2CH 3, - (CH 2) 2-S-CH 2CH 3, - (CH 2) 3-S-CH 2CH 3, -CH 2-S-CH 2CH 2CH 3, - (CH 2) 2-S-CH 2CH 2CH 3, - (CH 2) 3-S-CH 2CH 2CH 3, -CH 2-S-CH (CH 3) 2, - (CH 2) 2-S-CH (CH 3) 2, - (CH 2) 3-S-CH (CH 3) 2, -CH 2-O-CH 3, - (CH 2) 2-O-CH 3, - (CH 2) 3-O-CH 3, -CH 2-O-CH 2CH 3, - (CH 2) 2-O-CH 2CH 3, - (CH 2) 3-O-CH 2CH 3, -CH 2-O-CH 2CH 2CH 3, - (CH 2) 2-O-CH 2CH 2CH 3, - (CH 2) 3-O-CH 2CH 2CH 3, -CH 2-O-CH (CH 3) 2, - (CH 2) 2-O-CH (CH 3) 2, - (CH 2) 3-O-CH (CH 3) 2, -NH 2, -NHCH 3, -NHCH 2CH 3, -NHCH 2CH 2CH 3, -NHCH (CH 3) 2, -N (CH 3) 2, -N (CH 2CH 3) 2, -N (CH 2CH 2CH 3) 2, -N (CH (CH 3) 2) 2, carboxyl, -C 5 aryl, -C 6 aryl, -C 7 aryl, -C 8 aryl, -C 9 aryl, -C 10 aryl, -C 5 aryl substituted by F, -C 6 aryl substituted by F, -C 7 aryl substituted by F, -C 8 aryl substituted by F, -C 9 aryl substituted by F, -C 10 aryl substituted by F, -C 5 aryl substituted by Cl, -C 6 aryl substituted by Cl, -C 7 aryl substituted by Cl, -C 8 aryl substituted by Cl, -C 9 aryl substituted by Cl, -C 10 aryl substituted by Cl, -C 1 haloalkyl, -C 2 haloalkyl, and –C 3 haloalkyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any one of claims 1-6, whereinR 1 and R 1’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, isopropyl,
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any one of claims 1-7, whereinX is selected from the group consisting of–C (=O) -W- (CR X1R X2) m-NR 5R 5’, C (=O) -W- (CR X1R X2) m-SR 11, C (=O) -W- (CR X1R X2) m-SO 2R 11, C (=O) -W- (CR X1R X2) m-SO 2R 11, and –C (=O) -W- (CR X1R X2) m-OR 11;W is oxygen or a bond;m is selected from 1, 2, or 3;R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C 1-3 alkyl, -C 1-3 alkylene-SH, -C 1-3alkylene-C 2-3 alkenyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 3-6 cycloalkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-CONH 2, -C 1-3 alkylene-Se-C 1-3 alkyl, -C 1-3 alkylene-SH, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-CO 2-C 1-3 alkyl, C 5-10aryl, -C 1-3 alkylene-C 5-10 aryl, -C 1-3 alkylene-5-10 membered heteroaryl, -C 1-3 alkylene-5-10 membered heterocyclyl, and 5-10 membered heteroaryl, and wherein said C 1-3 alkyl, said -C 1-3 alkylene-SH, said -C 1-3alkylene-C 2-3 alkenyl, said -C 3-6 cycloalkyl, said -C 1-3 alkylene-C 3-6 cycloalkyl, said -C 1-3 alkylene-S-C 1-3 alkyl, said -C 1-3 alkylene-CONH 2, said said said -C 1-3 alkylene-Se-C 1-3 alkyl, said -C 1-3 alkylene-SH, said -C 1-3 alkylene-SO 2-C 1-3 alkyl, said -C 1-3 alkylene-CO 2-C 1-3 alkyl, said C 5-10aryl, said -C 1-3 alkylene-C 5-10 aryl, said -C 1-3 alkylene-5-10 membered heteroaryl, said -C 1-3 alkylene-5-10 membered heterocyclyl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;or R X1 and R X2 together with the carbon atom to which they are attached form 5-8 membered carbocyclic ring, C 3-6 cycloalkyl, C 2-3 alkenyl, 5-8 membered heterocyclyl, and wherein said 5-8 membered carbocyclic ring, said C 3-6 cycloalkyl, said C 2-3 alkenyl, and said 5-8 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 5 and R 5’ are each independently selected from the group consisting of hydrogen, deuterium, -C 1-3 alkyl, -C 3-6 cycloalkyl, -C (=O) -C 1-3 alkyl, -C (=O) -C 5-10 carbocyclic, -C (=O) -adamantanyl, -C (=O) -C 3-6 cycloalkyl, and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;or R X1 and R 5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5-10 membered heterocyclyl, and wherein said 5-10 membered heterocyclyl can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2, and said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 11 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any one of claims 1-8, whereinX is selected from the group consisting of –C (=O) -W- (CR X1R X2) m-NR 5R 5’,W is a bond;m is 1;R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, methyl, ethyl, propyl, isopropyl,or R X1 and R X2 together with the carbon atom to which they are attached form5 membered carbocyclic ring, 6 membered carbocyclic ring, 7 membered carbocyclic ring, 8 membered carbocyclic ring, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloalkyl, C 6 cycloalkyl, C 2 alkenyl, C 3 alkenyl, C 4 alkenyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, and wherein said 5 membered carbocyclic ring, said 6 membered carbocyclic ring, said 7 membered carbocyclic ring, said 8 membered carbocyclic ring, said C 3 cycloalkyl, said C 4 cycloalkyl, said C 5 cycloalkyl, said C 6 cycloalkyl, said C 2 alkenyl, said C 3 alkenyl, said C 4 alkenyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO 2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -CH 2-vinyl, - (CH 2) 2-vinyl, - (CH 2) 3-vinyl, -CH 2-allyl, - (CH 2) 2-allyl, - (CH 2) 3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH 3, -COO-CH 2CH 3, -COO-CH 2CH 2CH 3, -COO-CH (CH 3) 2, -CH 2-COO-CH 3, - (CH 2) 2-COO-CH 3, - (CH 2) 3-COO-CH 3, -CH 2-COO-CH 2CH 3, - (CH 2) 2-COO-CH 2CH 3, - (CH 2) 3-COO-CH 2CH 3, -CH 2-COO-CH 2CH 2CH 3, - (CH 2) 2-COO-CH 2CH 2CH 3, - (CH 2) 3-COO-CH 2CH 2CH 3, -CH 2-COO-CH (CH 3) 2, - (CH 2) 2-COO-CH (CH 3) 2, - (CH 2) 3-COO-CH (CH 3) 2, -CH 2-SO 2-CH 3, - (CH 2) 2-SO 2-CH 3, - (CH 2) 3-SO 2-CH 3, -CH 2-SO 2-CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 3, -CH 2-SO 2-CH 2CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 2CH 3, -CH 2-SO 2-CH (CH 3) 2, - (CH 2) 2-SO 2-CH (CH 3) 2, - (CH 2) 3-SO 2-CH (CH 3) 2, -CH 2-SO-CH 3, - (CH 2) 2-SO-CH 3, - (CH 2) 3-SO-CH 3, -CH 2-SO-CH 2CH 3, - (CH 2) 2-SO-CH 2CH 3, - (CH 2) 3-SO-CH 2CH 3, -CH 2-SO-CH 2CH 2CH 3, - (CH 2) 2-SO-CH 2CH 2CH 3, - (CH 2) 3-SO-CH 2CH 2CH 3, -CH 2-SO-CH (CH 3) 2, - (CH 2) 2-SO-CH (CH 3) 2, - (CH 2) 3-SO-CH (CH 3) 2, -CH 2-S-CH 3, - (CH 2) 2-S-CH 3, - (CH 2) 3-S-CH 3, -CH 2-S-CH 2CH 3, - (CH 2) 2-S-CH 2CH 3, - (CH 2) 3-S-CH 2CH 3, -CH 2-S-CH 2CH 2CH 3, - (CH 2) 2-S-CH 2CH 2CH 3, - (CH 2) 3-S-CH 2CH 2CH 3, -CH 2-S-CH (CH 3) 2, - (CH 2) 2-S-CH (CH 3) 2, - (CH 2) 3-S-CH (CH 3) 2, -CH 2-O-CH 3, - (CH 2) 2-O-CH 3, - (CH 2) 3-O-CH 3, -CH 2-O-CH 2CH 3, - (CH 2) 2-O-CH 2CH 3, - (CH 2) 3-O-CH 2CH 3, -CH 2-O-CH 2CH 2CH 3, - (CH 2) 2-O-CH 2CH 2CH 3, - (CH 2) 3-O-CH 2CH 2CH 3, -CH 2-O-CH (CH 3) 2, - (CH 2) 2-O-CH (CH 3) 2, - (CH 2) 3-O-CH (CH 3) 2, -NH 2, -NHCH 3, -NHCH 2CH 3, -NHCH 2CH 2CH 3, -NHCH (CH 3) 2, -N (CH 3) 2, -N (CH 2CH 3) 2, -N (CH 2CH 2CH 3) 2, -N (CH (CH 3) 2) 2, carboxyl, -C 5 aryl, -C 6 aryl, -C 7 aryl, -C 8 aryl, -C 9 aryl, -C 10 aryl, -C 5 aryl substituted by F, -C 6 aryl substituted by F, -C 7 aryl substituted by F, -C 8 aryl substituted by F, -C 9 aryl substituted by F, -C 10 aryl substituted by F, -C 5 aryl substituted by Cl, -C 6 aryl substituted by Cl, -C 7 aryl substituted by Cl, -C 8 aryl substituted by Cl, -C 9 aryl substituted by Cl, -C 10 aryl substituted by Cl, -C 1 haloalkyl, -C 2 haloalkyl, and –C 3 haloalkyl; R 5 and R 5’ are each independently selected from the group consisting of hydrogen, deuterium, -C (=O) -CH 3, -C (=O) -CH 2CH 3, -C (=O) -CH (CH 3) 2,or R X1 and R 5 together with the carbon atom and nitrogen atom to which they are attached respectively form 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, and wherein said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2, and said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO 2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, allyl, ethyne, propyne, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -CH 2-vinyl, - (CH 2) 2-vinyl, - (CH 2) 3-vinyl, -CH 2-allyl, - (CH 2) 2-allyl, - (CH 2) 3-allyl, -4 membered heterocyclyl, -5 membered heterocyclyl, -6 membered heterocyclyl, -COO-CH 3, -COO-CH 2CH 3, -COO-CH 2CH 2CH 3, -COO-CH (CH 3) 2, -CH 2-COO-CH 3, - (CH 2) 2-COO-CH 3, - (CH 2) 3-COO-CH 3, -CH 2-COO-CH 2CH 3, - (CH 2) 2-COO-CH 2CH 3, - (CH 2) 3-COO-CH 2CH 3, -CH 2-COO-CH 2CH 2CH 3, - (CH 2) 2-COO-CH 2CH 2CH 3, - (CH 2) 3-COO-CH 2CH 2CH 3, -CH 2-COO-CH (CH 3) 2, - (CH 2) 2-COO-CH (CH 3) 2, - (CH 2) 3-COO-CH (CH 3) 2, -CH 2-SO 2-CH 3, - (CH 2) 2-SO 2-CH 3, - (CH 2) 3-SO 2-CH 3, -CH 2-SO 2-CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 3, -CH 2-SO 2-CH 2CH 2CH 3, - (CH 2) 2-SO 2-CH 2CH 2CH 3, - (CH 2) 3-SO 2-CH 2CH 2CH 3, -CH 2-SO 2-CH (CH 3) 2, - (CH 2) 2-SO 2-CH (CH 3) 2, - (CH 2) 3-SO 2-CH (CH 3) 2, -CH 2-SO-CH 3, - (CH 2) 2-SO-CH 3, - (CH 2) 3-SO-CH 3, -CH 2-SO-CH 2CH 3, - (CH 2) 2-SO-CH 2CH 3, - (CH 2) 3-SO-CH 2CH 3, -CH 2-SO-CH 2CH 2CH 3, - (CH 2) 2-SO-CH 2CH 2CH 3, - (CH 2) 3-SO-CH 2CH 2CH 3, -CH 2-SO-CH (CH 3) 2, - (CH 2) 2-SO-CH (CH 3) 2, - (CH 2) 3-SO-CH (CH 3) 2, -CH 2-S-CH 3, - (CH 2) 2-S-CH 3, - (CH 2) 3-S-CH 3, -CH 2-S-CH 2CH 3, - (CH 2) 2-S-CH 2CH 3, - (CH 2) 3-S-CH 2CH 3, -CH 2-S-CH 2CH 2CH 3, - (CH 2) 2-S-CH 2CH 2CH 3, - (CH 2) 3-S-CH 2CH 2CH 3, -CH 2-S-CH (CH 3) 2, - (CH 2) 2-S-CH (CH 3) 2, - (CH 2) 3-S-CH (CH 3) 2, -CH 2-O-CH 3, - (CH 2) 2-O-CH 3, - (CH 2) 3-O-CH 3, -CH 2-O-CH 2CH 3, - (CH 2) 2-O-CH 2CH 3, - (CH 2) 3-O-CH 2CH 3, -CH 2-O-CH 2CH 2CH 3, - (CH 2) 2-O-CH 2CH 2CH 3, - (CH 2) 3-O-CH 2CH 2CH 3, -CH 2-O-CH (CH 3) 2, - (CH 2) 2-O-CH (CH 3) 2, - (CH 2) 3-O-CH (CH 3) 2, -NH 2, -NHCH 3, -NHCH 2CH 3, -NHCH 2CH 2CH 3, -NHCH (CH 3) 2, -N (CH 3) 2, -N (CH 2CH 3) 2, -N (CH 2CH 2CH 3) 2, -N (CH (CH 3) 2) 2, carboxyl, -C 5 aryl, -C 6 aryl, -C 7 aryl, -C 8 aryl, -C 9 aryl, -C 10 aryl, -C 5 aryl substituted by F, -C 6 aryl substituted by F, -C 7 aryl substituted by F, -C 8 aryl substituted by F, -C 9 aryl substituted by F, -C 10 aryl substituted by F, -C 5 aryl substituted by Cl, -C 6 aryl substituted by Cl, -C 7 aryl substituted by Cl, -C 8 aryl substituted by Cl, -C 9 aryl substituted by Cl, -C 10 aryl substituted by Cl, -C 1 haloalkyl, -C 2 haloalkyl, and –C 3 haloalkyl; orR 11 is selected from the group consisting of hydrogen, deuterium.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any one of claims 1-9, whereinR 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 3 and R 3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;Y is - (CR Y1R Y2) n-;n is selected from 1, 2, or 3;R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl;R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl; orR 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-6 alkyl, -C 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 3-8 cycloalkyl, -C 1-6 alkylene-C 2-6 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-6 alkyl, -C 1-6 alkylene-COO-C 1-6 alkyl, -C 1-6 alkylene-SO 2-C 1-6 alkyl, -C 1-6 alkylene-SO-C 1-6 alkyl, -C 1-6 alkylene-S-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -NH 2, -NH (C 1-6 alkyl) , -N (C 1-6alkyl) 2, carboxyl, -C 5-12 aryl, -C 5-12 aryl substituted by halogen and -C 1-6 haloalkyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any one of claims 1-10, whereinR 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl;R 3 and R 3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl;Y is - (CR Y1R Y2) n-;n is 1;R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl;R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl; orR 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 2-3 alkenyl, -4-8 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3 haloalkyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any one of claims 1-11, whereinR 2 is hydrogen, or deuterium;R 3 and R 3’ are each independently hydrogen, or deuterium;Y is - (CR Y1R Y2) n-;n is 1;R Y1 and R Y2 are each independently hydrogen or deuterium;R 4 is hydrogen or deuterium; orR 10 is hydrogen or deuterium.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of claim 14, wherein R 1 and R 1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, -C 1-3 alkyl, -C 2-3 alkenyl, C 2-3 alkynyl, -C 5-10 aryl, -C 1-3 alkylene-COO-C 1-3 alkyl, -C 1-3 alkylene-C 5-10 aryl, -5-10 membered heteroaryl, -5-10 membered heterocyclyl, -C 1-3 alkylene-N (C 1-3 alkyl) 2, -C 1-3 alkylene-O-C 1-3 alkyl, -C 1-3 alkylene-CO-NH-C 1-3 alkyl, -C 1-3 alkylene-CO-5-10 membered heterocyclyl, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-SO-C 1-3 alkyl and C 3-6 cycloalkyl-C 5-10 aryl, each of which can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl;R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, halogen, C 1-3 alkyl, -C 1-3 alkylene-SH, -C 1-3alkylene-C 2-3 alkenyl, -C 3-6 cycloalkyl, -C 1-3 alkylene-C 3-6 cycloalkyl, -C 1-3 alkylene-S-C 1-3 alkyl, -C 1-3 alkylene-CONH 2, -C 1-3 alkylene-Se-C 1-3 alkyl, -C 1-3 alkylene-SH, -C 1-3 alkylene-SO 2-C 1-3 alkyl, -C 1-3 alkylene-CO 2-C 1-3 alkyl, C 5-10aryl, -C 1-3 alkylene-C 5-10 aryl, -C 1-3 alkylene-5-10 membered heteroaryl, -C 1-3 alkylene-5-10 membered heterocyclyl, and 5-10 membered heteroaryl, each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -C 2-4 alkenyl, -C 2-4 alkynyl, -C 3-6 cycloalkyl, -C 1-4 alkylene-C 2-4 alkenyl, -4-10 membered heterocyclyl, -COO-C 1-3 alkyl, -C 1-4 alkylene-COO-C 1-3 alkyl, -C 1-4alkylene-SO 2-C 1-3 alkyl, -C 1-4 alkylene-SO-C 1-3 alkyl, -C 1-4 alkylene-S-C 1-3 alkyl, -C 1-4 alkylene-O-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl, -C 5-10 aryl, -C 5-10 aryl substituted by halogen and -C 1-3haloalkyl; orR 5 and R 5’ are each independently selected from the group consisting of hydrogen, deuterium, -C 1-3 alkyl, -C 3-6cycloalkyl, -C (=O) -C 1-3 alkyl, -C (=O) -5-10 membered heterocyclyl, -C (=O) -5-10 membered carbocyclic, -C (=O) -adamantanyl, -C (=O) -C 1-3 alkylene-O-C 1-3 alkyl, -C (=O) -C 1-3 alkylene-NH-C 1-3 alkyl, -C (=O) -C 1-3 alkylene-N (C 1-3 alkyl) 2, -C (=O) -C 3-6 cycloalkyl, each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -NO 2, -C 1-3 alkyl, -C 1-3 alkoxy, -COO-C 1-3 alkyl, -NH 2, -NH (C 1-3 alkyl) , -N (C 1-3alkyl) 2, carboxyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of of claim 14 or 15, wherein R 1 and R 1’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, vinyl, allyl, ethyne, propyne, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, -CH 2-COO-CH 3, - (CH 2) 2-COO-CH 3, - (CH 2) 3-COO-CH 3, -CH 2-COO-CH 2CH 3, - (CH 2) 2-COO-CH 2CH 3, - (CH 2) 3-COO-CH 2CH 3, -CH 2-COO-CH 2CH 2CH 3, - (CH 2) 2-COO-CH 2CH 2CH 3, - (CH 2) 3-COO-CH 2CH 2CH 3, -CH 2-COO-CH (CH 3) 2, - (CH 2) 2-COO-CH (CH 3) 2, - (CH 2) 3-COO-CH (CH 3) 2, -CH 2-C 5 aryl, -CH 2-C 6 aryl, - (CH 2) 2-C 6 aryl, - (CH 2) 3-C 6 aryl, -CH 2-C 7 aryl, - (CH 2) 2-C 7 aryl, - (CH 2) 3-C 7 aryl, -CH 2-C 8 aryl, - (CH 2) 2-C 8 aryl, - (CH 2) 3-C 8 aryl, -CH 2-C 9 aryl, - (CH 2) 2-C 9 aryl, - (CH 2) 3-C 9 aryl, -CH 2-C 10 aryl, - (CH 2) 2-C 10 aryl, - (CH 2) 3-C 10 aryl, -5 membered heteroaryl, -6 membered heteroaryl, -7 membered heteroaryl, -8 membered heteroaryl, -9 membered heteroaryl, -10 membered heteroaryl, each of which can be optionally substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -NO 2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -NH 2, -NHCH 3, -NHCH 2CH 3, -NHCH 2CH 2CH 3, -NHCH (CH 3) 2, -N (CH 3) 2, -N (CH 2CH 3) 2, -N (CH 2CH 2CH 3) 2, -N (CH (CH 3) 2) 2, carboxyl;R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, -CO-CH 3, -SO-CH 3, -SO 2-CH 3, -NH-CO-CH 3, and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, ; orR 5 and R 5’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C (=O) -CH 3, -C (=O) -CH 2CH 3, -C (=O) -CH 2CH 2CH 3, -C (=O) -CH (CH 3) 2, -C (=O) -CH 2-O-CH 3, -C (=O) - (CH 2) 2-O-CH 3, -C (=O) - (CH 2) 3-O-CH 3, -C (=O) -CH 2-O-CH 2CH 3,-C (=O) -CH 2-NH-CH 3, -C (=O) - (CH 2) 2-NH-CH 3, -C (=O) - (CH 2) 3-NH-CH 3,-C (=O) -CH 2-NH-CH 2CH 3, -C (=O) -CH 2-N (CH 3) 2, -C (=O) - (CH 2) 2-N (CH 3) 2, -C (=O) - (CH 2) 3-N (CH 3) 2, -C (=O) -CH 2-N (CH 2CH 3) 2, each of which can be optional substituted with one or more substituents, and said substituents are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -COO-CH 3, -COO-CH 2CH 3, -NH 2, -NHCH 3, -NHCH 2CH 3, -NHCH 2CH 2CH 3, -NHCH (CH 3) 2, -N (CH 3) 2, -N (CH 2CH 3) 2, -N (CH 2CH 2CH 3) 2, -N (CH (CH 3) 2) 2, carboxyl.
- The compound, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof of any one of claims 14-16, wherein the compound is of formula Ia-3 R 1 and R 1’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, tert-butyl,R X1 and R X2 are each independently selected from the group consisting from hydrogen, deuterium methyl, ethyl, propyl, isopropyl, tert-butyl, or
- A pharmaceutical composition comprising the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of any one of claims 1-18; and a pharmaceutically acceptable carrier, diluent or excipient.
- A method of treating a subject having a cancer, said method comprising administering to the subject a therapeutically effective amount of the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of any one of claims 1-18; or the pharmaceutical composition of claim 19.
- The method of claim 20, wherein the cancer is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, colon cancer, leukemia, glioblastoma or head and neck cancer..
- Use of the compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of any one of claims 1-18; or the pharmaceutical composition of claim 19 for the manufacture of a medicament for the treatment of a cancer.
- The use of claim 22, wherein the cancer is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, colon cancer, leukemia, glioblastoma or head and neck cancer..
- The compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof of any one of claims 1-18; or the pharmaceutical composition of claim 19 for use in the treatment of a cancer.
- The compound, the stereoisomer thereof, the pharmaceutically acceptable salt thereof or the pharmaceutically acceptable salt of the stereoisomer thereof; or the pharmaceutical composition of claim 24, wherein the cancer is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, colon cancer, leukemia, glioblastoma or head and neck cancer.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020121114 | 2020-10-15 | ||
CNPCT/CN2020/121114 | 2020-10-15 | ||
CN2021072122 | 2021-01-15 | ||
CNPCT/CN2021/072122 | 2021-01-15 | ||
CN2021072115 | 2021-01-15 | ||
CNPCT/CN2021/072115 | 2021-01-15 | ||
CN2021076480 | 2021-02-10 | ||
CNPCT/CN2021/076480 | 2021-02-10 | ||
CN2021076483 | 2021-02-10 | ||
CNPCT/CN2021/076483 | 2021-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022078462A1 true WO2022078462A1 (en) | 2022-04-21 |
Family
ID=81207670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/123878 WO2022078462A1 (en) | 2020-10-15 | 2021-10-14 | Novel glutamine analogs |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022078462A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132776A1 (en) * | 2000-11-03 | 2002-09-19 | N-Zyme Biotech Gmbh | Inhibitors of transglutaminase |
CN108290827A (en) * | 2015-07-31 | 2018-07-17 | 约翰霍普金斯大学 | The prodrug of glutamine analogues |
CN108348492A (en) * | 2015-07-31 | 2018-07-31 | 约翰霍普金斯大学 | Use the method for cancer and immunotherapy of the glutamine analogues including DON |
WO2019071110A1 (en) * | 2017-10-06 | 2019-04-11 | The John Hopkins University | Novel glutamine antagonists and uses thereof |
-
2021
- 2021-10-14 WO PCT/CN2021/123878 patent/WO2022078462A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132776A1 (en) * | 2000-11-03 | 2002-09-19 | N-Zyme Biotech Gmbh | Inhibitors of transglutaminase |
CN108290827A (en) * | 2015-07-31 | 2018-07-17 | 约翰霍普金斯大学 | The prodrug of glutamine analogues |
CN108348492A (en) * | 2015-07-31 | 2018-07-31 | 约翰霍普金斯大学 | Use the method for cancer and immunotherapy of the glutamine analogues including DON |
WO2019071110A1 (en) * | 2017-10-06 | 2019-04-11 | The John Hopkins University | Novel glutamine antagonists and uses thereof |
Non-Patent Citations (19)
Title |
---|
DATABASE REGISTRY STN; 16 July 2018 (2018-07-16), ANONYMOUS : "L-Norleucine, 6-diazo-N-[(1,1-dimethylethoxy)carbonyl]-5-oxo-,methyl ester", XP055921400, Database accession no. RN 2230815-45-7 * |
DATABASE REGISTRY STN; 16 March 1933 (1933-03-16), ANONYMOUS : "Carbamic acid, [5-diazo-1-[(dimethylamino)carbonyl]-4-oxopentyl]-,phenylmethyl ester, (S)- (9CI)", XP055921369, Database accession no. N 146467-16-5 * |
DATABASE REGISTRY STN; 16 March 1993 (1993-03-16), ANONYMOUS : "Carbamic acid, [5-diazo-1-[(dimethylamino)carbonyl]-4-oxopentyl]-,2-propenyl ester, (S)- (9CI)", XP055921366, Database accession no. RN 146467-17-6 * |
DATABASE REGISTRY STN; 16 November 1984 (1984-11-16), ANONYMOUS : "Carbamic acid, [5-diazo-4-oxo-1-[[(phenylmethyl)amino]carbonyl]pentyl]-,phenylmethyl ester, (S)- (9CI)", XP055921397, Database accession no. RN 58456-29-4 * |
DATABASE REGISTRY STN; 16 November 1984 (1984-11-16), ANONYMOUS : "Glycine, N-(6-diazo-5-oxo-L-norleucyl)- (9CI)", XP055921370, Database accession no. RN 78081-74-0 * |
DATABASE REGISTRY STN; 16 November 1984 (1984-11-16), ANONYMOUS : "L-Serine, O-(2-diazoacetyl)-", XP055921415, Database accession no. RN 115-02-6 * |
DATABASE REGISTRY STN; 16 November 1984 (1984-11-16), ANONYMOUS CH2 : "Carbamic acid, [5-diazo-4-oxo-1-[[(phenylmethyl)amino]carbonyl]pentyl](hydroxymethyl)-,phenylmethyl ester, (S)- (9CI)", XP055921399, Database accession no. RN 58456-28-3 * |
DATABASE REGISTRY STN; 19 December 2005 (2005-12-19), ANONYMOUS : "Glycine, 6-diazo-5-oxo-N-[(phenylmethoxy)carbonyl]-L-norleucyl- (9CI)", XP055921355, Database accession no. RN 870152-23-1 * |
DATABASE REGISTRY STN; 19 December 2005 (2005-12-19), ANONYMOUS : "Glycine, 6-diazo-5-oxo-N-[(phenylmethoxy)carbonyl]-L-norleucyl-,methyl ester (9CI)", XP055921359, Database accession no. RN 870152-22-0 * |
DATABASE REGISTRY STN; 19-12-2005, ANONYMOUS : "L-Phenylalanine, 6-diazo-5-oxo-N-[(phenylmethoxy)carbonyl]-L-norleucyl-, methyl ester (9CI)", XP055921353, Database accession no. RN 870152-25-3 * |
DATABASE REGISTRY STN; 2 March 2017 (2017-03-02), ANONYMOUS : "L-Norleucine, 6-diazo-5-oxo-, 1-methylethyl ester", XP055921404, Database accession no. RN 2079939-24-3 * |
DATABASE REGISTRY STN; 2 March 2017 (2017-03-02), ANONYMOUS : "L-Norleucine, 6-diazo-5-oxo-N2-[(2-propen-1-yloxy)carbonyl]-", XP055921414, Database accession no. RN 2079939-15-2 * |
DATABASE REGISTRY STN; 2 March 2017 (2017-03-02), ANONYMOUS : "L-Norleucine, 6-diazo-N-[[1-(2,2-dimethyl-1-oxopropoxy)-2-methylpropoxy]carbonyl]-5-oxo-, 1-methylethyl ester", XP055921407, Database accession no. RN 2079939-22-1 * |
DATABASE REGISTRY STN; 2 March 2017 (2017-03-02), ANONYMOUS : "L-Norleucine, 6-diazo-N-[[1-(2,2-dimethyl-1-oxopropoxy)ethoxy]carbonyl]-5- oxo-,ethyl ester", XP055921410, Database accession no. RN 2079939-20-9 * |
DATABASE REGISTRY STN; 2 March 2017 (2017-03-02), ANONYMOUS : "L-Norleucine, 6-diazo-N-[[1-(2-methyl-1-oxopropoxy)ethoxy]carbonyl]-5-oxo- ,ethyl ester", XP055921409, Database accession no. RN 2079939-21-0 * |
DATABASE REGISTRY STN; 2 March 2017 (2017-03-02), ANONYMOUS : "L-Norleucine, 6-diazo-N2-[[(1S)-1-(2-methyl-1-oxopropoxy)ethoxy]carbonyl]-5-oxo-, ethyl ester", XP055921401, Database accession no. RN 2079939-28-7 * |
DATABASE REGISTRY STN; 2 March 2017 (2017-03-02), ANONYMOUS : "L-Norleucine, N-[[[4-(acetyloxy)phenyl]methoxy]carbonyl]-6-diazo-5-oxo-,ethyl ester", XP055921402, Database accession no. RN 2079939-26-5 * |
DATABASE REGISTRY STN; 2 March 2017 (2017-03-02), ANONYMOUS : "Norleucine, 6-diazo-N-[[1-(2-methyl-1-oxopropoxy)ethoxy]carbonyl]-5-oxo-, ethyl ester", XP055921412, Database accession no. RN 2079939-19-6 * |
DATABASE REGISTRY STN; 28 May 2002 (2002-05-28), ANONYMOUS : "Glycine, 6-diazo-5-oxo-N-[(phenylmethoxy)carbonyl]-L-norleucyl-,phenylmethyl ester (9CI)", XP055921363, Database accession no. RN 422322-73-4 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021121367A1 (en) | Kras mutant protein inhibitors | |
WO2021185233A1 (en) | Kras mutant protein inhibitors | |
WO2021078285A1 (en) | Cycloalkyl-based and heterocycloalkyl-based inhibitors, preparation method therefor and use thereof | |
WO2022184178A1 (en) | Kras g12d inhibitors | |
CN111499634B (en) | Quinazoline compound and application thereof in medicine | |
US9962383B2 (en) | Compounds, compositions and methods of agelastatin alkaloids | |
EP4365178A1 (en) | Nitrogen-containing heterocyclic compound, and preparation method therefor, intermediate thereof, and application thereof | |
WO2023041055A1 (en) | Kif18a inhibitor | |
EP2021334B1 (en) | Synthesis and uses of pyroglutamic acid derivatives | |
WO2022078462A1 (en) | Novel glutamine analogs | |
WO2015113521A1 (en) | Deuterated quinazolinone compound and pharmaceutical composition comprising same | |
EP3470410A1 (en) | Crystalline form of compound suppressing protein kinase activity, and application thereof | |
WO2022022612A1 (en) | Novel glutamine analogs | |
US7960420B2 (en) | Diazonamide analogs with improved solubility | |
US10351586B2 (en) | Cytidine derivative dimers and applications thereof | |
WO2022078416A1 (en) | Novel glutamine analogs | |
WO2022188889A1 (en) | Compound as parp7 inhibitor | |
EP4183788A1 (en) | Crystal of pyrimidine compound | |
EP2699580B1 (en) | Diazonamide analogs | |
WO2024125551A1 (en) | Cyclin k degrader and use thereof | |
WO2022184103A1 (en) | Tricyclic compound and pharmaceutical composition and use thereof | |
WO2023221900A1 (en) | Selective her2 and her2 mutation inhibitor | |
CN118084844A (en) | PI3K alpha inhibitor and application thereof in medicine | |
AU2015228385A1 (en) | Compounds for eradicating or inhibiting proliferation of cancer stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21879504 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21879504 Country of ref document: EP Kind code of ref document: A1 |